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Primary Ovarian Insufficiency (POI) is a heterogeneous group of disorders with an incidence of 
1:10,000 women by age 20, 1:1,000 by age 30, 1:100 by age 40. POI describes the progression 
toward the cessation of ovarian function and can occur in the most serious form as primary 
amenorrhea (PA), with absent pubertal development and/or ovarian dysgenesis (OD), or in 
milder phenotype with post-pubertal onset and secondary amenorrhea (SA). Several are the 
etiological causes that may induce ovarian dysfunction, among which the genetic component is 
considered prevalent (as supported by the occurrence of families with more than one affected 
women and the existence of several idiopathic cases) but highly heterogeneous.  
46,XX non-syndromic women showing the most severe phenotype, characterized by the absence 
of pubertal development with PA and OD, are very rare but the search for genetic variations in 
this extreme phenotype may be more effective in identifying novel pathogenic mechanisms. 
Hence, using high resolution array-CGH we searched for rare high-penetrant CNVs involving 
genes essential for ovarian function in a cohort of 67 46,XX non-syndromic patients affected by 
PA, namely 53 sporadic (79.1%) and 14 familial (20.9%) cases. 28 out of 67 women resulted 
positive to array-CGH analysis because having at least one rare “ovarian” CNV: a total number 
of 32 CNVs involving 37 ovarian genes was selected.  
Population from Database of Genomic Variants (DGV) was used to evaluate the rarity of POI 
CNVs, but it does not match to the ideal set of controls for POI disease (neither age nor gender 
of DGV controls are known). Thus, to better understand the CNVs contribution in disease 
onset, the rare “ovarian” CNVs found in patients according to DGV were searched in an ad hoc 
control cohort, previously screened by array-CGH, consisting in 140 healthy women with 
normal reproductive life and physiological menopause. 28 out of 32 rare “ovarian” CNVs 
detected in patients were not found in the control group thus supporting their role in the POI’s 
pathogenesis. Moreover, to evaluate the presence of a significant enrichment in ovarian genes in 
the POI group, array-CGH of the ad hoc control cohort were analyzed with the same approach 
adopted for patients cohort and 49 CNVs involving 54 ovarian genes were selected. Several 
statistical analyses were performed comparing patients’ to controls’ data and revealed no 
significant differences. Nevertheless, the CNVs found in the POI cohort containing ovarian 
genes are more harmful respect to the CNVs identified in the controls cohort. 
The 37 genes perturbed or possibly perturbed by POI CNVs are implicated in several ovarian 
processes (e.g., regulation of cytoskeleton dynamics for oocytes asymmetric division, 
maintenance of oocytes genomic integrity, ovarian differentiation, follicular development, and 
meiotic resumption), thus supporting their involvement in POI etiology. Validation and 
characterization of selected CNVs, as well as the study of a possible gene perturbation at mRNA 
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level, was also crucial in order to perform a correct genotype-phenotype correlation and to 
propose new candidate genes for POI disease (e.g. TP63, VLDLR). 
39 out of 67 women resulted negative for rare “ovarian” CNVs (58.2%) suggesting to combine 
different genomic approaches in order to increase the detection rate of the disorder. Hence, 17 
out of 67 collected patients, were submitted to a preliminary WES analysis searching for rare 
SNVs in a total of 191 genes selected from array-CGH data, and literature regarding POI and 
ovary. The WES preliminary analysis allowed to confirm the importance of some array CGH 
new candidate genes in POI onset (e.g. VLDLR) and the complex heterogeneity of POI.  
The combination of these molecular evidences, with major or minor contribution, might have 
been at the basis of POI supporting the existence of a disease genetic model characterized by 
oligogenic heterozygosity (i.e., the simultaneous presence in a single patient of multiple 
heterozygous quantitative variants/rare mutations, both de novo and/or inherited, affecting 
multiple genes).  
The present approach using both array-CGH and WES techniques, resulted an efficient tool to 
identify rare variants (CNVs and SNVs) involving both genes already reported in POI, and new 
candidate genes with a role in oocyte maturation and differentiation. The results of this study 
are promising to expand the knowledge about the molecular pathways involved in POI 
pathogenesis and probably provide the basis for a more accurate genetic diagnosis of POI 
patients. 
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1.1 Physiological aspects of ovarian growth and differentiation 
The main function of the female gonad is the development of mature oocytes for future 
fertilization. Moreover it produces ovarian hormones allowing the development of female 
secondary sexual features and supporting pregnancy [1].  
Oogenesis and folliculogenesis are the two biological processes that occur to ensure oocyte 
growth and differentiation. 
1.1.1 Oogenesis 
Oogenesis consists in the formation of haploid gametes from primordial germ cells 
(oogonia) through meiosis [2], which starts in the first three months during fetal life and ends 
only when a mature oocyte is fertilized [3]. The number of oogonia is fixed at birth and it is 
thought that no additional primary oocytes are created during life, while male spermatogenesisis 
a continuous process [4,5]. Female reproductive process differs from spermatogenesis in several 
features: it takes place in a rhythm called menstrual cycle and for every primordial germ cell 
provides just one functional gamete. The others cells originated from meiosis cellular divisions 
are little polar bodies that die fast [3,4]. 
In detail, during human embryogenesis, primordial germ cells migrate from the epithelium of the 
yolk sack to colonize the gonadal ridge. When primordial germ cells reach the genital ridge they 
lose their motility and in females become oogonia [6,7]. Germ cells start to proliferate by mitosis 
and develop in cluster of cells called germ line cysts or oocyte nests, which are connected by 
intercellular bridges [2]. At 11–12 weeks of gestation some of the oogonia end mitosis, enter the 
first stages of meiosis becoming primary oocytes stalling in profase I (diplotene) [8]. They are 
stopped in the first meiosis division till preovulatory stage that occurs shortly before pubertal 
age [4]. At 20th week of gestational age, the number of primary oocytes arrested in meiosis 
achieve their maximum development, when approximately 7,000,000 have been created (Fig.1) 
[1,5]. Then, the rate of oogonial mitotic division declines [1]. Besides, the majority of primary 
oocytes die before birth and in childhood, through a physiological programmed cell death 
mechanism known as “atresia”. Conversely, the oocytes survived remain quiescent till pubertal 
age [9].  
A female has about 400,000 primary oocytes at the beginning of pubertal age (Fig.1), which 
constitutes the ovarian reserve (OR) for her entire life. Once reached puberty, menstrual cycle 
starts and about 20-25 primary oocytes restart growth and differentiation processes monthly to 
complete meiosis I division and produce a secondary haploid oocyte with a second polar body. 
Secondary oocyte arrests the cycle at metaphase II of meiotic division waiting for ovulation and 
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meiosis II process will end only after the fertilization of the mature oocyte, unless it will die by 
apoptosis and will never end meiosis [3]. 
 
 
Fig.1. Oocyte dynamics in physiology. Stages of female reproductive life are shown with the respective number of 
oocyte reserve. Atresia occurs from the 20th week of gestation, whereas ovulation starts from pubertal age; about 
400-500 oocytes become dominant ovulating follicles. This image was adapted from Persani et al, 2010 [10]. 
 
1.1.2 Folliculogenesis 
Folliculogenesis is a physiological process that runs at the same time of oogenesis and it is 
regulated both by endocrine as well as paracrine factors [11,12,13]. 
It consists in the maturation of the ovarian follicle, formed by an oocyte wrapped by tightly 
packed layers of somatic cells. The main role of the ovarian follicle is oocyte support. Follicular 
development starts during fetal life in the internal part of the ovary immediately after the 
primary oocytes reach diplotene [2] and consists in the growth of a number of small primordial 
follicles into primary, secondary and then large preovulatory follicles that enter the menstrual 
cycle (Fig.2). Follicular maturation is a very long process, where the primary oocytes are 
incorporated in primordial follicles before birth and remain quiescent in the ovary, until 
recruitment into the growing pool every month during reproductive life [8,14,15]. 
As well as oocytes, only a few follicles survive to complete the differentiation process and 
ovulation, while immature follicles (more than 99% of follicles) will undergo atresia [1,16,17]. In 
the mammalian ovary, follicular development and atresia are closely regulated and seem to rely 
on a balance between cell death (inhibin, Bax, FasL, TNF-α, caspase, etc.) and survival-
promoting factors (FSH, insulin-like growth factor-I, interleukin-1β, epidermal growth factor, 
Bcl-2, etc.) [9]. Although atresia can occur any time throughout follicular development, most 
follicles become atretic during the early antral stage of folliculogenesis after exposure of the 
granulosa cells to gonadotropin. At this time granulosa cells start to differentiate thus being 
more susceptible to apoptosis and becoming early and progressed atretic follicles [12,18,19].  
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The follicular development can be divided into two stages (Fig.2) based on the subsequently 
follicular maturative phases and on the involvement of ovarian, hypothalamic and pituitary 
hormones:  
- gonadotropin independent or preantral phase (primordial, primary, secondary follicles 
included);  
- gonadotropin dependent or antral phase (tertiary, graafian, preovulatory follicles 
included) [20,21].  
 
 
Fig.2. Schematic representation of follicular development. Preantral and antral phases of folliculogenesis are 
depicted. Atresia occurs during all the growing and differentiation process. Oogonia develop from primordial germ 
cells and differentiate into mature oocytes. All the preantral follicles have a primary oocyte; the tertiary follicles are 
characterized by an antral cavity which contains follicular fluid. Graafian preovulatory follicles have more antral 
fluid and contain a secondary oocyte. This image was adapted from Araujo, Gastal et al.[22]. 
 
1.1.2.1 Gonadotropin independent stage: from primordial to pre-antral follicles 
Primordial follicles formation begins around midgestation and continues until just after 
birth with the recruitment of pregranulosa cells to each oogonia nest. In particular, the oocyte 
nests break apart into individual cells, lose their intercellular bridges and become enclosed in a 
layer of flattened pregranulosa cells, becoming the primordial follicles [2,8,12,23]. Oocytes not 
surrounded by granulosa cells enter apoptosis [24,25,26]. 
As aforementioned when mitosis stops, the oogonia enter the early stages of meiosis I as primary 
oocytes. These immature oocytes within the primordial follicles stall in meiosis I [8,27], and 
remain quiescent for months or years showing little to no biological activity [28]. During 
maturation, some of the primordial follicles leave the resting pool and are stimulated to grow 
and develop into primary follicles. The process by which primordial cells “wake up” is known as 
initial recruitment [1,8] and it is mediated by secretion and communication of various 
stimulatory, inhibitory hormones and growth factors between oocyte and granulosa cells 
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[29,30]. During primordial follicle development, the primary oocytes grow as well, but remain 
arrested in the prophase of meiosis I. For those follicles not recruited, the default pathway is to 
stay dormant [1]. 
Subsequently, the granulosa cells of primordial follicle start to change from a flat to a 
cuboidal structure and both the oocyte and the follicle grow significantly, increasing up to 0.1 
mm in diameter: primary follicles are forming. During this development phase the oocyte 
genome is activated and several genes are transcribed [31] among which those encoding proteins 
ZP-1, ZP-2, ZP-3 are relevant for the extracellular matrix production called zona pellucida [32]. 
Granulosa cells send out some extensions through zona pellucida to form gap junctions with the 
oocyte membrane. To note, connexin 37 (Cx37) is a component of the ovarian gap junction with 
a critical role in folliculogenesis, ovulation and fertility [33]. Indeed, the communication 
between oocyte and granulosa cells is crucial to allow the passage of ions, metabolites, signaling 
factors [34,35] and it is responsible for the positive or negative regulation of all the follicular 
growth process. Moreover, primary follicles express receptors for follicle stimulating hormone 
(FSH), but they remain gonadotropin-independent until the antral stage [28,36]. 
Vascularization is not present in primary follicles [20].  
The most important change that occurs in the development of a secondary follicle is the 
formation of a theca layer. This tissue, made of stroma cells, further differentiates in inner theca 
interna and outer theca externa [20]. Theca interna is characterized by a vascularization system 
and is able to produce steroid hormones through endocrine activity: i.e. androstenedione 
(intermediate of both estrogens and androgens), testosterone, progesterone. The outer layer 
(theca externa) is composed by smooth muscular cells innervated by autonomic nerves [37]. 
At this stage more than one layer of granulosa cells is present due to mitotic divisions. These 
cells are able to produce estrogens, converting steroid hormones produced by theca cells. 
Moreover at this time, each granulosa cell bears FSH receptors whereas theca cells start to 
express LH receptors [38].  
The hallmark of a tertiary pre-antral follicle is the formation of an antrum through a 
process called cavitation. It begins to form at one pole of the oocyte with the accumulation 
between granulosa cells of a follicular fluid, which is a medium in which regulatory molecules 
are found. The ending of cavitation, corresponds to the formation of a Graafian dominant follicle 
which is mature for ovulation. Antral formation starts in a gonadotropin independent manner, 
but it is controlled by autocrine paracrine mechanism through growth factors as activin and kit 
ligand [20,39,40]. Meanwhile the follicle reaches the pre-antral stage, the oocyte has been 
enlarging considerably and has become competent enough to resume the meiotic process [41]. 
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1.1.2.2 Gonadotropin dependent stage and menstrual cycle 
A Graafian follicle can be defined as a family composed by heterogeneous large follicles 
characterized by a cavity (or antrum) containing a follicular fluid. The antral follicles maintain 
the same structural complexity even though dramatic changes occur in their size. 
After pubertal onset, a small number of the large antral follicles can be rescued to continue the 
growth in a gonadotropins-dependent manner through a process called cyclic recruitment that 
overlaps with the follicular phase of the menstrual cycle [1,4]; indeed, it takes only 14 days for an 
antral follicle to become a dominant Graafian follicle [1,21].  
At this stage, as a result of the increase in circulating FSH, only a limited number of follicles 
survive, and the fate of the others is to undergo atresia. Among the recruited follicles, one is 
considered as dominant and secrets high levels of estrogens and inhibins to suppress pituitary 
FSH release as a negative selection of the remaining follicles. At the same time, an increase in 
growth factors secretion allows a positive selection for the dominant follicle, thus ensuring its 
final growth and ovulation [1].  
Once reached puberty, together with follicular development as explained above, a primary 
oocyte completes every month the first meiotic division and starts the second one arresting in 
metaphase II and becoming secondary oocyte. This cyclic process is called menstrual cycle and 
it is composed by: 
- ovarian cycle (ovarian functional and structural changes)  
- uterine cycle (uterine functional and structural changes)  
- cycle changes in the secretion of ovarian, hypothalamic and pituitary hormones [4]. 
The ovarian cycle can be divided in two phases: follicular stage and luteal stage, each lasting 
about 14 days. The former starts at the beginning of menstruation and ends with ovulation, the 
latter matches with the other part of the cycle [4]. In particular, as mentioned before, in the 
follicular phase a pool of antral follicles is recruited and continues to grow; the dominant 
Graafian follicle that receives the major FSH surge ovulates in the 14th day of menstrual cycle to 
release the mature oocyte for fertilization, whereas the remaining theca and granulosa cells 
become the corpus luteum [1]. This structure is named from a yellow lipid that accumulates in 
theca layers and it is important to prepare the uterus for a possible pregnancy ensuring a proper 
hormonal supply. Contrary it atrophies and becomes a scar tissue named corpus albicans [3]. 
 
Hormonal changes during menstrual cycle 
Several hormones participate in a complex process of positive and negative feedback to 
regulate folliculogenesis (Fig.3): 
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- gonadotropin releasing hormone (GnRH) secreted by the hypothalamus; 
- gonadotropins: follicle-stimulating hormone (FSH); luteinizing hormone (LH); 
- estrogen and progesterone. 
Early follicular stage is characterized by low levels of estrogen and progesterone in the plasma 
and represents the final stage of luteal phase as a consequence of luteum body degeneration. 
Since these two hormones tend to inhibit gonadotropin secretion from pituitary, plasmatic 
levels of FSH and LH start to increase (Fig.3). Furthermore, GnRH stimulates the release of 
FSH and LH from the anterior pituitary gland that will have a stimulatory effect on follicle 
growth during antral stage of folliculogenesis. In particular, FSH stimulates follicles growth and 
differentiation through binding FSH receptors on granulosa cells, whereas the theca cells of the 
growing oocytes show LH receptors. Thus, LH binding triggers the secretion of androgens that 
are converted via aromatization into estrogens by granulosa cells [42]. The estrogen surge and 
inhibin produced by granulosa cells of the growing follicles act in a negative feedback pathway 
on hypothalamus, inhibiting LH and FSH release. While LH levels tends to be stable, as a 
feedback mechanism, FSH levels decrease due to inhibin secretion. Besides, the reduction of 
FSH level is partially responsible of the atretic process of non dominant follicles [3,9]. 
In the late stage of follicular phase, as more estrogen is secreted, more LH receptors are 
expressed by the theca cells, triggering theca cells to produce more androgen that will become 
estrogen. This positive feedback loop causes LH to increase sharply. A peak level of LH is critical 
to ensure ovulation because causes nuclear maturation with the end of meiosis I. Moreover 
estrogen secretion decreases and granulosa cells start to produce progesterone and some enzyme 
able to disrupt the follicular wall for ovulation [8,43] (Fig.3).  
After ovulation, the dominant follicle with no oocyte becomes a corpus luteum, which produces 
a huge amount of progesterone that inhibits GnRH, FSH and LH secretion and stimulates the 
uterus to prepare for a possible pregnancy. When it reaches the maturity starts to secrete also a 
little amount of estrogens (Fig.3). After about 10 days from ovulation, without the fertilization 
of the mature oocyte, the corpus luteum degenerates causing a drastic decrease of estrogen and 
progesterone that leads to menstruation [3]. 
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Fig.3. Hormonal changes during menstrual cycle. Above, changes in concentration of anterior pituitary (blue and 
yellow continuos lines) and ovarian hormones (green and red dashed lines) are shown during the three follicular 
phases. Below, hormones regulatory feedback loops acting during follicular phase (1), ovulation (2), and luteal 
phase (3). 
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1.2 Primary Ovarian Insufficiency (POI) 
1.2.1 Prevalence and clinical overview 
The age of menopause in a woman is determined by both genetic and environmental factors. 
The average age at which this process occurs in Caucasian women is 50.7 years [44,45]. 
However, about 1% of women before 40 years experience a premature cessation of the ovarian 
reserve and suffer from a fertility defect named Primary Ovarian Insufficiency (POI) [46]. This 
condition, firstly described by Fuller Albright in 1942 [47,48], has an incidence of 1 in 10,000 
women by age 20, 1 in 1,000 by age 30, 1 in 100 by age 40 and 1 in 10 by age 45 [10]. The 
prevalence of POI, however, varies by ethnicity, with women of oriental origin having a lower 
risk and African Americans a higher risk compared to Caucasian Americans [44]. 
According to the onset age, the disorder can manifest i) in the most serious form as primary 
amenorrhea (PA), with absent pubertal development and/or ovarian dysgenesis (a condition in 
which the ovaries are completely free of follicles), or ii) in milder phenotype with post-pubertal 
onset characterized by secondary amenorrhea (SA) and defect in folliculogenesis [46,49,50]. 
Based on evidence that the disorder has a long and heterogeneous clinical course, the term 
Primary Ovarian Insufficiency has been recently proposed to better describe the progression 
toward the cessation of ovarian function [51,52]. Indeed, POI is commonly adopted to indicate 
diagnostically similar conditions as hypergonadotropic hypogonadism, premature ovarian 
failure (POF) and ovarian dysgenesis [10,49]. 
Biochemically, the disorder is characterized by elevated serum gonadotropin levels as in the 
menopausal range (usually FSH over 40 IU/L, obtained at least 1 month apart) and serum 
estradiol levels less than 50 pg/mL, which indicate hypoestrogenism [53,54,55]. For this reason, 
compared with healthy women, patients with POI are more likely to experience long-term 
consequences of hypoestrogenism including osteoporosis, cardiovascular diseases (myocardial 
infarction and stroke), neurocognitive disorders (sleep disturbance and decreased mental 
concentration), loss of sexual desire or vaginal dryness. However, infertility is the major 
consequence of POI [10,49,53,56]. 
 
1.2.2 Diagnosis and management of POI 
As mentioned before, POI is characterized by low levels of gonadal hormones (estrogens 
and inhibins), and high levels of gonadotropins (LH and FSH) before the age of 45. The 
diagnosis is confirmed if the FSH value is in the menopausal range (> 40 IU/L) in at least two 
serial measurements after 4-6 months of amenorrhea or primary amenorrhea manifestation. 
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Although standard diagnostic criteria for POI have yet to be established, another indicator to be 
evaluated is the anti-Mullerian hormone (AMH), which can help to assess the state of follicular 
senescence and it is considered a putative marker of the ovarian reserve even before menarche 
[57]. Ultrasonography of ovaries, together with age, are traditional indicators to evaluate ovarian 
aging. Furthermore it is advisable to collect a comprehensive family history and to perform 
physical examination to exclude other causes of POI: pregnancy, polycystic ovary syndrome, 
lifestyle habits, hypothalamic amenhorrea, hypothalamic or pituitary lesions, 
hyperprolactinemia, hypothyroidism, hyperthyroidism, autoimmune disorders, fragile X 
syndrome or intellectual disability [46,49]. In this regard, karyotype to determine X 
chromosomal abnormalities and FMR1 premutation screening are usually carried out [54,58]. 
Considering that unexpected diagnosis of POI affects woman’s physical and emotional well-
being, management is crucial for this disorder. Therapeutic strategies include hormone 
replacement therapy (HRT), fertility management, psychological support and annual screening 
to assess women’s health care. Long-term HRT (estrogen and progestin) is advised to provide 
relief from menopausal symptoms due to hypoestrogenism, to prevent osteoporosis, 
caridiovascular diseases and it is usually recommended to continue this treatment till the age of 
natural menopause [49]. Even though some POI patients show a milder phenotype and present 
clinical findings similar to menopause, almost 50% have some residual ovarian function, and 5-
10% are able to accomplish pregnancy [56]. For this reason, fertility preservation is important to 
allow future childbearing. Particularly, infertility rescue includes ovarian hyperstimulation 
followed by oocyte or embryo cryopreservation, and ovarian tissue preservation, but the fertility 
treatment with the highest success rate is still the assisted reproductive technique using donor 
oocytes [49,56]. Besides medical treatment, professional and family support is essential [53]. 
 
1.2.3 Etiopathogenesis 
Most of primordial follicles formed during embryonic development are lost in fetal and 
postnatal life by atresia, and out of them only about 400-500 generally ovulate before 
physiological menopause. The three alterantive mechanisms that might lead to POI can be i) an 
initial reduction in the primordial follicle pool, ii) an accelerated atresia or iii) an altered 
maturation of primordial follicles [10,56]. However, the etiological causes that may induce 
ovarian dysfunction are highly heterogeneous and include: 
- Chromosomal abnormalities and gene mutations (see chapter 1.3); 
- Autoimmune diseases (e.g. hypothyroidism, adrenal insufficiency, hypoparathyroidism, 
type 1 diabetes mellitus, pernicious anemia, myasthenia gravis, rheumatoid arthritis, 
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systemic lupus erythematosus, Addison’s disease, autoimmune polyglandular syndrome 
and steroid cell autoimmunity primary ovarian insufficiency (SCA-POI), caused by 
autoimmune destruction of theca cells [49,54,56,59]); 
- Metabolic disorders (e.g. galactose 1-phosphate uridylyltransferase deficiency 
(galactosemia), characterized by toxic accumulation of galactose during infancy, leading 
to ovarian, ocular, renal, hepatic and neurological defects; 17-OH hydroxylase deficiency 
(CYP17) as well as aromatase deficiency (CYP19), cause defects in the pathway involved 
in sex steroid biosynthesis [49,56]); 
- Infections (e.g. mumps oophoritis, characterized by mononuclear cell infiltration into 
the theca layer of antral follicles; HIV); 
- Iatrogenic treatments (e.g. ovarian surgery, radiotherapy or chemotherapy for several 
neoplastic diseases) accounting for about 25% of all forms; 
- Environmental/lifestyle factors (e.g. repeated doses of the ovotoxic substance 4-
vinylcyclohexene diepoxide (VCD), cigarette smoking, epilepsy [10,56]). 
Nevertheless, in more than 50% of POI women the main causative event remains elusive, 
strongly suggesting a genetic origin of the disease. These cases are classified as idiopathic or 
spontaneous ovarian insufficiency [10,50,51,53,55,60]. 
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1.3 Genetic causes of POI 
In the pathogenesis of idiopathic POI patients, genetic causes are considered prevalent as 
supported by the occurrence of families with several affected women, corresponding to an 
incidence from 4 to 31%, depending on the studied population [10,60,61]. Dominant or recessive 
forms of inheritance have been demonstrated, but the most frequent form follows an X-linked 
maternal inheritance pattern with incomplete penetrance, indicating that X chromosome 
defects are an important cause of familial POI [59,62,63,64]. Furthermore, the presence in the 
same family of women with heterogeneous phenotypes indicates that primary ovarian 
insufficiency is a genetic disorder with high variability, supporting the idea of POI as a complex 
multigenic disease [62]. Indeed, the existence of mouse models with absent ovarian function 
(knockouts in more than 100 genes [65]) and of monogenic forms of POI indicates also the 
relevance of autosomal genes implicated in POI pathogenesis [54]. The genes involved have 
several biological functions as regulation of the hypothalamic-pituitary ovarian axis, regulation 
of oogenesis and folliculogenesis, coordination of endocrinal functions, that in turn cause 
reduction of the reserve of primordial follicles and accelerate atresia leading to POI phenotype. 
Even though a large number of genes have been found, with some understanding of their 
pathogenesis, the precise genetic mechanisms underlying POI are unclear [10,56]. 
 
1.3.1 Chromosomal aneuploidies and structural abnormalities 
X chromosome abnormalities have been described in both familial and non-familial POI 
patients, and represent about 13% of POI cases, which make them one of the commonest genetic 
causes [55]. Almost all chromosomal defects are involved, i.e. aneuploidies and rearrangements. 
Regarding chromosomal aneuploidies, X monosomy or Turner’s syndrome, corresponds 
to a syndromic condition of POI with a prevalence of about 1 in 2,500 female births [66]. Among 
the various clinical features it is associated with gonadal dysgenesis with primary amenorrhea, 
sexual infantilism, webbing of the neck, cubitus valgus, short stature and cognitive deficits. 
Infertility in 45,X patients is caused by oocyte loss in the early stages of meiotic prophase 
resulting in ovarian dysgenesis. However, about 10% of Turner patients reach menarche because 
of a mosaic condition of chromosome X (45,X/46,XX) [53,67]. 
POI may be also associated with triple X syndrome or trisomy X (47,XXX) with endocrine 
findings of hypergonadotropic hypogonadism. Although not present in all cases, 21 POI patients 
have been reported until 2010 [68,69,70]. Hence, POI is not an essential characteristic of X 
chromosome tetrasomy (48,XXXX), even if detected in a 16-years-old girl without ovaries [71]. 
Introduction 
 
16 
 
Regarding structural abnormalities, the commonest is Xq isochromosome, where the 
resulting chromosome contains structurally identical arms with the same gene content. In 
particular, the isochromosome for the long arm (q) is the most common X structural 
abnormality in POI patients [49]. X chromosome deletions (mainly within Xp11 and Xq13-q26) 
and inversions, undetectable by conventional karyotyping, are also found in women with 
primary or secondary amenorrhea as well as with balanced and unbalanced X/autosomal 
translocations [56,72,73,74]. Conversely, very few cases of POI are reported to be carriers of 
translocation within autosomes, being up to date only three: two cases with a karyotype 
46,XX,t(2;15)(q32.3;q13.3) and one with a translocation between chromosomes 13 and 14 
[53,75,76].  
Molecular cytogenetic analyses of POI patients bearing X-rearrangements allowed the 
identification of two “critical regions” for ovarian growth and development. The first is located 
on the long arm of the X chromosome, spanning from Xq13.3 to Xq27 [53,59,77,78] with the 
following two main subregions further being identified: region 1 (Xq13.3-Xq21.1, locus POF2) 
associated more frequently with translocations and region 2 (Xq26-q27, locus POF1) where 
deletions are more frequent.  
The second critical region is located on the short arm of the X chromosome between Xp11.1 and 
Xp21: patients with deletion in this region display primary amenorrhea and gonadal dysgenesis 
[53,55,79]. Although these regions have been associated with POI phenotype, several studies 
emphasized the role of other autosomal genes in the etiopathogenesis of the disorder.  
 
1.3.2 Genes associated with 46,XX POI 
1.3.2.1 Syndromic POI 
As previously mentioned for Turner Syndrome, POI in some patients is associated with 
syndromic conditions whose responsible genetic cause is usually identified. The main genes 
whose mutations cause some of the syndromes associated with POI are listed and discussed 
below: GALT, GNAS, POLG, AIRE, EIF2B, ATM, STAR, CYP17A1, CYP19A1 and FOXL2.  
- POI occurs in all women affected by Galactosemia (OMIM #230400), a hereditary disorder of 
galactose metabolism due to homozygous mutation in GALT gene leading to GALT enzyme 
(galactose-1-phosphatase uridyltransferase) deficiency. Considering that optimum galactose 
concentrations are essential for normal ovarian development and function, its toxic 
accumulation cause oocytes apoptosis. Moreover these patients present complications in 
other organs such as liver, kidney and heart [10,80]. 
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- Also loss of function mutations in the GNAS gene, encoding a G protein involved in the 
hormonal regulation of adenylate cyclase, cause a form of hormone resistance named 
pseudohypoparathyroidism type 1a which leads to ovarian insufficiency [48]. 
- Mutations in POLG gene (OMIM #174763), an enzyme that replicates human mitochondrial 
DNA, cause the autosomal dominant or recessive form of progressive external 
ophthalmoplegia (PEO) characterized by ptosis, limited eye movements and by variable POI 
manifestations from PA to SA. 
- Mutations in the AIRE (Autoimmune Regulator protein) gene cause a disease called 
Autoimmune polyglandular syndrome type I (APS1; OMIM #240300) or autoimmune-
polyendocrinopathycandidiasis-ectodermal dystrophy (APECED), an autosomal recessive 
disorder characterized by the presence of Addison’s disease, hypoparathyroidism, and 
chronic mucocutaneous candidiasis. More than half of the patients present POI due to an 
autoimmune response to steroidogenic enzymes and steroid ovarian cells, leading to ovarian 
depletion [81]. 
- Ovarian leukodystrophy characterized by degeneration of brain white matter and POI 
(OMIM #603896) was firstly described by Schiffmann et al. [82]. The genetic basis of the 
disease is represented by mutations in any of the five subunits of the eukaryotic translation 
initiation factor EIF2B. 
- Another syndromic condition of POI is ataxia teleangiectasia (AT; OMIM #208900), an 
autosomal recessive neurodegenerative disorder characterized by infertility, degeneration of 
the brain which controls movement and speech, ocular telangiectases, chromosome 
instability, immunodeficiency, and cancer predisposition. Mutations in the ATM gene, which 
encodes for a protein kinase implicated in cell cycle regulation, DNA damage and metabolism, 
generally result in the total loss of the protein and are the underlying cause of this syndrome 
[10]. 
- Furthermore, also genes implicated in the pathways of steroid hormone synthesis are 
associated to syndromic POI. For instance, the StAR gene (Steroidogenic Acute Regulatory) 
encodes a protein involved in the conversion of cholesterol into pregnenolone; mutations in 
this gene lead to lipoid congenital adrenal hyperplasia, characterized by cholesterol 
accumulation with damage to ovarian cells. As well, mutations in enzyme of the cytochrome 
P450 superfamily CYP17A1, which converts pregnenolone and progesterone into androgens 
(dehydroepiandrosterone and androstenedione), cause congenital adrenal hyperplasia with 
primary amenorrhea. Moreover, the CYP19A1 gene, encoding the aromatase enzyme, converts 
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androgens into estrogens and mutations are associated to aromatase deficiency syndrome 
[10,53]. 
- Finally, the FOXL2 (Forkhead Box L2) gene, belonging to the forkhead transcription factors 
family, encodes a transcription regulatory protein involved in ovarian development and 
function. It can be considered both a syndromic and a non-syndromic POI gene (POF3, 
OMIM #608996): indeed, mutations in this gene are associated with blepharophimosis-
ptosis-epicanthus inversus syndrome (BPES, OMIM #110100) characterized by dominant 
malformation of the eyelids, but recently, mutations in this gene leading to POI without any 
malformations have also been found [83,84]. Moreover, Foxl2 knockout murine ovaries are 
characterized by an altered granulosa cells differentiation leading to premature activation of 
primordial follicles and consequent atresia [85]. 
 
1.3.2.2 Non-syndromic POI 
Contrary to what described so far, in other patients POI appears to be isolated and its cause 
is not usually identified [53]. Nevertheless, there are many causative or candidate genes 
responsible for non-syndromic POI (Fig.4). The following list includes the genes whose 
involvement in the disorder is supported by several experimental evidences: FMR1 and FMR2, 
TGFβ superfamily (BMP15, GDF9, INHA), FSHR, LHR, NR5A1, FOXO family, NOBOX, FIGLA, STAG3, 
DIAPH2, POF1B, HFM1, NANOS3, MCM8, MCM9 ,SYCE1 [10,86]. 
- FMR1 and FMR2 
The fragile X mental retardation 1 gene (FMR1; OMIM #309550) is located at Xq27.3 and is 
responsible for the fragile X syndrome, a form of X-linked mental retardation (FRAXA). 
Mutations in FMR1 lead to the expansion of a polymorphic CGG repeat in the 5’ untraslated 
region, which can become unstable. Based on the number of repeats, three allelic groups can be 
found: normal alleles (from 6 to 55 repeats), premutated alleles (from 55 to 200 repeats) and full 
mutated allele (> than 200 repeats). When a full mutation is present, the gene is silenced by 
methylation, resulting in the absence of the FMR protein, which causes intellectual disability. 
Contrary, the premutation of the gene represents the cause of spontaneous 46,XX POI (POF1, 
OMIM #311360) in about 7% of sporadic cases and 21% of familial POI [87]. The underlying 
molecular mechanisms of how the triplet expansion causes POI are unknown, although it is 
hypothesized that premutated alleles remaining unmethylated might lead to increase in FMR1 
transcript levels that in turn can have a toxic effect during the reproductive life. In the same 
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way, the accumulation of FMR protein may impair the expression of genes required for oocyte 
development [56,87,88]. 
FMR2 (AFF2) gene (Fragile Mental Retardation 2, FRAXE, OMIM #309548) is located at 
Xq28, 600 kb distal from FMR1 and likewise it has a trinucleotide repeat (GCC) within the 
untraslated region of exon 1. FMR2 has also normal, premutated and full mutated alleles; thus, 
even if the mechanism underlying the pathogenesis of POI is not well known, it has been 
proposed a mechanism similar to that mentioned for FMR1. Moreover, microdeletions in this 
gene are associated with about 1.5% of POI cases, a higher percentage compared to the general 
population [55,80,89]. 
- BMP15 
BMP15 (also named GDF9b) gene (POF4, OMIM #300510), located at Xp11.2 within the Xp 
critical region, belongs to the TGFβ superfamily and encodes a pre-pro-protein consisting of a 
signal peptide, a pro-region and a mature domain that can form homo- or hetero-dimers with 
related factors, such as GDF9 (see below) [10,90]. The main roles of BMP15 include: follicle 
maturation since the primordial phases of folliculogenesis; promotion of oocyte developmental 
competence; and determination of the ovulation quota for establishing the final number of 
ovarian follicles [10,91,92]. 
Regarding animal models, Bmp15 knockout female mice and sheep were subfertile, with reduced 
ovary size [93]. In humans, the first BMP15 genetic alteration associated with POI was detected 
in 2004 in two Italian sisters with hypergonadotropic ovarian failure characterized by primary 
amenorrhea and ovarian dysgenesis, who inherited the mutation from the father. Particularly, 
the p.Y235C mutation generated aberrant high-molecular weight products that were shown to 
act as dominant negative factor decreasing in vitro the growth of granulosa cells after stimulation 
with wild-type BMP15 [94]. Afterwards, many other mutations in BMP15 gene have been 
identified in women with primary ovarian insufficiency, each involving the pro-domain 
[95,96,97,98,99,100]. The BMP15 role in female fertility was also emphasized in a publication by 
Castronovo et al. [67] in which 40 patients with Turner syndrome (TS) have been screened by 
array comparative genomic hybridization (array-CGH) aiming at discovering genes with a 
possible role in ovarian development. Interestingly, one of the six TS patients, who presented 
spontaneous menarche, was found to bear a duplication involving the entire BMP15 gene. Thus, 
the double dose of the genes might have preserved the correct amount of the protein needed for 
follicular functionality and pubertal development in the TS patient [67]. 
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Nevertheless, the contribution of BMP15 in the pathogenesis of the disorder is still uncertain in 
some cases because studies failed to find association of the gene with POI; moreover, BMP15 
mutations were also found at low percentage in control populations. Thus the overall findings 
merge in suggesting that mutations in the gene might confer predisposition to POI, considered 
as a multigenic disorder [10,55]. 
- GDF9 
Among the TGFβ family members, the growth differentiation factor 9 (GDF9, OMIM #601918) is 
located on chromosome 5 (5q31.1) and is homologous of BMP15. It encodes an oocyte-secreted 
growth factor with a pivotal role in the progression of folliculogenesis, mainly in the early stages 
of this process as proved by the presence in the human ovary of abundant expression levels of 
GDF9 mRNA and protein [101]. According to animal models, homozygous Gdf9 null female mice 
are infertile and characterized by significantly smaller ovaries with follicular growth blocked at 
the primary stages [102]. 
Therefore, GDF9 can be considered a candidate gene for human POI [10,56]. Indeed, several 
studies have been performed for mutational screening of this gene in different populations, 
starting from the study of Takebayashi et al., in which no mutation was found in 15 Japanese 
women with POI [103]. However, further screening performed on a more extensive number of 
patients revealed several point mutations probably causative of the disorder. Variations are all 
heterozygous and affects exclusively the pro-region (like the homologous BMP15) with a 
prevalence of 1.4% [98,104,105,106]. 
- INHA 
The inhibin (OMIM #147380), is a dimeric glycoprotein mainly produced in the gonads and 
constituted by two subunits a and b encoded by INHA and INHB genes respectively. These two 
genes present a different mode of action during the ovarian cycle: the mRNA levels of the first 
(INHA) increase in the middle of the cycle, whereas those of INHB increase in the middle of the 
follicular phase [107]. They play a role in the inhibition of the hypothalamic-pituitary-gonadal 
axis, regulating the secretion of FSH and allowing the ovulation of one mature oocyte. 
Particularly, given its pivotal role in regulating pituitary hormones secretion, INHA has become 
another candidate gene for mutational studies in humans [10,108]. Nevertheless several studies 
performed on different populations reported INHA variations, the association with POI never 
reached the statistical significance [109,110,111]. Thus, it is likely that variations in this gene may 
only confer susceptibility to develop POI [112]. 
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- FSHR and LHCGR 
As part of the hypothalamo-pituitary-ovarian axis, FSH (Ovarian Dysgenesis 1, ODG1, OMIM 
#233300) and LH (OMIM #152790) glycoprotein hormone receptors, together with their 
binding hormones (FSH and LH) are pivotal for normal ovarian function. FSHR gene, mapping 
to 2p16.3 and encoding FSH receptor, is crucial for recruitment of ovarian follicles and follicular 
maturation from and beyond the preantral stage. Conversely LHR gene, which maps to 2p16.3 
close to FSHR locus and encoding LH receptor, plays an important role in the maintenance of 
progesterone production by corpus luteum and promotes ovulation throughout oocyte 
maturation. Loss of function mutations involving these receptors cause gonadotropin resistance 
with hypergonadotropic hypogonadism and gonadal dysgenesis. Similar to the human 
condition, Fshr knockout mice are characterized by absent pubertal development, high 
gonadotropin and low estrogen levels, respectively, whereas Lhcgr knockout mice have small 
ovaries, and no preovulatory follicles [113,114]. 
The first mutation in FSHR gene related to POI etiology was reported by Aittomaki et al. [115], 
and up to date nine additional mutations have been described [86,116]. The mutant receptor 
shows an altered folding which affects its trafficking to the plasma membrane. When complete 
FSH resistance is found, the patients have no pubertal development and primary amenorrhea; on 
the other hand, partial forms of resistance are characterized by post-pubertal POI and secondary 
amenorrhea [10,115]. Regarding LHR gene and POI etiology, the first causative homozygous 
nonsense mutation was described by Latronico et al. [117], although biallelic inactivating variants 
of this gene are very rare in 46,XX POI women. Indeed, they represent a particular form of POI 
disease characterized by LH levels higher than those of FSH [86].  
- NR5A1  
NR5A1 (POF7, OMIM #612964) gene, also termed steroidogenic factor 1 (SF1), is located at 11q13 
and encodes a nuclear receptor essential for gonadal development. In particular, it is a key 
transcriptional regulator of genes involved in ovarian steroidogenesis, including STAR, CYP17A1, 
CYP19A1, LH/CGR, and INHA [10]. Its pivotal role in the ovary is also emphasized by the Sf1 
knockout mice, which are sterile, have fewer follicles, lack corpora lutea and have hemorrhagic 
cysts [55,118]. Mutations were firstly associated in patients with sex developmental disorders 
(46,XY DSD), but recently more than 19 mutations associated with gonadal dysgenesis with PA 
or SA, were detected in families affected by both 46,XY DSD and 46,XX POI, and families with 
isolated POI, establishing its involvement in the onset of the disorder [119]. 
 
 
Introduction 
 
22 
 
- FOXO family 
The family of forkhead transcription factors comprises over 100 members involved in several 
developmental processes. Similar to FOXL2 gene cited before, FOXO3a (OMIM #602681), 
FOXO1a (OMIM #136533), and FOXO4 (OMIM #300033) have been shown to play a key role in 
ovarian development and function. Regarding FOXO3a gene, located at 6q21, several studies 
revealed that in oocytes of knockout mice, the follicles prematurely activated result in an earlier 
reserve depletion and infertility. Furthermore, constitutive expression of Foxo3a determines a 
significant reduction in BMP15 expression, suggesting a negative regulatory effect on this factor 
[120,121]. Thus, keeping into account that the ovarian mouse model phenotype well 
recapitulates the phenotype of POI patients, it is reasonable to consider FOXO3a a candidate 
gene for the disorder. 
- NOBOX 
NOBOX gene (POF5, OMIM #611548), mapping at 7q35, is a homeobox gene preferentially 
expressed in oocytes, mainly from the primordial follicle stage through metaphase II, encoding a 
transcription factor that regulates oocyte-specific genes [122]. It is essential for folliculogenesis 
as demonstrated by Nobox knockout mice which are infertile and with atrophic ovaries. 
Moreover, follicles do not differentiate and become fibrous tissue in a manner similar to non-
syndromic POI in human [123]. Mutational screening of the gene in several cohorts of POI 
women affected by primary or secondary amenorrhea, revealed many variations not reported in 
female controls [124,125,126].  
- FIGLA 
FIGLA gene (POF6, OMIM #612310), located at 2p13.3, encodes a basic helix-loop-helix 
transcription factor that regulates the expression of zona pellucida genes. It is expressed during 
every ovarian follicular stage and in mature oocyte. Hu et al. [127] found that FIGLA expression 
in ovary is involved in activating genes required for oogenesis: effectively female knockout mice 
show rapid oocytes loss after birth and no primordial follicles formation. The ovarian phenotype 
noticed in mice is highly suggestive that this gene may be involved in human POI. This 
hypothesis has been supported by screening for mutations in FIGLA gene in 100 Chinese women 
with primary ovarian insufficiency as this study identified some variants not reported in female 
controls [10,128]. 
- DIAPH2 and POF1B 
As aforementioned, Xq13.3-21.1 is designated as critical region for premature ovarian failure 2 
(POF2), clustering several breakpoints of translocation found in many POI patients [79,129]. 
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One of the genes interrupted by the rearrangements involving this or the surrounding region, is 
diaphanous related formin 2, DIAPH2 (POF2A, OMIM #300511). The gene is located at Xq21.33 
and encodes a protein associated with cytoskeleton and involved in metaphase chromosome 
alignment during oogenesis. Its mutations may lead to alteration in the normal follicle cell 
proliferation, but its role in the etiology of the disorder is still unclear [130]. 
Despite no causal relationship between mutations of DIAPH2 and POI phenotype has been 
reported, recent evidences describe overexpression of DIAPH2 due to a position effect (mediated 
by a balanced X;1 translocation) in a girl with short stature, ovarian dysgenesis, and hirsutism 
[74]. The other gene mapping at Xq21 is POF1B (POF2B, OMIM #300604) associated with non-
muscle myosin, which plays a pivotal role in cell division. Its role in POI etiology has been 
proved by Lacombe et al. who identified in 5 affected members of a Lebanese family a causative 
homozygous point mutation [131]. 
- HFM1  
This gene (POF9, OMIM #615724), located at 1p22.2, is an ATP-dependent DNA helicase 
exclusively expressed in ovary and testis with a role in genome integrity [132]. Hfm1-null mice 
ovaries, due to alteration in the formation of synaptonemal complex, showed a significant 
reduction in size, an increase in stromal cells, and a reduced number of follicles [133]. A recent 
study has identified recessive mutations in 2 sisters and an unrelated woman with POI, 
supporting the role of HFM1 in ovarian failure also in human [134]. 
- STAG3  
The STAG3 gene (POF8, OMIM #615723), located at 7q22.1, encodes a subunit of cohesin, a large 
protein complex that plays an important role in proper pairing and segregation of chromosomes 
during meiosis. It is the most recently reported gene, whose homozygous point mutations have 
been associated to non-syndromic POI (PA) by two studies (Caburet et al. [135] and Le Quesne 
Stabej et al. [136]). Moreover, the ovaries of Stag3-null female mice presented with a distinct lack 
of oocytes and ovarian follicles, indicating severe and very early ovarian dysgenesis [86,135].  
- NANOS3 
The gene encodes a CCHC zinc finger RNA interacting protein (OMIM #608229), recently 
reported to be an important gene for germ cell development, controlling their migration and 
survival in the first stage of development. The knockout mouse model of Nanos3 had reduced 
gonad size and was infertile, in keeping with the relationship of low levels of mRNA with a 
decreased number of germ cells [137]. Two pathogenic mutations, a missense variant in a 
Chinese POF woman, and a homozygous variant in two Brazilian PA sisters, have been reported 
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so far highlighting a role of the gene in the etiogenesis of the disorder, mainly mediating a 
protective effect against apoptosis in primordial germ cells [138,139]. 
- MCM8 and MCM9 
The proteins encoded by these genes (MCM8, POF10, OMIM #612885; MCM9, ODG4, OMIM 
#616185) are two highly conserved mini-chromosome maintenance proteins (MCM), which are 
essential for mediating Double Strand Break repair during gametogenesis, and for replication 
fork maintenance. Evidences about their role in POI pathogenesis are reported in two studies in 
which whole exome sequencing analysis of consanguineous Saudi Arabian and Kurdish families 
disclosed two homozygous mutations in MCM8 and MCM9, respectively [140,141]. In addition, 
Mcm8 null female mice are sterile and have arrested primary follicles, whereas Mcm9 null females 
are sterile as well and ovaries lack oocytes completely [142]. 
- SYCE1 
The synaptonemal complex central element protein 1 gene encodes a component of the 
synaptonemal complex which is important for maintaining paired chromosome homologues for 
crossover during meiosis [143,144,145]. Only one homozygous mutation has been described so 
far in human by de Vries et al. [146], namely in two Muslim Arab POI sisters from a 
consanguineous family. Considering that female mice Syce1-/- are infertile and had small ovaries 
with a decreased number of follicles [147], the mutation has been strongly suggested to be the 
causative factor in the POI sisters. 
 
 
Fig.4. Schematic view of the principal genes known to be involved in POI pathogenesis. Enlargement of oocyte, 
granulosa and theca cells is shown to highlight the site of expression of each ovarian gene. The image was modified 
from Persani et al., 2010 [10].  
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1.4 High throughput genome wide analyses in POI 
Whereas POI is considered idiopathic in 50-80% of cases, it is clear that some genes responsible 
of the POI phenotype are not yet known and the molecular pathways underlying the complex 
mechanism of fertility in women still need to be elucidated in order to achieve a more accurate 
genetic characterization of the patients, formulate a proper diagnosis, and ensure the correct 
therapeutic intervention. 
The best approach to understand and discover the molecular basis of a complex and 
heterogeneous disorder is a genome wide investigation. As a matter of fact, the genetic of POI 
has been recently explored through: 
- Genome Wide Association studies (GWAS); 
- array Comparative Genomic Hybridization (array CGH) looking for associated POI 
common CNVs; 
- rare SNVs and CNVs detection via Next Generation Sequencing (NGS) and array CGH, 
respectively; 
Regarding the investigation for common variants possibly causal or risk factor for POI, in 
several studies employing GWAS evaluated the frequency of polymorphisms in unrelated 
affected individuals and healthy controls, discovering common variants with a high significant 
association with POI (e.g. in ADAMTS19, IGF2R, PTHB1 genes) [148,149,150]. Moreover, Qin et al. 
conducted in 2012 the first largest-scale GWAS, investigating 391 Chinese Han patients with 
POI (32 PA patients were included because of the early SA of the other 359 women) and 895 
Chinese female controls. No candidate genes emerged but several SNPs with a high association 
were found at 8q22.3 [151]. 
In the same way, Aboura and collaborators [152] published in 2009 the first study searching for 
common CNVs possibly associated with the disorder by array CGH. The project included a 
cohort of 99 46,XX Caucasian POI women (66 SA and 33 PA patients) and reported eight 
statistically significant common CNVs with different frequency compared to a control group. 
The new putative candidate genes associated to POI and identified in the CNVs were involved 
in reproductive disease (DNAH5 and NAIP), in reproductive endocrinology (DUSP22 and 
NUPR1), and in folliculogenesis (AKT1). Nevertheless, this finding was not confirmed by a recent 
publication by Castronovo et al. [67], in which the frequency of common CNVs found in 34 
Turner syndrome (TS) patients was compared with that found in a control population of 55 
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healthy women as no enrichment of these common CNVs was detected in TS patients in 
comparison to controls. 
In 2011, Liao and collaborators [153], following the previous approach, analyzed 15 Chinese 
primary amenorrea patients through array-CGH to discover common CNVs. The study allowed 
to evidence in four patients a microdeletion at 17q21.31-21.32 containing the NSF gene (N-
ethylmalemide-sensitive factor), encoding a factor involved in female reproductive secretory 
pathway. 
Processing these patients by high throughput technologies allowed to shed light not only on 
genes and pathways possibly related to POI etiology but also on genes and pathways involved in 
ovarian-related homeostasis conditions and ovarian aging [154]. This concept is supported by 
the recent paper by Day et al. [155] on the GWAS screening of 70,000 women between 40-60 
years old to identify common and low-frequency variants associated with age at natural 
menopause. In addition to findings on SNPs strongly associated to DNA Damage Response 
pathways, the statistical analysis performed allowed to identify an enrichment in known POI 
genes, thus highlighting that some genes involved in physiological menopause are also 
responsible, if disrupted, for primary ovarian insufficiency.  
However, common variants might have only a susceptibility role in the onset of the disease, 
and can explain only a small proportion of the genetic basis of POI. Recently there is an 
increasing interest towards the identification of rare and highly penetrant variants (CNVs and 
SNVs) able to play an important role in POI pathogenesis. To this purpose, array CGH 
technology as well as NGS are the two main approaches recently used. 
 
1.4.1 array CGH and NGS technologies searching for rare variants 
CNVs are at the basis of genetic variability in the population and their key role in 
modulating the expression of the genes included has been widely demonstrated for pathological 
conditions including schizophrenia, autism, attention deficit hyperactivity disorder, etc. 
[156,157,158]. 
Up to now, two studies have been published searching for rare CNVs in cohorts of 46,XX POI 
patients [159,160]. In the first [160], the analysis of 30 patients with PA and 44 with SA by a low 
resolution array-CGH platform (105A), revealed 44 rare CNVs containing genes involved in 
meiosis, DNA repair and folliculogenesis. In the most recent study by Norling et al. [159], custom 
1M high resolution array CGH enriched for 78 genes involved in ovarian development was used 
to analyze 17 PA and 9 SA women. Eleven rare CNVs have been indentified, involving GDF9, 
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three NOBOX-binding elements, and other candidate genes (e.g. DNAH6, TSPYL6, SMARCC1, 
CSPG5, ZFR2). 
Studies using whole genome SNP array [161,162] and array CGH targeted analysis of the X 
chromosome [163,164,165] have also been reported, allowing the detection of several novel genes 
involved in ovarian development, both on autosomes and on X chromosome.  
However, many of the patients analyzed by array approaches turned out to be negative for 
any rare variant involving genes possibly related to POI: for this purpose the application of NGS 
might be a valuable complementary tool to discover the molecular defects of the pathology. 
Based on the present literature, whole exome sequencing (WES) analysis has been performed in 
a few familial and sporadic cases. Particularly, in two POI cases from consanguineous families 
(PA patients), SNVs implicated in ovarian function, namely in STAG3 and SYCE1, were revealed 
respectively [135,136,146]. Katari et al [116], recently analyzed by array-CGH+SNP and WES two 
Indian sisters with PA born to consanguineous parents and reported a homozygous mutation in 
the FSHR gene. Actually in a publication by Fonseca et al. [166] a targeted-sequencing method of 
70 candidate genes performed in twelve unrelated Colombian women affected by non-
syndromic POI (SA patients) allowed the identification of novel mutations in ADAMTS19 and 
BMPR2, probably related to POI onset [166]. Furthermore Qin et al. performed WES in three 
related women with SA and found a missense mutation in PGBD3 [167], encoding a protein with 
a role in DNA repair and transcription regulation. To validate exome data and detect 
independent mutations, they further performed Sanger sequencing of PGBD3 in 432 sporadic 
POI patients and 400 matched control females. This analysis revealed another missense 
mutation and a nonsense mutation in two SA patients [167]. 
Based on the above breakthroughs, the whole genome high throughput approaches could 
unveil the genetic heterogeneity of POI and represent powerful tools for future diagnostic and 
prognostic purposes aimed at the analysis of a subset of POI candidate genes. 
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2.1 Patients 
Genomic DNA (gDNA) from 67 women affected by the most severe POI phenotype (primary 
amenorrhea, PA) were collected. From the biochemical and endocrinological standpoint, the 
patients presented hypergonadotropic hypogonadism with high levels of gonadotropins (FSH > 
40 IU/L). Conventional karyotyping resulted 46,XX for all the women and the genetic tests 
usually performed for POI diagnosis (e.g. genetic screening of low XO mosaicism, FMR1 
premutation [49]), were negative. Previous ovarian surgery, or exposure to chemotherapy or 
radiotherapy were not present in any patients. 
The cohort of 67 POI patients includes 53 sporadic (79.1%) and 14 familial (20.9%) cases. Among 
familial cases six couples of sisters, and two patients with a relative affected by SA were 
included in the analyzed cohort. 
In order to detect copy number variants (CNVs), gDNA from all patients was used to perform 
array CGH analysis (Agilent Technology). Two kits with different resolutions were used, 
specifically:  
- 9 women by 244K Human Genome CGH Microarray, spanning approximately 236,381 
probes with an average spatial resolution of 8.9 kb (7.4 kb in gene-enriched genomic 
regions); 
- 58 patients by 400K Human Genome CGH Microarray, spanning approximately 411,056 
probes with an average spatial resolution of 5.3 kb (4.6 kb in RefSeq genes).  
In the event of detection of rare CNVs, where possible, patients’ parents were analyzed to 
characterize the origin of the unbalanced microrearrangement (de novo or inherited).  
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2.2 Molecular karyotyping by array-based Comparative Genomic 
Hybridization (array CGH) analysis 
 
2.2.1 Extraction of genomic DNA (gDNA) from peripheral blood 
For gDNA extraction from fresh or frozen (-80°C) peripheral blood collected in anticoagulant 
(EDTA) tubes, the GenElute Blood Genomic DNA Kit (Sigma) was used following the manufacturer’s 
instructions. Briefly: 
- collect 500 µl of whole blood in a 2 ml tube; 
- add 50 µl of Proteinase K; 
- add 40 µl of RNase A Solution and incubate for 2 minutes at room temperature; 
- add 550 µl of Lysis Solution C, then vortex thoroughly for 15 seconds and incubate at 55°C for 
10 minutes; 
- add 550 µl of ethanol (95-100%) to the lysate and mix thoroughly by vortexing for 15 seconds;  
- in the meantime, add 550 µl of the Column Preparation Solution to each pre-assembled 
GenElute Miniprep Binding Column, then centrifuge at 12,000 X g for 1 minute and discard the 
flow-through liquid; 
- transfer 600 μl of the sample into the treated column, centrifuge at 6,500 X g for 1 minute and 
discard the flow-through liquid; 
- repeat this step until the entire sample was loaded into the column, discard the collection tube 
containing the flow-through liquid and place the binding column in a new 2 ml tube; 
- add 500 μl of Prewash Solution and centrifuge at 6,500 X g for 1 minute. Discard the collection 
tube containing the flow-through liquid and place the binding column in a new 2 ml tube; 
- add 500 μl of Wash Solution and centrifuge for 3 minutes at maximum speed (12,000–16,000 X 
g) to dry the binding column; 
- place the binding column in a new 2 ml tube and let it dry under a safety hood for 10 minutes; 
- add 50 µl of Elution Solution directly into the centre of the binding column and incubate for 5 
minutes at room temperature, then centrifuge at 6,500 X g for 2 minutes. 
- The concentration and quality of the gDNA are determined by agarose gel electrophoresis and 
by a spectrophotometric analysis by using the NanoDrop ND-1000 UV-VIS Spectrophotometer.  
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2.2.2 gDNA restriction digestion (SureTag DNA Labeling Kit, Agilent) 
Test and reference DNA must be processed separately. The amount of DNA required, which 
must be the same for test and reference, depends on the slide used as indicated in the table 
below.  
 array 244K array 400K 
DNA (μg) 0.5-3 μg 0.5-1.5 μg 
For 244K and 400K arrays:  
- add the amount of gDNA to nuclease-free tube and add nuclease-free water up to a volume of 
20.2 μl;  
- prepare for each sample the following Digestion Master Mix: 
 2 μl of nuclease-free water 
 2.6 μl of 10X Restriction Enzyme Buffer  
 0.2 μl of BSA  
 0.5 μl of AluI (10 U/μl) 
 0.5 μl of RsaI (10 U/μl) 
- add 5.8 μL of Digestion Master Mix to each reaction tube containing the gDNA to make a total 
volume of 26 μl;  
- incubate at 37°C for 2 hours; 
- incubate at 65°C for 20 minutes to inactivate the restriction enzymes;   
- move the sample tubes to ice;  
- assess the quality of the digestion by agarose gel electrophoresis run (Agarose 0.8% in TAE 1X 
and Gel Red Nucleic Acid Stain) loading 2 μl of digested gDNA. The majority of the digested 
products should be between 200 bp and 500 bp in length. 
 
2.2.3 Fluorescent Labeling of gDNA (SureTag DNA Labeling Kit, Agilent) 
For labeling reaction fluorescent cyanines (Cy3 and Cy5) are used. The reaction must be 
performed in the dark. The test sample is labeled with Cy3 and the reference with Cy5. 
For 244K and 400K arrays:  
- add 5 μl of Random Primers to each reaction tube containing 24 μl of digested gDNA;  
- incubate at 95-100°C for 5 minutes;  
- move to ice and incubate on ice for 5 minutes;  
- prepare for each sample the following Labeling Master Mix: 
 2 μl of nuclease-free water 
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 10 μl of 5X Reaction Buffer 
 5 μl of 10X dNTPs 
 3 μl of Cy3-dUTP (test DNA) or Cy5-dUTP (reference DNA) 
 1 μl of Exo-Klenov enzyme 
- add 21 μl of Labeling Master Mix to digested gDNA to make a total volume of 50 μL; 
- incubate at 37°C for 2 hours;  
- incubate at 65°C for 10 minutes to inactivate the enzyme, then move to ice. 
 
2.2.4 Clean-up of labeled gDNA 
- Add 430 μl of 1X TE (pH 8, Promega) to each sample and transfer into a 2 ml collection tube 
with a purification column; 
- spin for 10 minutes at 14,000 X g, discard the flow-through and place the columns back in the 
collection tubes; 
- add 480 μl of 1X TE to each column and spin for 10 minutes at 14,000 X g; 
- invert the filter into a fresh 2 ml tube, spin for 1 minute at 1,000 X g to collect purified sample; 
- measure the volume of each eluate; 
- add 1X TE to bring the sample volume to 80.5 μl (244K) or 41 μl (400K); 
- take 1.5 μl of each sample to determine the yield and specific activity by using the NanoDrop 
ND-1000 UV-VIS Spectrophotometer.  
 
2.2.5 Hybridization with Oligo aCGH Hybridization Kits (Agilent) 
The hybridization reaction must be performed in the dark:  
- combine test and reference sample;  
- add the reagents as described in the table below to prepare the Hybridization Master Mix: 
 244K 400K 
Labeled gDNA 158 μl 79 μl 
Human Cot-1 DNA (1mg/ml) 50 μl 25 μl 
Agilent 10X Blocking agent 52 μl 26 μl 
Agilent 2X Hybridization buffer 260 μl 130μl 
Total volume 520 μl 260 μl 
- incubate at 95°C for 5 minutes and subsequently at 37°C for 30 minutes;  
- dispense hybridization sample mixture slowly onto the gasket well, previously loaded into the 
Agilent Hybridization Chamber; 
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- put a microarray slide onto the gasket, with the numeric barcode side facing up and the 
Agilent-labeled barcode facing down, and close the Agilent Hybridization Chamber;  
- place the assembled chamber into a preheated oven at 67°C and leave for 24-48 hours. 
 
2.2.6 Microarray wash with Oligo aCGH Wash Buffer 1 and 2 (Agilent) 
All steps must be performed in the dark and under fume hood: 
- disassemble the Agilent Hybridization Chamber; 
- dry the microarray-gasket sandwich submerging in Wash Buffer 1 for the disassembly; 
- put the microarray slide into the slide rack in the slide-staining dish containing Wash Buffer 1 
and keep stirring for 5 minutes in a magnetic stirrer; 
- wash the slide in Wash Buffer 2 pre-warmed at 37°C for 1 minute; 
- submerge the slide in Acetonitrile for 1 minute; 
- transfer slide rack in Stabilization and Drying Solution, and stir for 30 seconds; 
- slowly remove the slide rack trying to minimize droplets on the slides and put in the slide 
holder for the scanning with Microarray Scanner (Agilent). 
 
2.2.7 Microarray Scanning and Analysis 
After scanning is completed, Feature Extraction software extracts data from the scanned 
microarray image .tif and translated into a file .txt. CytoGenomics 3.0 software associates each 
oligo probe on the slide with the corresponding position in the genome and the log ratios, 
allowing to identify aberrations.  
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2.3 CNVs classification, analysis of the gene content, and 
evaluation of ovarian genes enrichment 
Once a CNV was detected, the first step was to understand whether it was a rare variant or a 
CNV already reported in healthy controls according to the Database of Genomic Variants (DGV, 
http://projects.tcag.ca/variation/). In the case of rare CNVs, namely never reported in their full 
extension in the DGV or reported at very low frequency (<< 1%), array CGH analysis was 
extended to the parents (only when available), to determine whether the rearrangement is de 
novo or inherited. Of note, considering the Primary Ovarian Insufficiency disease, which shows 
an oligo-/polygenic genetic etiology, it cannot be assumed a priori that an inherited CNV is 
benign per se. Indeed, the combination of several variants in different loci, both de novo and/or 
inherited, often leads to the onset of the disease, which is not present in the parents as they do 
not share the same combination of variants identified in the children. Besides we cannot exclude 
the possibility that any of the “common” CNVs detected in our series may have contributed to 
POI susceptibility. 
 
2.3.1 Analysis of the gene content of the identified rare CNVs 
The analysis of the gene content of rare CNVs was carried out investigating public databases ad 
hoc, useful for the evaluation of possible pathogenetic significance of the imbalances identified. 
In detail: 
- the UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway), NCBI Entrez 
Gene (http://www.ncbi.nlm.nih.gov/gene), GeneCards (http://www.genecards.org/) 
which are useful to collect information about the genes involved in CNVs (i.e. gene 
function, molecular structure, presence of different isoforms, expression in different 
tissues, pathways in which they are involved, etc.); 
- the Decipher database (http://decipher.sanger.ac.uk/) and ISCA Consortium database 
(www.iscaconsortium.org), which collect pathogenetic CNVs reported to date as well as 
the clinical description of the related patients; 
- the OMIM database (http://www.ncbi.nlm.nih.gov/omim; Online Mendelian Inheritance 
in Man), which provides information about all Mendelian disorders described to date 
and about more than 12000 genes, focusing particularly on genotype-phenotype 
correlation; 
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- PubMed (http://www.ncbi.nlm.nih.gov/pubmed), which is useful to examine the 
international medical literature; 
- the Ovarian Kaleidoscope Database (OKdb) (http://okdb.appliedbioinfo.net), a public 
database which provides information regarding the known biological function, the 
expression pattern, the mutations identified in human or animal model and a collection 
of all the literature of the genes known to play a role in the ovary. 
Thus, based on the gene content, the rare CNVs identified were classified as possibly related and 
unrelated to POI pathogenesis. Moreover, for the genes possibly related to POI, an association 
score to the disease from 1 (low) to 4 (high) was established. In addition, their classification in 
four functional categories was performed (A, B, C, D).  
To discover interactions between the proteins encoded by target genes several bioinformatic 
tools were interrogated: 
- STRING (http://string-db.org/), medium confidence 0.400, without textmining; 
- ToppGene (https://toppgene.cchmc.org/); 
- geneMania (http://www.genemania.org/). 
 
2.3.2 Analysis of an ad hoc control group 
To find a real enrichment in potentially pathogenic ovarian CNVs in POI women, a comparison 
between array CGH data of patients and controls was performed. Ad hoc control group 
composed by 140 healthy women with normal 46,XX karyotype who had a normal reproductive 
life and reached physiological menopause was used. Array CGH 244K and 400K previously 
performed in our laboratory on 140 control women were analyzed and CNVs classification was 
carried out as in POI patients. Moreover, a POI association score from 1 (low) to 4 (high) to the 
ovarian genes found in controls was assigned.  
A statistical comparison to investigate significant differences between array CGH data of 
patients and controls was performed using the chi-square test. Fisher’s exact test was used to 
evaluate whether the prevalence of the common CNVs was significantly different between POI 
and controls. P-value < 5% assigns a statistically significant test. 
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2.4 Validation and molecular characterization of rare ovarian 
CNVs 
Once a rare ovarian CNV has been identified, a validation following the flow chart described 
below has been performed (Fig.5). 
 
 
 
 
 
 
 
 
Fig.5. Flow-chart used to validate the rare ovarian CNVs.  
 
2.4.1 Validation and molecular characterization of rare ovarian CNVs by qPCR 
To verify that rare “ovarian” CNVs covered by a number of spots between 3 and 5 were not 
fakes, experiments of Real Time PCR on gDNA (qPCR) using the method of SYBR® Green were 
carried out to monitor the fluorescence during the amplification reaction. Moreover qPCR was 
used to characterize the breakpoints of some rare CNVs identified in patients POI 9, 11 and 46 
and to investigate in patients POI 9, 11, 17, 60, 62 and some controls (C_F38, C_F40, C_F77, 
C_F99, C_F103) the “common” rearrangement at 10q26.3 involving SYCE1 gene previously 
associated to the disorder.  
Specific primers for the genomic regions to be investigated were picked by the software Primer3 
(http://frodo.wi.mit.edu/primer3/) (Tab.1). Particularly, the qPCR primers need different 
features compared to the primers normally used in a standard PCR reaction. Before proceeding 
with their order, the following variables have to be modify in the input command: 
Product Size Ranges (n. of bases) →60-100  
Primer size (n. of bases) →Min 18; Opt 20; Max 22  
Primer Tm (°C) →Min 59; Opt 60; Max 63  
Product Tm (°C) →Min 65; Opt 80; Max 90  
Max Self Complementarity →4 
 
rare ovarian CNVs validation 
CNV > 5 spots 3 ≤ CNV ≥ 5 spots 
de novo/inheritance not available  
validated by the spots’ number 
de novo/inheritance not available  
validated by qPCR and LR-PCR 
inherited 
familial validation 
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Tab.1. List of validated and characterized CNVs and qPCR primers used.  
ID POI Gain/Loss qPCR 
Probe 
Primers 
7 Loss in 9p21.3 1 
Primer Forward: AGTCCCAGGAATCAAGGAATC 
Primer Reverse:GAAAAGAGCTTCACAGGCAGTT 
Amplicon: 77 bp 
  2 
Primer Forward: GGCAAATGACAAACACACAAA 
Primer Reverse:TGCTCCAACATCAGACATCC 
Amplicon: 100 bp 
  3 
Primer Forward: CGAACCCTGTAACCTGTTGG 
Primer Reverse:CGCCTGTTTCACCCTATGAA 
Amplicon: 84 bp 
9-11 Loss in 5p13.1 1 
Primer Forward: AGGGGCTTTTGCATACCAC 
Primer Reverse:aactCAACACTGCCCTCTGC 
Amplicon: 66 bp 
  2 
Primer Forward: GGTTGCTGACATTTTGATGC 
Primer Reverse:AATGGAAGGGTAAGCTGTTCTG 
Amplicon: 87 bp 
  3 
Primer Forward: CACATCAAGGCTCCGAATCT 
Primer Reverse:CATGAATTGACTGGGCATAAAG 
Amplicon: 69 bp 
  4 
Primer Forward: GGCTTGGCACAGACTTTCTC 
Primer Reverse:TTGTGGCTATTTCCCAGTCC 
Amplicon: 63 bp 
  5 
Primer Forward: CTCCTACCCCACCACCACTA 
Primer Reverse:CCAAAGTCAGGAAATGAGTTGA 
Amplicon: 74 bp 
  6 
Primer Forward: AATAGCTTAATCCTGGGGAAGG 
Primer Reverse:TATTTGGAATGCCCTTGGTG 
Amplicon: 98 bp 
18 Loss in 14q22.2 1 
Primer Forward: AAGTCTCCAAAAATCGTGCAA 
Primer Reverse:TTCCATACCTGGGTCCATAAA 
Amplicon: 71 bp 
  2 
Primer Forward: TTGAAGGCAGAAGCCCTGT 
Primer Reverse:CAACAACACAGCACAAGATGC 
Amplicon: 68 bp 
  3 
Primer Forward: TGTTGCTGTTATCTTTGCATGG 
Primer Reverse:TCCATTGTTCAGTGCATTCC 
Amplicon: 70 bp 
46 Loss in 15q25.2 1 
Primer Forward: TCCTGCCCTTATTTTCAGCA 
Primer Reverse:CCTTCTTTCCCGTTGACAGT 
Amplicon: 98 bp 
  2 
Primer Forward: CAAAGGTGAGGGAAATGGTC 
Primer Reverse:AAGGAGGAGGAGGAGGATTTT 
Amplicon: 72 bp 
  3 
Primer Forward: GGCTCACCAGGAATAAACGA 
Primer Reverse: CTTTCCGACACAGGAAGGAG 
Amplicon: 61 bp 
  4 
Primer Forward: TGGGATTTGGGGTTTTAGGT 
Primer Reverse: TGAGACAACTCTGGAGCCTTT 
Amplicon: 76 bp 
  5 
Primer Forward: AGCCTGTCTTTCCCTAGCATC 
Primer Reverse: GGCCGTAGAGATGGGGTACT 
Amplicon: 61 bp 
  6 
Primer Forward: ACGCATTCGGTAGTCCAATC 
Primer Reverse: TGACTGTTGTGTGCCCAAGT 
Amplicon: 88 bp 
  7 
Primer Forward: AAGCTCAACCCCAGTCAGTC 
Primer Reverse: GGGATTATTTTGCCACCCTAA 
Amplicon: 84 bp 
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  8 
Primer Forward: CATCCGTAAGTGTGGCTGTG 
Primer Reverse: TAAAATAGCCCTGCCCCAGA 
Amplicon: 93 bp 
  9 
Primer Forward: ACTACCAGGCCACCCAAAG 
Primer Reverse: CTGGCTGAGTTTCGCTTTTT 
Amplicon: 64 bp 
  10 
Primer Forward: CAACGTGCTCTGGGAATACA 
Primer Reverse:TTTGGGGACTCATCACTGGT 
Amplicon: 78 bp 
  11 
Primer Forward: CCTGTGCCTTCCAGAATAGG 
Primer Reverse:TCAACTACTGGGCTGTGTCG 
Amplicon: 72 bp 
  12 
Primer Forward: CCTCTAGGAATGAGGCAGCA 
Primer Reverse: CCGAGGCTTTTTCATGTCA 
Amplicon: 72 bp 
  13 
Primer Forward: CTCGCGCCACACTACCTG 
Primer Reverse:GCTTCACACCTTCGCTTGG 
Amplicon: 70 bp 
  14 
Primer Forward: ACCCCGGCAGCTTATGAA 
Primer Reverse:ACACAGGTGCTCCGCATC 
Amplicon: 74 bp 
  15 
Primer Forward: GTCCTCTTTGGACCGGAGTT 
Primer Reverse: TCCCTTGCCCTATTTCTGTG 
Amplicon: 90 bp 
  16 
Primer Forward: TCCTCTCCTGGCACTTAGGA 
Primer Reverse:CCCTCTCCCCTTAGCCATTA 
Amplicon: 72 bp 
  17 
Primer Forward: TCGTTTCCTCCTCTCTGACC 
Primer Reverse: TGGGCACTATTCTGGGTTTC  
Amplicon: 65 bp 
55 Loss in Xq21.33 1 
Primer Forward: CAGGCTCTTACAAATGGAGCA 
Primer Reverse: GCGGAGTGGAGGGACATATT 
Amplicon: 98 bp 
 
 
2 
Primer Forward: CCACCTTGGGAATTTTGTGT 
Primer Reverse: AGATATTGGGGGCACATCAT 
Amplicon: 60 bp 
  3 
Primer Forward: GTTCTTGTGGCGATGCTTTT 
Primer Reverse: GCCCACTGCTGGAACACTA 
Amplicon: 64 bp 
62 Gain in 20q13.2 1 
Primer Forward: TAGAAAGCAAAGCGGGAGAG 
Primer Reverse:CACCCCCACCCAACTCTT 
Amplicon: 66 bp 
  2 
Primer Forward: TTCAGCTTCTCAACTCCAGGT 
Primer Reverse: AAGTCGTAACCAGCCCAATG 
Amplicon: 69 bp 
 
 
3 
Primer Forward: AAAACAACCAAAAATGGGAAAA 
Primer Reverse: GAGCCCGCTGGGAGTCTA 
Amplicon: 72 bp 
 
 
4 
Primer Forward: GCTGGTCTCAAATGCTCGAT 
Primer Reverse: AAACACTGGATTGGCTGAGTG 
Amplicon: 82 bp 
66 Loss in 2p14 1 
Primer Forward: GCGTCAGTAATAGCCATCAAAA 
Primer Reverse: TTGCACCCAGATATTCAGGA 
Amplicon: 67 bp 
  2 
Primer Forward: ATGGCAGATGAGGAAAATGC 
Primer Reverse: GGCTCTGTGTTGCTGAGGTT 
Amplicon: 71 bp 
  
3 
Primer Forward: GAGGAGGGGGAGCAGTAAAT 
Primer Reverse: ATGGAGAGTCAGAGCCTGGA 
Amplicon: 60 bp 
9-11-17- Gain/Loss in 1 Primer Forward: TGCAGCCAGTTAGGTGAAGA 
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60-62 10q26.3 Primer Reverse:GCAGGGATGTTATCTAGGGTCA 
Amplicon: 78 bp 
  
2 
Primer Forward: TGCCACATCTCACTGTAGGG 
Primer Reverse:GCAGGTGCTCTGTCATGTTC 
Amplicon: 89 bp 
  
3 
Primer Forward: CCCCACTGTCAAGAACCAGT 
Primer Reverse:TCCTCTCCCTAGAACCAGCA 
Amplicon: 67 bp 
  
4 
Primer Forward: CTGCCTCCCACCACTACCT 
Primer Reverse:AGGTCCCTGACATCGAAGG 
Amplicon: 81 bp 
  
5 
Primer Forward: CAGAGGCTTTCGGGAGAAC 
Primer Reverse:TCTTCCCCTGGCTCTTCAC 
Amplicon: 85 bp 
 
Each experiment was performed in triplicate on patients and two controls gDNA. For each 
couple of primers Mix 1 and Mix 2 has been prepared: 
Mix 2  
DNA [10 ng] 
H2O   up to 3 μl 
Total volume 3 μl 
 
 
 
Each qPCR reaction, performed in a final volume of 15 μl, is composed by 12 μl of Mix 1 and 3 μl 
of Mix 2. The reactions were incubated using the ABI Prism 7900 (Applied Biosystem) with the 
SDS software v2.3. The PCR conditions used are the following: 
50 °C 2 min  
95 °C 10 min  
95 °C 15 sec 
x 40 cycles 
60 °C 1 min 
The experiment is analyzed by calculating the "threshold cycle" (Ct) of each reaction using the 
RQ Manager 1.2 software (Applied Biosystem). The gDNA copy number in the regions of 
interest in patients and controls was determined by the 2
-ΔΔCt 
relative quantification method 
[168] using PCNT and FGFR3 as normalizing genes (Tab.2). In this study the values with 
standard deviation over 0.5 were excluded and the results were analyzed by two-tailed 
Student’s t test in order to investigate the statistical significance of the DNA copy number in 
patients compared to controls (p< 0.05). 
 
Mix 1  
SYBR Green PCR Master Mix 
(Applied Biosystem) 2X 
7.5 μl 
Primer Forward (10 pmol/µl) 0.45 μl   
Primer Reverse (10 pmol/µl) 0.45 μl   
H2O 3.6 μl   
Total volume 12 μl   
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Tab.2. List of the normalizing genes qPCR primers.  
Gene Primers 
PCNT  
Primer Forward: TCCAGAACATTCCTTGACAGAG 
Primer Reverse: GTACCCCTCCCAATCTTTGC 
Amplicon: 68 bp 
FGFR3 
Primer Forward: TAGGGTACTTTGGGGCACGA 
Primer Reverse: GCGTTCTGACTTCCACCAG 
Amplicon: 65 bp 
 
2.4.2 Validation and molecular characterization of some rare ovarian CNVs by 
Long Range PCR and Sanger sequencing 
Long Range PCR 
In order to validate and to characterize the breakpoint junctions of the rare ovarian CNVs 
identified in patients POI 3, 8, 10, 44 and 46 we designed specific primer pairs using Primer3 
software (Tab.3). The Long Range PCR (LR-PCR) primers need different features compared to 
the primers normally used in a standard PCR reaction: 
Primer size (n. of bases)→Min 22; Opt 28; Max 34  
Primer Tm (°C) →Min 58; Opt 65; Max 80  
The melting temperature (Tm) of each primer, the respective annealing temperature (Ta) and 
the PCR conditions, were obtained by the software Optimase™ ProtocolWriter 
(www.mutationdiscovery.com). 
Tab.3. List of LR-PCR primers used for CNVs validation and characterization.  
ID 
POI 
Gene 
LR-PCR 
Probe 
Primers 
PCR 
Conditions 
3 RYR3 1 
Primer Forward: CCCTGAACCTTGTTTCTTTCTGTCTAT 
Primer Reverse: AGAGGGAGATAACATCTTACCAGATCA 
Amplicon expected: ~ 6-7 kb 
Tm = 59.9°C 
Tm = 58.4°C 
Ta = 62.2°C 
8-10 TP63 1 
Primer Forward: AGGGACATTACTTCTCTTGCAATCACT  
Primer Reverse: GACAACAGAATGATGAAGGGATTAGAC  
Amplicon expected: ~ 7-8 kb 
Tm = 58.4°C 
Tm = 59.9°C 
Ta = 62.2°C 
44 VLDLR 1 
Primer Forward: CATATCATATATAGGGGAGTTGGCTTA 
Primer Reverse:ATTCCTGATCTTAGGGTGAGAGCAGTC 
Amplicon expected: ~ 6-8 kb 
Tm = 58.4°C 
Tm = 61.3 °C 
Ta = 62.9 °C 
46 CPEB1 1 
Primer Forward: TAGCCATGATCATCAACTAGGACAACA 
Primer Reverse: CTTTTTCATGTCATGGGTTCCTCAG 
Amplicon expected: ~ 3-4 kb 
Tm = 58.4°C 
Tm = 57.8°C 
Ta = 61.1°C 
 
Another test tube containing only the reaction mix with no DNA was prepared as a negative 
control (C-). LR-PCR reactions has been performed using the TaKaRa LA TaqTM kit (TaKaRa), 
mixing the following reagents in a 0.2 ml tube: 
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10X LA PCRTM Buffer II (Mg2+ free) 5 µl 
dNTPs Mixture (2.5 mM) 8 µl 
Forward primer (25pmol/μl) 0.5 µl 
Reverse primer (25pmol/μl) 0.5 µl 
DNA ~100 ng 
TaKaRa LA TaqTM (5U/µl) 0.5 µl 
H2O up to 50 µl 
The reactions are incubated in the iCycler thermocycler (Bio-Rad), with the following 
conditions (the time of elongation at 68°C from 1 to 8 minutes depends on length of the 
amplicon expected):  
94°C  3 min  
94°C  30 sec  
Ta °C (Tab.3)  30 sec   x 35 cycles 
68°C  1-8 min  
72°C  10 min  
4°C  ∞  
 
At the end of the reaction, an agarose gel electrophoresis run (Agarose 0.8% in TAE 1X and Gel 
Red Nucleic Acid Stain) is carried out to assess the real presence of the amplification product, 
loading 5µl of reaction product mixed with 5 µl of Gel Loading Buffer 2X and a marker for 
nucleic acid size determination (StoS1kb DNA Ladder, GeneSpin). The PCR products will serve 
as a template for the subsequent sequencing reaction. 
 
Purification and concentration of PCR products 
Before going on with the sequencing reaction, it is necessary to purify and concentrate the DNA 
obtained from the PCR reaction using the illustra GFX PCR DNA and Gel Band Purification Kit (GE 
Haelthcare). This method uses the silica membrane contained in GFX MicroSpinTM column, 
which binds selectively the DNA. The procedure is the following: 
- add 250 µl of Capture buffer type 3 to up to 50 µl of sample and mix thoroughly;  
- check that the Capture buffer type 3-sample mix is yellow or pale orange in color to verify if 
the pH is optimal (pH ≤ 7.5) for the DNA binding to the silica membrane; 
- for each purification, place one GFX MicroSpin column into one Collection tube; 
- load the Capture buffer type 3-sample mix into the column and Collection tube; 
- spin the assembled column and Collection tube at 16,000 X g for 30 seconds; 
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- discard the flow through by emptying the Collection tube, then place the GFX MicroSpin 
column back inside the same Collection tube; 
- add 500 µl of Wash buffer type 1 to the column and spin at 16,000 X g for 60 seconds; 
- discard the Collection tube and transfer the column to a fresh DNase-free 1.5 ml tube;  
- add 10-50 µl of Elution buffer type 6 to the center of the membrane in the column; 
- incubate at room temperature for 60 seconds; 
- spin the assembled column and 1.5 ml tube at 16,000 X g for 60 seconds to recover the 
purified DNA. Store the purified DNA at -20°C. 
 
Sanger sequencing reaction 
The sequencing reactions were performed in a total volume of 20 μl using the BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystem). The reaction is prepared in a 0.2 ml tube mixing the 
following reagents: 
5X Sequencing Buffer 3.5 µl 
PreMix v3.1 1.6 µl 
Primer Forward or Reverse (3 pmol/µl) (Tab.3,4) 2 µl 
Purified PCR sample 7 µl 
H2O up to 20 µl 
 
The reactions are incubated in the iCycler thermocycler (Bio-Rad), with the following 
conditions:  
95°C 1 min  
95°C 10 sec  
55°C 6 sec  x 35 cycles 
60°C 3 min  
4°C ∞  
Because of method’s limits, other specific primers were chosen in order to read more than 600-
700 bp of target sequence (Tab.4). 
Tab.4. List of primers used for Sanger sequencing of the CNVs breakpoint junction. 
Gene Sequencing Probe Primers 
RYR3 1 LR-PCR probe 1 
 2 
Primer Forward: TTTAGTAGAGGCAGCATTTCATCATGT 
Primer Reverse: AGCAAATCCTCTACCCAGCTTTATTTGT 
TP63 1 LR-PCR probe 1 
 2 
Primer Forward: ATGGGTGAGGAAAAACTCCA 
Primer Reverse: CAAGACCCTGCCCAGTCTAC 
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 3 
Primer Forward: ACGCCCACTAATTTTTGCAC 
Primer Reverse: CAAAAATATTGGAAAGCCACTC    
 4  
Primer Forward: CACAAAAGGGCCAAGAGTGT 
Primer Reverse: GCAAAGCTAAAATGCTTCATCTG 
VLDLR 1 LR-PCR probe 1 
 2 
Primer Forward: GCAGCTGAAGTCTCTTTTTCTTCCTCT 
Primer Reverse:CAGAGATTTGTCCTTTTGAATAAACATGG 
CPEB1 1 LR-PCR probe 1 
 2 
Primer Forward: GCACCTACTTTGCAGACTTCG 
Primer Reverse:TTTGGGGACTCATCACTGGT 
 
Purification of the sequencing product 
The purification of the reaction products was carried out by using CENTRI-SEP Columns kit 
(Applied Biosystems). This step allows to remove the excess of DyeDeoxy™ terminators from 
completed DNA sequencing reactions. The procedure is the following: 
- gently tap the column and ensure that the dry gel has settled in the bottom of the spin column; 
- remove the top column cap and reconstitute the column by adding 800 µl of nuclease-free 
water, then replace the column cap and hydrate the gel by shaking and inverting the column or 
vortexing briefly; 
- allow at least 30 minutes of room temperature hydration time before using the columns; 
- remove air bubbles from the column gel by inverting the column;  
- remove the top column cap and the column end stopper from the bottom, then transfer the 
column into a 2 ml wash tube; 
- spin the assembled column and wash tube at 750 X g for 2 minutes to remove interstitial fluid; 
- discard the wash tube and the interstitial fluid, then transfer the column into a new 1.5 ml 
collection tube; 
- load 20 µL of sequencing reaction onto the center of the gel bed, without disturbing the gel 
surface; 
- spin the assembled column and collection tube at 750 X g for 2 minutes, to collect the sample. 
The purified sample can be stored at -20°C. 
 
Sequencing data processing  
The ABI PRISM 3500 Genetic Analyzer, used in the laboratory, exploits capillary 
electrophoresis as mechanism analysis. These devices use a polymer contained in a capillary that 
acts as a sieve to detect DNA molecules. The result of this analysis is a sequence represented by a 
series of colored peaks corresponding to each nucleotide: the electropherogram. Each sequence 
is analyzed by the ChromasPro program (version 1.5).  
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2.5 Gene expression evaluation on peripheral blood, commercial 
fetus and ovary RNAs 
2.5.1 RNA extraction from peripheral blood 
RNA from peripheral blood was collected using the TempusTM Blood RNA Tube and isolated using 
the TempusTM Spin RNA Isolation Kit (Applied Biosystem) according to manufacturer instructions: 
- draw 3 ml of blood directly into Tempus Blood RNA Tube, which contains 6 ml of Stabilizing 
Reagent that lyses blood cells and inactivates cellular RNases, to make a total volume of 9 ml, 
- shake the tube vigorously to ensure that the Stabilizing Reagent makes uniform contact with 
the sample; it is possible to store Tempus tubes containing stabilized samples for seven days at 
4°C; 
- put the contents of the tube into a clean 50 ml FalconTM tube; 
- add 3 ml of PBS 1X to each sample to bring the total volume to 12 ml; 
- replace the cap on the tube and vortex vigorously for at least 30 seconds; 
- centrifuge the tube at 4°C at 3,000 X g for 30 minutes; 
- carefully pour off the supernatant and leave the tube inverted on absorbent paper for 1 to 2 
minutes; 
- add 400 µL of RNA Purification Resuspension Solution into the tube, then vortex briefly to 
resuspend the RNA pellet; 
- keep the resuspended RNA on ice while preparing for the next steps; 
- insert the filter into a waste collection tube and pre-wet the filtration membrane by adding 100 
μl of RNA Purification Wash Solution 1; 
- transfer the resuspended RNA (~400 μl) into the purification filter and centrifuge at 16000 X g 
for 30 seconds; 
- remove the purification filter, discard the supernatant and re-insert the purification filter into 
the waste tube; 
- add 500 μl of RNA Purification Wash Solution 1 into the purification filter, then centrifuge at 
16000 X g for 30 seconds; 
- remove the purification filter, discard the supernatant and re-insert the purification filter into 
the waste tube; 
- add 500 μl of RNA Purification Wash Solution 2 into the purification filter, then centrifuge at 
16000 X g for 60 seconds; 
- remove the purification filter, discard the supernatant and re-insert the purification filter into 
the waste tube; 
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- perform a DNase treatment: 
a) add 100 μl of AbsoluteRNA Wash Solution into the purification filter, then incubate at room 
temperature for 15 minutes; 
b) add 500 μl of RNA Purification Wash Solution 2 into the purification filter, incubate at room 
temperature for 5 minutes, then centrifuge at 16000 X g for 30 seconds; 
c) remove the purification filter, discard the supernatant and re-insert the purification filter into 
the waste tube. 
- Add 500 μl of RNA Purification Wash Solution 2 into the purification filter, then centrifuge at 
16000 X g for 30 seconds; 
- remove the purification filter, discard the supernatant and re-insert the purification filter into 
the waste tube; 
- centrifuge at 16000 X g for 30 seconds to dry the membrane; 
- transfer the purification filter to a new collection tube; 
- add 100 μl of Nucleic Acid Purification Elution Solution into the purification filter, incubate at 
70°C for 2 minutes, then centrifuge at 16000 X g for 30 seconds; 
- pipet the collected RNA eluate back into the purification filter and centrifuge at maximum 
speed (16,000 -18,000 X g) for 2 minutes; 
- discard the purification filter, then transfer approximately 90 µl of the RNA eluate to a new 
collection tube. Extracted RNA can be stored at – 80°C for long-term storage. 
The concentration and quality of the RNA are determined by a spectrophotometric analysis 
using the NanoDrop ND-1000 UV-VIS Spectrophotometer.  
 
2.5.2 Reverse Transcription 
To obtain cDNA the High Capacity cDNA Reverse Transcription Kit was used (Applied Biosystem). 
For each sample the following reaction mix using 500 ng of RNA is prepared in a 0.2 ml tube: 
10X RT Buffer 2 μl 
dNTP Mix 100 mM 0.8 μl 
RT Random Primers 10X 2 µl 
RNase Inhibitor 1 µl 
MultiScribeTM Reverse Trascriptase 1 µl 
RNA 500 ng 
DEPC H2O up to 20 μl 
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The reaction is incubated in the iCycler thermocycler (Bio-Rad) and the reverse transcription 
conditions used are the following: 
25°C 10 min 
37°C 2 hours 
85°C 5 min 
4°C ∞ 
At the end of the reaction the cDNA is stored at -20°C. 
 
2.5.3 Polymerase Chain Reaction (PCR) 
With the purpose to assess the expression of the 37 genes (and 1 non-coding RNA) involved in 
the rare CNVs on RNA from peripheral blood, commercial fetus and ovary (Human Fetus, Whole 
Poly A+ RNA and Human Ovary Poly A+ RNA, Clontech), PCR reactions on cDNA has been 
performed by the AmpliTaq Gold® kit (Applied Biosystems).  
The forward and reverse primers used were specific for the exon junctions in order to amplify 
only the cDNAs. The software Primer3 standard PCR conditions are reported below (Tab.5): 
Primer size (n. of bases)→Min 18; Opt 20; Max 27  
Primer Tm (°C) →Min 57; Opt 6; Max 63  
The melting temperature (Tm) of each primer, the respective annealing temperature (Ta) and 
the PCR conditions, have been obtained by Optimase™ ProtocolWriter. 
Tab.5. List of primers used for the PCR reaction on cDNA. 
AMFR 
Primer Forward 
Primer Reverse 
Amplicon 
GCCCTCTTCGAGTGAGTGAG 
GATCCTTGCAGAGCTGAACC  
180 bp 
Tm = 58.3°C 
Tm = 56.3°C 
Ta = 60.3°C 
BMP4 
Primer Forward 
Primer Reverse 
Amplicon 
TGAGCCTTTCCAGCAAGTTT 
GCGCAGCCCAAACATC 
288 bp 
Tm = 52.2°C 
Tm = 51.8°C 
Ta = 55.0°C 
BNC1 
Primer Forward 
Primer Reverse 
Amplicon 
CCAGGTGGAGATTGTCCAGT 
CTCCAAAACGAAGGAACTGC 
284 bp 
Tm = 56.3°C 
Tm = 54.2°C 
Ta = 58.3°C 
BRDT 
Primer Forward 
Primer Reverse 
Amplicon 
ATGCGAAGGCTTCAGAATGT 
TGCTCTTCTTGTGGCATCTG 
151 bp 
Tm = 52.2°C 
Tm = 54.2°C 
Ta = 56.2°C 
BTBD1 
Primer Forward 
Primer Reverse 
Amplicon 
CAAAAGCACAATGGATGCAA 
CCTGCTGCAAATTCCTCAAT 
252 bp 
Tm = 50.1°C 
Tm = 52.2°C 
Ta = 54.2°C 
CAPZA1 
Primer Forward 
Primer Reverse 
Amplicon 
TCGGATGAGGAGAAGGTACG 
AGGCGTGAACTGATCCATGT 
168 bp 
Tm = 56.3°C 
Tm = 54.2°C 
Ta = 58.3°C 
CPEB1 
Primer Forward 
Primer Reverse 
Amplicon 
CCAAAGACCCCTTCAGCATA  
ATACCCTTTGGGAGGACACC  
263 bp  
Tm = 54.2°C 
Tm =  56.3°C 
Ta = 58.3°C 
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CYP2E1 
Primer Forward 
Primer Reverse 
Amplicon 
CGTGGAAATGGAGAAGGAAA  
GGTGATGAACCGCTGAATCT  
277 bp 
Tm = 52.2°C 
Tm = 54.2°C 
Ta = 56.2°C 
DDX1 
Primer Forward 
Primer Reverse 
Amplicon 
GAGGAATTGATATCCACGGTGT 
CAGCCTCCATCTTCCTTGAG 
217 bp 
Tm = 55.1°C 
Tm = 56.3°C 
Ta = 58.7°C 
DIAPH2 
Primer Forward 
Primer Reverse 
Amplicon 
ATGTGCGTGACCGAATTACA  
CCGGATTGCTGGTTAAAGAA 
423 bp 
Tm = 52.2°C 
Tm = 52.2°C 
Ta = 55.2°C 
DIAPH2-AS1  
Primer Forward 
Primer Reverse 
Amplicon 
CAGCCGGACTGTCTTGAAAC  
TTGCATCGAGTTGTTATGTCTTC  
300 bp 
Tm = 56.3°C 
Tm = 53.7°C 
Ta = 58.0°C 
EEF2 
Primer Forward 
Primer Reverse 
Amplicon 
AGCGAGGACAAGGACAAAGA  
CCGAGAAGACTCGTCCAAAG  
283 bp 
Tm = 54.2°C 
Tm = 56.3°C 
Ta = 58.3°C 
ELAVL2 
Primer Forward 
Primer Reverse 
Amplicon 
GAGCTTGGGATATGGCTTTG  
GCTTCTTCTGCCTCAATTCG  
312 bp  
Tm = 54.2°C 
Tm = 54.2°C 
Ta = 57.2°C 
FZD6 
Primer Forward 
Primer Reverse 
Amplicon 
TCGCAAATCTGGAATGTTCA  
ATGCCTTGGACACCAAAATC  
302 bp 
Tm = 50.1°C 
Tm = 52.2°C 
Ta = 54.2°C 
GRIA1 
Primer Forward 
Primer Reverse 
Amplicon 
CTGTGAATCAGAACGCCTCA 
TTGGGTCTCTTCCAGTCCAC 
252 bp 
Tm = 54.2°C 
Tm = 56.3°C 
Ta = 58.3°C 
HBE1 
Primer Forward 
Primer Reverse 
Amplicon 
GAATGTGGAAGAGGCTGGAG 
ACCATCACGTTACCCAGGAG 
279 bp 
Tm = 56.3°C 
Tm = 56.3°C 
Ta = 59.3°C 
IMMP2L 
Primer Forward 
Primer Reverse 
Amplicon 
TGCAGCCTTCTTTGAATCCT 
CCGGTTTTTGTGTCCTATGG 
197 bp 
Tm = 52.2°C 
Tm = 54.2°C 
Ta = 56.2°C 
LRIG2 
Primer Forward 
Primer Reverse 
Amplicon 
CCGCTATCCTGGATTTCAGT 
CTGGAGTGCCTGTGCATTTA 
194 bp 
Tm = 54.2°C 
Tm = 54.2°C 
Ta = 57.2°C 
MAP2K2 
Primer Forward 
Primer Reverse 
Amplicon 
AGGAAGCTGATCCACCTTGA  
ATGTTGGAGGGCTTCACATC  
302 bp 
Tm = 54.2°C 
Tm = 54.2°C 
Ta = 57.2°C 
MOV10 
Primer Forward 
Primer Reverse 
Amplicon 
GACCCCCAGTTCATAACCAA 
TTACGCCGTGAAAGATGATG 
184 bp 
Tm = 54.2°C 
Tm = 52.2°C 
Ta = 56.2°C 
MSL3 
Primer Forward 
Primer Reverse 
Amplicon 
TCTTAAAAGGCCTCCCCACT  
GTTGGTCTGGCATGGAAGTT  
281 bp 
Tm = 54.2°C 
Tm = 54.2°C 
Ta = 57.2°C 
MYCN 
Primer Forward 
Primer Reverse 
Amplicon 
CCCTGAGCGATTCAGATGAT 
AGGATCAGCTCGCTGGACT 
184 bp 
Tm = 54.2°C 
Tm = 55.9°C 
Ta = 58.1°C 
NRP1 
Primer Forward 
Primer Reverse 
Amplicon 
GAGAGAACAAGGTGTTCATGAGG 
CGTGGAGAGAGCTGGAAAAG 
161 bp 
Tm = 57.2°C 
Tm = 56.3°C 
Ta = 59.8°C 
PARD3 
Primer Forward 
Primer Reverse 
Amplicon 
ATTAATGATGGCGACCTTCG 
AGGGCTAAAACGGCTTGAAT 
174 bp 
Tm = 52.2°C 
Tm = 52.2°C 
Ta = 55.2°C 
PCSK5 
Primer Forward 
Primer Reverse 
Amplicon 
GCCAGCAAGTACGGATTCAT 
ATCCCTCTTTGTCCGCTTTT 
186 bp 
Tm = 54.2°C 
Tm = 52.2°C 
Ta = 56.2°C 
PRKAA1 
Primer Forward 
Primer Reverse 
Amplicon 
CCTCAAGCTTTTCAGGCATC  
CGCCGACTTTCTTTTTCATC  
198 bp 
Tm = 54.2°C 
Tm = 52.2°C 
Ta = 56.2°C 
RHOC 
Primer Forward 
Primer Reverse 
Amplicon 
AAGGATCAGTTTCCGGAGGT 
ATGTTTTCCAGGCTGTCAGG 
206 bp 
Tm = 54.2°C 
Tm = 54.2°C 
Ta = 57.2°C 
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RREB1 
Primer Forward 
Primer Reverse 
Amplicon 
CAGAAGGAACCAGGAAACGA 
TCAGTGACTTTCCGCAGATG 
161 bp 
Tm = 54.2°C 
Tm = 54.2°C 
Ta = 57.2°C 
RUNX2 
Primer Forward 
Primer Reverse 
Amplicon 
GACAGCCCCAACTTCCTGT 
CCGGAGCTCAGCAGAATAAT 
159 bp 
Tm = 55.9°C 
Tm = 54.2°C 
Ta = 58.1°C 
RYR3 
Primer Forward 
Primer Reverse 
Amplicon 
CACAGGAGAAGCCTGTTGGT  
GTGCTGGGAATCATTCTGGT  
310 bp 
Tm = 56.3°C 
Tm = 54.2°C 
Ta = 58.3°C 
SH3GL3 
Primer Forward 
Primer Reverse 
Amplicon 
CTTACCTGGACCTCCCAACA  
CATTGCCAAAGGTGGAGTCT  
313 bp  
Tm = 56.3°C 
Tm = 54.2°C 
Ta = 58.3°C 
SIRT6 
Primer Forward 
Primer Reverse 
Amplicon 
GAGAGCTGAGGGACACCATC  
CATGACCTCGTCAACGTAGC  
251 bp 
Tm = 58.3°C 
Tm = 56.3°C 
Ta = 60.3°C 
SLC5A5 
Primer Forward 
Primer Reverse 
Amplicon 
GCGGGACTTTGCAGTACATT 
GTCCAGACCACAGCCTTCAT 
175 bp 
Tm = 54.2°C 
Tm = 56.3°C 
Ta = 58.3°C 
SLMAP 
Primer Forward 
Primer Reverse 
Amplicon 
TCAGAAATTGAGGCAAAGCA  
AACCTTTGCTGCTGCTTGAT 
312 bp 
Tm = 50.1°C 
Tm = 52.2°C 
Ta = 54.2°C 
SMYD3 
Primer Forward 
Primer Reverse 
Amplicon 
CAGGCAATCATAAGCAGCAA 
TCTTCATTGCTTGGGGAAAC 
247 bp 
Tm = 52.2°C 
Tm = 52.2°C 
Ta = 55.2°C 
SUPT3H 
Primer Forward 
Primer Reverse 
Amplicon 
TGGATCTGGCTCTTCTTGTG 
TGTGAGCCTCAACACCACAG 
135 bp 
Tm = 54.2°C 
Tm = 56.3°C 
Ta = 58.3°C 
SYCE1 
Primer Forward 
Primer Reverse 
Amplicon 
TTGCCAGGAAAAGGAAAGTG 
 TGATGCTTCACGTCTTCCAG  
291 bp 
Tm = 52.2°C 
Tm = 54.2°C 
Ta = 56.2°C 
TM6SF1 
Primer Forward 
Primer Reverse 
Amplicon 
ACGCAATTTCAAGAGCCCTA  
AACGATAGGCCAAGAGCTGA 
310 bp 
Tm = 52.2°C 
Tm = 54.2°C 
Ta = 56.2°C 
TP63 
Primer Forward 
Primer Reverse 
Amplicon 
CCACCTTCGATGCTCTCTCT  
GGATAACAGCTCCCTGAGGA  
216 bp  
Tm = 56.3°C 
Tm = 56.3°C 
Ta = 59.3°C 
TSHZ2 
Primer Forward 
Primer Reverse 
Amplicon 
ACTCCAGCTGGGGATACAGA  
TGGTAGCTGAAGCAGCCTTT  
252 bp 
Tm = 56.3°C 
Tm = 54.2°C 
Ta = 58.3°C 
VLDLR 
Primer Forward 
Primer Reverse 
Amplicon 
CCAATTCCAGTGCACAAATG 
TGAACCATCTTCGCAGTCAG 
196 bp 
Tm = 52.2°C 
Tm = 54.2°C 
Ta = 56.2°C 
WHAMM 
Primer Forward 
Primer Reverse 
Amplicon 
GGCAACCATGTTCTTCCAGT  
CGCATCCTGTTCCATTTCTT 
262 bp 
Tm = 54.2°C 
Tm = 52.2°C 
Ta = 56.2°C 
XPO1 
Primer Forward 
Primer Reverse 
Amplicon 
CAGCAAAGAATGGCTCAAGA 
TATTCCTTCGCACTGGTTCC 
183 bp 
Tm = 52.2°C 
Tm = 54.2°C 
Ta = 56.2°C 
ZNF217 
Primer Forward 
Primer Reverse 
Amplicon 
GGAAGGTGGTTCTGAAGACG  
CGCACTGTCAGCGGTTAATA  
346 bp 
Tm = 56.3°C 
Tm = 54.2°C 
Ta = 58.3°C 
Another test tube containing only the reaction mix with no cDNA has been prepared as a 
negative control (C-). PCR reactions are set up in 0.2 ml sterile tubes mixing the following 
reagents: 
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10X PCR Gold Buffer 2.5 μl 
25 mM MgCl2 (2.5 mM) 2 μl 
dNTPs (2 mM) 2.5 μl 
Primer Forward (25 pmol/µl) 1 μl 
Primer Reverse (25 pmol/µl) 1 μl 
AmpliTaq Gold DNA Polymerase (5U/ µl) 0.25 µl 
cDNA template 1 µl 
H2O up to 25 μl 
The reactions are incubated in the iCycler thermocycler (Bio-Rad), the time and temperature 
conditions used are the following: 
95°C  5 min  
95°C  30 sec  
Ta °C (Tab.5)  30 sec  x 35 cycles 
72°C  30 sec  
72°C  5 min  
4°C  ∞  
At the end of the reaction, purification of PCR product is performed as previously described in 
paragraph 2.4.2. An agarose gel electrophoresis run (Agarose 2% in TAE 1X and Gel Red Nucleic 
Acid Stain) is then carried out to assess the real presence of the amplification product, loading 
5µl of reaction product mixed with 5 µl of Gel Loading Buffer 2X and a marker for nucleic acid 
size determination (ФX174 DNA/HaeIII 50 μg/μl, Invitrogen).  
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2.6 Transcript relative quantification analysis by Real Time RT-
PCR 
Only for 4 out of 67 patients (POI 6, 9, 10, 11), RNA samples were available. RNA extraction and 
retrotranscription reactions were carried out as explained in paragraph 2.5.1 and 2.5.2. To 
evaluate the presence of a quantitative alteration in the transcript levels of the interested genes 
DIAPH2, TP63, and PRKAA1, involved in rare CNVs, Real Time RT-PCR experiments were 
carried out using the universal protocol TaqMan (Applied Biosystem). Particularly, to investigate 
the transcript amount of the genes previously cited and of the genes used as housekeeping (TBP, 
GUSB, RPLP0, HMBS), commercial TaqMan probes, recommended for these genes and cDNA 
specific, were selected from the on-line shop at www.appliedbiosystems.com (Tab.6 and 7).  
Tab.6. List of the TaqMan assays of the target genes used for RT-qPCR analyses. The rearrangements 
involving the genes are summarized and the housekeeping genes used are shown.  
Gene Position ID Assay 
Amplicon 
lenght 
Housekeeping gene 
DIAPH2 (NM_007309) 
Intronic gain between ex 26-27 
ex 15-16 Hs00246501_m1 62 bp TBP, GUSB*, RPLP0 
ex 26-27 Hs00963595_g1 65 bp TBP, GUSB*, RPLP0 
TP63 (NM_003722) 
Intragenic gain from ex 2 to 10 
ex 7-8 Hs00978343_m1 85 bp TBP, GUSB, RPLP0* 
ex 11-12 Hs00978347_m1 76 bp TBP, GUSB, RPLP0* 
PRKAA1 (NM_206907) 
Intronic loss between ex 1-2 
ex 1-2 Hs01562307_mH 60 bp  GUSB, RPLP0, HMBS 
ex 9-10 Hs01562315_m1 118 bp GUSB, RPLP0, HMBS 
*the normalization graphical view is shown in results. 
 
 
Tab.7. List of the TaqMan assays of the housekeeping genes used for the RT-qPCR analyses. 
Gene ID Assay Amplicon lenght 
HMBS Hs00609297_m1 64 bp 
GUSB Hs00939627_m1 96 bp 
RPLP0 Hs99999902_m1 105 bp 
TBP Hs00427620_m1 91 bp 
 
Two TaqMan assays were chosen for each genes, one “outside” the rearrangements, and the 
other “inside” them (Tab.6). The experiments were performed on the patients and 10 healthy 
controls (both male and female) without any CNVs involving the target genes; one 
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retrotranscription of about 500 ng for each sample was made and the reactions were performed 
in triplicate. 
The reactions have been set up in a 96-plate, preparing a Mix 1 for each genes, and a Mix 2 for 
each retrotranscription in a final volume of 10 μl: 
 
Mix 1  Mix 2 
Master Mix (Applied Biosystem) 2X 5 μl DNA 2.5 μl 
Assay TaqMan 20X 0.5 μl H2O 1 μl 
H2O 1 μl Total volume 3.5 μl 
Total volume 6.5 μl   
Each experiment was replicated three times using different housekeeping genes. The details are 
shown in Tab.6. The reactions were performed using the ABI Prism 7900 (Applied Biosystem) 
with the SDS software v2.3, and the PCR conditions used are the following: 
50 °C 2 min  
95 °C 10 min  
95 °C 15 sec 
x 40 cycles 
60 °C 1 min 
 
At the end of Real Time RT-PCR, the experiment is analyzed calculating the “threshold cycles” 
of each PCR by the program RQ Manager 1.2 (Applied Biosystem). For each assay the transcript 
amount of the target genes in POI women and in healthy controls was determined using the 
relative quantification method of 2-ΔΔCt, and the housekeeping genes as normalizers. 
In these analyses the standard deviation values greater than 0.5 were excluded and the results 
obtained were analyzed by Student t-test with the aim to investigate a statistically significant 
value relative to the transcript amount of the patients compared to controls (p< 0.05). 
 
2.6.1VLDLR: position effect assessment 
RT-qPCR with Syber Green assays were performed in POI 44 using GAPDH as normalizing 
gene. PCR and Sanger sequencing were used for heterozygosity analysis on VLDLR. Luciferase 
assay using pGL3 vector (SV40 promoter) was carried out both on HeLa and COV434 cell lines, 
whereas pGL3b vector (VLDLR promoter) was transfected only in COV434 cell line. The 
analyses were performed thanks to a collaboration with Dott.ssa Caslini Cecilia, Department of 
Medical Biotechnology and Translational Medicine.  
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2.7 Whole Exome Sequencing preliminary analysis 
Thanks to a collaboration with the Genetics of common disorders Lab. at San Raffaele Hospital, 
WES analysis was carried out for 17 out of 67 POI women. The raw data (Fastq files) obtained 
were processed through a in-house pipeline. Briefly, using BWA software, the Fastq data of each 
sample were concatenated, indexed, and aligned to a reference genome (assembling hg19) 
generating a SAM file. Then, using SAMtools, the data were sorted, indexed and PCR duplicated 
were excluded; finally total BAM files were created. Quality control and estimation of bad 
coverage were investigated using FastQC and BEDtools, respectively. Variant calling of each 
exome analysis was performed using GATK [169], and VCF files were created.  
The preliminary analysis performed consists in a filtering based on 191 genes composed by: 
- 41 genes derived from array CGH results; 
- 135 genes implicated in non-syndromic form of POI, or in syndromic POI, or in ovarian 
growth and development. Namely, the selection of most of them was performed 
considering the supplementary tables S14, and S15 of the paper by Day Felix [155], which 
includes genes associated to POI and ovarian genes, respectively; 
- 15 genes known to be interactors of VLDLR, TP63, CPEB1 (data obtained from STRING 
analysis). 
A coordinate BED file related to the target genes was created. Table browser of UCSC was used 
and only exonic sequences were considered. 
VCF files of each patients were intersected with the BED file created using BEDtools and a new 
targeted VCF file was obtained. Then, annotation of the variants was carried out using 
wANNOVAR (http://wannovar.usc.edu/index.php) on-line software and a CSV file for each 
patient was created. 
To prioritize rare variants with potentially pathogenetic role in POI, several filtering steps were 
carried out as shown in Fig.6. In Step 1, irrelevant variants were excluded, namely synonymous 
and variants mapping in repeated regions (e.g. locus AR), whereas in Step 2 variants covered by 
more than 20 reads were considered. Based on the information provided by the 1000 Genomes 
Project (http://1000genomes.org/) and ExAC Variant Server (http://exac.broadinstitute.org/), 
variants falling above > 0.5% in the 1000G Project (Step 3) were considered not rare and were 
filtered out as well as ExAC variants exceeding 5% (Step 4). 
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Fig.6. Flowchart used for WES data analysis. 
 
The obtained variants were then analyzed using several databases to establish their potential 
pathogenicity:  
- dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), 
- Ensembl (http://www.ensembl.org/index.html), 
- SIFT (http://sift.bii.a-star.edu.sg/)[170], 
- PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/)[171], 
- MutationTaster (http://www.mutationtaster.org/)[172],  
- ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/), 
- HGMD (http://www.hgmd.cf.ac.uk/ac/index.php). 
The variants with almost two of the following features were excluded because considered 
benign/likely benign (Step 5). 
- unreported in HGMD,  
- reported as benign, probably non pathogenic in ClinVar (when available), 
- predicted benign/likely benign in almost two out of the three prediction softwares used. 
 
2.7.1 Sanger sequencing validation (in progress) 
As final step, the direct sequencing using the classical Sanger method was performed to validate 
the variants identified (16 SNVs have been analyzed till now; Tab.8). PCR and Sanger 
sequencing reactions, as well as purification steps have been carried out as described in 
paragraph 2.4.2. 
Tab.8. List of primers used for the PCR and sequencing reactions. 
ID POI Gene Primers PCR Conditions 
49 SIRT6 Primer Forward: ACCATGCACCCTCTGTCC 
Primer Reverse: CTTGGCCTTCACCCTTTTG 
Tm = 55.4°C 
Tm = 53.7°C 
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Amplicon: 350 bp Ta =57.6°C 
50 POF1B Primer Forward:TTCCTAAAATATGTCCCATTACACAA 
Primer Reverse: AGATTTTAATTTGGGACTTTCTGTTC 
Amplicon: 270 bp 
Tm = 53.3°C 
Tm = 53.3°C 
Ta =56.3°C 
 RAD51C Primer Forward: TCTGTTGCCTTGGGGAGTAT 
Primer Reverse: GGTCTCAGATGGGCACAAAT 
Amplicon: 370 bp 
Tm = 54.2°C 
Tm = 54.2°C 
Ta =57.2°C 
 WHAMM Primer Forward: TTGAGAACATGAAGGTTTCTTTT 
Primer Reverse: TGGTAAACCCAAACAAAGTACAAA 
Amplicon: 379 bp 
Tm = 50.1°C 
Tm = 52.4°C 
Ta =54.3°C 
54 RREB1 Primer Forward: TGAACTGACTTCTTTGTTAGATCACAT 
Primer Reverse: GGGAAAACACACGTTAAGAGC 
Amplicon: 323 bp 
Tm = 55.2°C 
Tm = 54.7°C 
Ta =58.0°C 
 PCSK5 Primer Forward:CCTGACCACCATGTTTTTCC Tm = 54.2°C 
  Primer Reverse:AGTCGGATGGCATCTCTCAC Tm = 56.3°C 
  Amplicon: 282 bp Ta =58.3°C 
55 HFM1 Primer Forward: CCTCATCATTAAATATTGTCAGAATC 
Primer Reverse: GAGTGTGGCAGTGCAGACAT 
Amplicon: 288 bp 
Tm = 53.3°C 
Tm = 56.3°C 
Ta =57.8°C 
 ADAMTS19 Primer Forward: ATCTCCATGTATGGGCCTTG 
Primer Reverse: CGGGGCATTAACCAAAACTA 
Amplicon: 320 bp 
Tm = 54.2°C 
Tm = 52.2°C 
Ta =56.2°C 
 SH3GL3 Primer Froward: GCTAGGTCTTTGCTGCTGGT 
Primer Reverse: GAAGGGGGAGATGGAGAGAT 
Amplicon: 286 bp 
Tm = 56.3°C 
Tm = 56.3°C 
Ta=59.3°C 
 RELN Primer Forward: TGTGATGCCATGATAGGAAGA 
Primer Reverse: AGGTGGAGCAATCCAGATGA 
Amplicon: 177 bp 
Tm = 52.7°C 
Tm = 54.2°C 
Ta =56.5°C 
 POU5F1 Primer Forward: CGCCGTATGAGTTCTGTGG 
Primer Reverse: AGGTGACCACTTCCCCATC 
Amplicon: 288 bp 
Tm = 55.9°C 
Tm = 55.9°C 
Ta =58.9°C 
57 RYR3 PrimerForward: CCAACTTCTCTACATCCTCAACC 
Primer Reverse: CACCAACCCCCTATTTTCAG 
Amplicon: 354 bp 
Tm = 57.2°C 
Tm = 54.2°C 
Ta =58.7°C 
60 FMR1 Primer Forward: ACCTGCTGTTCACCAGATCC 
Primer Reverse: CAGTGTTTTGCACAGGCTAGA 
Amplicon: 300 bp 
Tm = 56.3°C 
Tm = 54.7°C 
Ta =58.5°C 
63 CYP19A1 Primer Forward: CACATTGCATTTGGAGCAAC 
Primer Reverse: AAAAGGCACATTCATAGACAAAAA 
Amplicon: 324 bp 
Tm = 52.2°C 
Tm =50.7°C 
Ta =54.5°C 
65 GALT Primer Forward: GGGTTTCTTGGCTGAGTCTG 
Primer Reverse: TGCTAAGGCCTCCTAGCAAGT 
Amplicon: 386 bp 
Tm = 56.3°C 
Tm = 56.6°C 
Ta =59.5°C 
67 VLDLR Primer Forward: TTCTAGCATGGCATGTTCAGTT 
Primer Reverse: AGAGAAACAAAGAAGAGAGATTCCA 
Amplicon: 290 bp 
Tm = 53.2°C 
Tm = 54.8°C 
Ta =57.0°C 
Furthermore this approach will be necessary to: i) cover the regions with low capture efficiency 
or bad sequencing coverage (< 20); ii) confirm they are not fakes emerged from sequencing or 
analysis irregularities.  
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3.1 Identification and classification of CNVs 
A cohort of 67 POI women was analyzed by high resolution array CGH to identify CNVs 
possibly implicated in POI pathogenesis. In 58 out of 67 patients (86.6%), rare CNVs (one or 
more) not yet reported in healthy subjects according to the DGV were detected. The group 
consists of: 
- 46 sporadic (79.3%) and 12 familial (20.7%) cases, including five sisters pairs, and two 
patients with a relative affected with POF (not included in the analyzed cohort). 
- 7 patients analyzed by array CGH 244K and 51 by higher resolution array CGH 400K. 
The detection rate for rare CNVs using the genome wide analysis was approximately 77.8% and 
87.9% for the patients processed with 244K and 400K, respectively.  
Overall 101 rare CNVs were detected, ranging from 5 kb to 1.7 Mb, including 45 gains (44.6%) 
and 56 losses (55.4%). Among them, 4 out of 101, 2 duplications and 2 deletions, were 
homozygous CNVs. The inheritance for 81 CNVs (80.2%) is unknown. None of the remaining 20 
CNVs was de novo, being all inherited, 12 from the father (60%) and 7 from the mother (35%). In 
one patient the homozygous CNV was inherited from both the consanguineous parents (5%).  
A detailed list of the identified rare CNVs is shown in Tab.9.  
Furthermore, high-resolution array CGH analysis allowed to identify in a subset of the POI 
cohort a few CNVs already reported in the DGV. Nevertheless these are “common” CNVs 
containing genes previously associated with the disorder (NAIP, DUSP22, SYCE1) [152,161], that 
were selected as putative loci for POI susceptibility. In detail: 
- 5 CNVs involving NAIP at 5q13.2 (1 duplication and 4 deletions), 
- 16 CNVs involving DUSP22 at 6p25.2 (5 duplications and 11 deletions),  
- 5 CNVs involving SYCE1, CYP2E1 at 10q26.3 (4 duplications and 1 deletion) (Tab.10). 
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Tab.9. Rare CNVs identified in the POI cohort by means of array CGH analysis 
POI ID 
Chromosomal 
Band 
Gain/ Loss Het/ Hom Size 
N° of 
genes 
Gene(s) Nucleotide position# Inheritance 
Array-CGH 244K        
1 4q32.1 Gain het 43 kb 1 GLRB chr4:158085813-158129097 NA 
 7q11.22 Loss het 28 kb 1 CALN1 chr7:71826130-71854571 NA 
3 15q14 Loss het 26 kb 1 RYR3 chr15:34125784-34151995 NA 
4 11q22.3 Loss het 221 kb - (GRIA4) chr11:105126944-105347752 NA 
6 Xq21.33 Gain het 53 kb 2 DIAPH2, DIAPH2-AS1 chrX:96774546-96827670 Pat 
7 6q24.1 Loss het 93 kb - - chr6:140576639-140669614 NA 
 9p21.3 Loss het 68 kb  - (ELAVL2) chr9:24242825-24310533 NA 
 9p21.3 Loss het 79 kb  - - chr9:24426310-24505824 NA 
8* 2q24.3 Loss het 6.5 kb 1 XIRP2 chr2:168116199-168122776 Pat 
 2q32.3 Loss het 20.5 kb  1 SDPR chr2:192679673-192700138 Pat 
 3q28 Gain het 158.5 kb 1 TP63 chr3:189427139-189585621 Pat 
 9p22.2 Loss het 59 kb 1 CNTLN chr9:17298850-17357754 Pat 
9* 2q37.2 Loss het 13 kb  1 AGAP1 chr2:236489321-236502202 Mat 
  5p13.1 Loss het 6.5 kb  1 PRKAA1 chr5:40779232-40785703      Pat 
Array-CGH 400K        
10* 2q24.3 Loss het 6.5 kb  1 XIRP2 chr2:168116199-168122776 Pat 
 3q28 Gain het 161 kb 1 TP63 chr3:189427139-189588477 Pat 
 7p14.1 Gain het 144 kb 1 CDK13 chr7:39999692-40144263 Mat 
 9p22.2 Loss het 69 kb 1 CNTLN chr9:17295644-17364986 Pat 
11* 2q37.2 Loss het 17 kb 1 AGAP1 chr2:236484897-236502202  Mat 
 5p13.1 Loss het 6.5 kb  1 PRKAA1 chr5:40779232-40785703 Pat 
 18q21.33 Loss het 9 kb  - (ZCCHC2, TNFRSF11A) chr18:60098813-60108560 Pat 
 Xp22.33 Gain het 59 kb 3 ASMTL, P2RY8, CRLF2 chrX:1553947-1612474 Pat 
12 4p15.1 Loss het 231 kb - (PCDH7) chr4:31744797-31975862 NA 
 58 
 
 
6p25.1-24.3 Gain het 36 kb 1 RREB1 chr6:7075538-7111544 NA 
13 1q44 Gain het 523.5 kb 1 SMYD3 chr1:246168808-246692300 NA 
 1q44 Gain het 321 kb 5 AHCTF1, ZNF695, ZNF670, ZNF669, 
ZNF124 
chr1:247088226-247409060 NA 
 11p15.4 Gain het 42 kb 3 HBG2, HBE1, OR51B5 chr11:5454730-5496463 NA 
14 Xp11.22 Loss hom 36 kb 1 BMP15 chrX:50653777-50689335 Mat, Pat
§ 
15* 15q26.1 Loss het 58 kb 1 ABHD2 chr15:89595324-89652892 Mat 
16* 8q21.3 Gain het 25 kb 1 TMEM64 chr8:91704940-91730316 Mat
¥ 
17 9p13.3 Loss het 12 kb  1 KIF24 chr9:34280912-34293051 NA 
18 14q22.2 Loss het 20 kb  - (BMP4) chr14:54195768-54215968 NA 
19 Xq28 Loss het 106 kb  - (GABRA3, GABRQ) chrX:151638056-151743864 NA 
20* 7p21.3 Loss het 19 kb - - chr7:10795079-10814265 Mat 
21* 7q22.3 Loss het 24 kb - - chr7:107262480-107286241 Mat 
23 8q13.3 Loss het 31 kb 1 XKR9 chr8:71613753-71645051 NA 
 9q32 Loss het 13 kb  - - chr9:115698459-115711373 NA 
24 21q21.1 Loss het 32 kb  1 NCAM2 chr21:22418118-22450219 NA 
25 1p13.2 Gain het 91 kb  - (MOV10, RHOC, PPM1J, FAM19A3,CAPZA1, 
SLC16A1, LRIG2) 
chr1:113339006-113430121 NA 
 1q31.3 Gain het 310 kb  - - chr1:194012929-194322620 NA 
26 5q34 Gain het 772.5 kb 2 GABRB2, ATP10B chr5:160019212-160791695 NA 
27 15q21.1 Gain het 41 kb  1 SORD chr15:45319178-45360400 NA 
 Xp11.21 Loss het 5 kb  - - chrX:56093719-56098999 NA 
 Xq13.3 Loss het 54 kb  - - chrX:74772380-74826319 NA 
28 2p22.3p22.2 Gain hom 23 kb  - (CRIM1) chr2:35967990-35990844 NA 
 17q12 Loss het 16 kb  1 ASIC2 chr17:32130833-32146606 NA 
29 5q22.2 Loss het 13 kb  1 APC chr5:112179040-112192379 NA 
30 4q26 Gain het 22 kb   - (NDST4) chr4:115711838-115734119 NA 
31 3p23 Gain het 447 kb 1 GADL1 chr3:30914366-31361404 NA 
33 8p23.1 Loss het 101 kb  1 ERI1 chr8:8790358-8891761 NA 
Tab.9. Continued 
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9q21.13 Gain het 542 kb  1 PCSK5 chr9:78117874-78659948 NA 
 12q12 Gain het 72.5 kb  2 GXYLT1, YAF2 chr12:42521259-42593754 NA 
34 9p21.3 Loss het 17 kb   - - chr9:21678040-21695476 NA 
35 1q32.1 Gain het 67 kb  1 GPR37L1 chr1:202027010-202093734 NA 
 21q21.1 Loss het 5 kb  1 CHODL chr21:19349121-19354449 NA 
38* 19p13.11 Gain het 61 kb 1 SLC5A5 chr19:17981993-18043097 NA 
39* 2p24.3 Gain het 1.1 Mb 3 NBAS, DDX1, MYCN chr2:15091702-16172000 NA 
 19p13.11 Gain het 61 kb 1 SLC5A5 chr19:17981993-18043097 NA 
40 2q21.2 Loss het 401 kb 1 NCKAP5 chr2:133725047-134126372 NA 
 2q32.1 Gain hom 193 kb 2 DUSP19, NUP35, (NCKAP1) chr2:183919175-184112630 NA 
41* 19p12 Loss het 429.5 kb 3 ZNF675, ZNF681, RPSAP58 chr19:23624728-24054225 NA 
42 2p15 Loss het  36 kb 1 (XPO1) chr2:61795359-61831792 NA 
43 1p34.1 Gain het  279 kb 4 GPBP1L1, TMEM69, IPP, MAST2 chr1:46116441-46395389 NA 
 Xp22.11 Loss het  254 kb 1 PTCHD1 chrX:23209046-23463336 NA 
44 9p24.2 Loss het  14.5 kb 1 VLDLR chr9:2654203-2668811 NA 
45 3q11.2 Loss het  134 kb - - chr3:94689602-94823543 NA 
 10p11.22 Gain het  97.5 kb - (PARD3, NRP1) chr10:34134992-34232568 NA 
46* 15q25.2 Loss hom 9 kb  1 CPEB1 chr15:83305533-83314278 NA 
 16q12.2 Gain het 25 kb  1 AMFR chr16:56436830-56461987 NA 
47 - - - - - - - - 
48 3p14.2 Gain het 1 Mb  1 FHIT chr3:59180080-60204731 NA 
 5q33.1 Loss het 58 kb  - (GRIA1) chr5:152263564-152321761 NA 
50 2q24.1 Loss het 108 kb  1 CCDC148 chr2:159142708-159250404 NA 
 Xp22.31 Gain het 1.7 Mb 3 STS, HDHD1, PNPLA4 chrX:6456036-8133172 NA 
52 2p22.3 Gain het 7 kb  - - chr2:35410756-35418046 NA 
 4p15.31 Loss het 6 kb  1 KCNIP4 chr4:20748440-20754466 NA 
 7q31.33 Loss het 18 kb  - - chr7:125886329-125904559 NA 
 10q26.2 Loss het 15 kb  1 ADAM12 chr10:127997316-128012550 NA 
 20q13.2 Loss het 114 kb - (TSHZ2) chr20:51258881-51372398 NA 
Tab.9. Continued 
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53 6q27 Gain het 257 kb 3 FAM120B, PSMB1, TBP chr6:170609029-170866001 NA 
 8q22.3 Loss het 28 kb  1 FZD6 chr8:104306192-104334440 NA 
54 3p14.3 Gain het 118 kb 2 DENND6A, SLMAP chr3:57671881-57790035 NA 
 15q25.2 Loss het 1.6 Mb 15 CPEB1, FAM103A1 C15orf40, EFTUD1P1, 
AP3B2, SCARNA15, FSD2, WHAMM, 
HOMER2, BTBD1, TM6SF1, HDGFRP3, 
BNC1, SH3GL3, ADAMTSL3 
chr15:83214012-84812693 NA 
 21q11.2 Loss het 10 kb  1 ABCC13 chr21:15666538-15676565 NA 
55 4q22.1 Gain het 258 kb 1 CCSER1 chr4:91157649-91415956 NA 
 8p22 Loss het 86 kb 1 DLC1 chr8:13034651-13120326 NA 
 22q13.33 Gain het 87 kb 2 ARSA, SHANK3 chr22:51059148-51146462 NA 
 Xq21.33 Loss het 26 kb  - (DIAPH2) chrX:97984949-98010783 NA 
56 8p21.2 Gain het 41 kb 2 NKX3-1, NKX2-6 chr8:23528632-23569976 NA 
57 1q23.1 Loss het 295 kb  1 CD1E chr1:158323371-158352947 NA 
58 3q26.31 Gain het 25 kb 1 NAALADL2 chr3:175345151-175370252 NA 
59 6q24.1 Loss het 28 kb  - - chr6:140376204-140403723 NA 
 13q22.2 Loss het 13 kb  1 LMO7 chr13:76256435-76269258 NA 
60 Xp22.2 Gain het 747 kb 3 ARHGAP6, AMELX, MSL3 chrX:11249664-11996670 NA 
61 11q25 Gain het 147 kb - - chr11:134623571-134770989 NA 
62 20q13.2 Gain het 21.5 kb  1 ZNF217, (TSHZ2) chr20:52163628-52185266 NA 
63 19p13.3 Gain het 885 kb 32 TJP3, APBA3, MRPL54, RAX2, MATK, ZFR2, 
ATCAY, NMRK2, DAPK3, SNORD37, EEF2, 
PIAS4, ZBTB7A, MAP2K2, CREB3L3, SIRT6, 
ANKRD24, EBI3, CCDC94, SHD, TMIGD2, 
FSD1, STAP2, MPND, SH3GL1, UBXN6, 
CHAF1A, HDGFRP2, PLIN4, PLIN5, LRG1, 
SEMA6B 
chr19:3718839-4604407 NA 
64 13q31.2 Gain het 41 kb  - - chr13:88282085-88323161 NA 
65 10p15.3 Gain het 108 kb 2 WDR37, ADARB2 chr10:1175097-1282960 NA 
Tab.9. Continued 
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66 2p14 Loss het 18 kb 1 MEIS1 chr2:66714797-66732973 NA 
 3q21.3 Gain het 102.5 kb 2 MGLL, KBTBD12 chr3:127533289-127635789 NA 
67 7q33 Gain het 11 kb   1 CALD1 chr7:134525335-134536040 NA 
#Physical position of the identified rare CNVs based on the UCSC Genome Browser, hg19, released February 2009. 
*Familial cases: 8-10, 9-11, 15-16, 20-21, 38-39, couple of sisters; 41 and 46 present a relative with SA who are not included in the analyzed cohort. 
§Parents of POI 14 are first cousins. 
¥The CNV is present also in the healthy sister. 
() Genes potentially perturbed by rare CNVs through a position effect. 
 
 
 
Tab.10. Common CNVs identified in the POI cohort by means of array CGH analysis 
POI ID Gain/Loss Size Genes/Locus Nucleotide position# POI ID Gain/Loss Size Genes/Locus Nucleotide position# 
1§ Loss 578 kb NAIP chr5:69767948-70345611 39* Loss 119 kb DUSP22 chr6:259881-378956 
2§ Loss 92 kb DUSP22 chr6:259528-293493 42 Loss 119 kb DUSP22 chr6:259881-378956 
4§ Loss 681 kb NAIP chr5:69741318-70422356 44 Gain 80 kb DUSP22 chr6:299363-378956 
6*§ Loss 92 kb DUSP22 chr6:283968-375949 48 Loss 350 kb NAIP chr5:70308101-70657747 
9*§ Gain 96 kb CYP2E1, SYCE1 chr10:135281682-135377532 50 Gain 80 kb  DUSP22 chr6:299363-378956 
11* Gain 97 kb CYP2E1, SYCE1 chr10:135281682-135378761   52 Gain 1.8 Mb NAIP chr5:68849594-70657747 
13 Gain 119 kb DUSP22 chr6:259881-378956 53 Loss 119 kb DUSP22 chr6:259881-378956 
17 Gain 126 kb CYP2E1, SYCE1  chr10:135252327-135378761 56 Loss 119 kb DUSP22 chr6:259881-378956 
20* Loss 1.8 Mb NAIP chr5:68818173-70657747 57 Loss 119 kb DUSP22 chr6:259881-378956 
 Loss 130 kb DUSP22 chr6:259881-389482 59 Gain 80 kb DUSP22 chr6:299363-378956 
26 Gain 43 kb DUSP22 chr6:259881-303298 60 Loss 126 kb CYP2E1, SYCE1 chr10:135252327-135378761 
33 Loss 119 kb DUSP22 chr6:259881-378956 62 Gain 123 kb CYP2E1, SYCE1 chr10:135281682-135404523 
36* Loss 99 kb DUSP22 chr6:279667-378956 65 Loss 389 kb DUSP22 chr6:259881-389482 
#Physical position of the identified rare CNVs based on the UCSC Genome Browser, hg19, released February 2009. 
*Familial cases. 
§POI patients analyzed by array CGH 244K. 
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3.2 Analysis of the gene content and validation of the ovarian rare 
CNVs 
Based on the gene content, 33 rare CNVs were selected as possibly related to POI pathogenesis 
in the group of 58 patients positive to the array CGH analysis. In 10 CNVs qPCR or Long-Range 
PCR validation was performed and only 1 CNV could not be confirmed (Tab.11). 
Tab.11. List of the ovarian rare CNVs with their molecular validation. 
POI ID 
Chromosomal 
Band 
Type of rearrangement Size Ovarian Gene(s) 
CNV 
validation  
3 15q14 Intragenic deletion  26 kb RYR3 LR-PCR 
6 Xq21.33 Intronic duplication 53 kb DIAPH2, DIAPH2-AS1 Familial 
7 9p21.3 Position effect 68 kb ELAVL2 qPCR 
8* 3q28 Intragenic duplication 158.5 kb TP63 Familial 
9* 5p13.1 Intronic deletion 6.5 kb  PRKAA1 Familial, qPCR 
10* 3q28 Intragenic duplication 161 kb TP63 Familial 
11* 5p13.1 Intronic deletion 6.5 kb PRKAA1 Familial, qPCR 
12 6p25.1-24.3 Partial gene duplication 36 kb RREB1  spots > 5 
13 1q44 Partial gene duplication 523.5 kb SMYD3 spots > 5 
 11p15.4 Intronic duplication 42 kb HBE1 spots > 5 
14 Xp11.22 Complete gene deletion 36 kb BMP15 Familial 
18 14q22.2 Position effect 20 kb  BMP4 qPCR 
25 1p13.2 Position effect 91 kb MOV10, RHOC, CAPZA1, LRIG2 spots > 5 
33 9q21.13 Partial gene duplication 542 kb PCSK5 spots > 5 
38* 19p13.11 Complete gene duplication 61 kb SLC5A5 spots > 5 
39* 2p24.3 Complete gene duplication 1.08 Mb DDX1, MYCN spots > 5 
 19p13.11 Complete gene duplication 61 kb SLC5A5 spots > 5 
42 2p15 Position effect 36 kb XPO1 spots > 5 
44 9p24.2 Partial gene deletion 14.5 kb VLDLR LR-PCR 
45 10p11.22 Position effect 97.5 kb PARD3, NRP1 spots > 5 
46* 15q25.2 Intronic deletion# 9 kb CPEB1 qPCR, LR-PCR 
 16q12.2 Partial gene duplication 25 kb AMFR spots > 5 
48 5q33.1 Position effect 58 kb GRIA1 spots > 5 
50 Xp22.31 Complete gene duplication 1.7 Mb STS spots > 5 
52 20q13.2 Position effect 114 kb TSHZ2 spots > 5 
53 8q22.3 Partial gene deletion 28 kb FZD6 spots > 5 
54 3p14.3 Partial gene duplication 118 kb SLMAP spots > 5 
 15q25.2 Complete gene deletion 1.6 Mb CPEB1, WHAMM, BTBD1, BNC1, 
SH3GL3 
spots > 5 
55 Xq21.33 Position effect 26 kb DIAPH2 qPCR 
60 Xp22.2 Complete gene duplication 747 kb MSL3 spots > 5 
62 20q13.2 Position effect 21.5 kb  TSHZ2 qPCR 
63 19p13.3 Complete gene duplication 885 kb EEF2, MAP2K2, SIRT6 spots > 5 
66 2p14 Intronic deletion 18 kb MEIS1 - 
* Familial cases; # Homozygous deletion; -, not validated. 
Results 
 
63 
 
Overall, 32 ovarian CNVs were selected in 28 POI patients attesting a detection rate of 31.7%. 
These CNVs include 18 duplications (56.2%) and 14 deletions (43.8%), ranging from 6.5 kb to 1.7 
Mb. According to the type of rearrangement affecting the involved the genes, the CNVs were 
classified as shown in Fig.7. 
 
 
 
Fig.7. Distribution of the 32 ovarian CNVs. 13 gains and 5 losses involve the genes coding region resulting in 
intragenic, partial and complete deletion/duplication; 2 gains and 3 losses involve intronic sequences; 9 CNVs (3 
gains and 6 losses) are located in desert genomic regions that may result in a possible position effect on the 
adjacent genes. 
 
Three POI patients (POI 39, 46, 54) bear more than one rare CNV. 
The analysis of the CNVs gene content using ad hoc databases revealed a total of 37 genes whose 
alteration might play a role in POI etiology. Based on genes expression and function in the ovary, 
literature evidences, presence of animal models (i.e, knock-out mice), and experimental studies 
in affected women (i.e., identification of mutations and/or rare CNVs involving the gene), an 
increased association score to POI was assigned to each gene (Tab.12).  
 
Tab.12. Criteria used for assigning genes POI association score. 
 
Known 
expression and/or 
function  
Literature 
evidences 
Relevance 
in animal  
Relevance 
in Human 
1 - Low  + - - - 
2 - Medium  + + - - 
3 - Moderate  + + + - 
4 - High  + + + + 
 
The percentage and the number of the genes in each score set is shown below and in Fig.8 
respectively. 
 
1 – Low  45.9% 2 – Medium  29.7%  3 – Moderate  24.3% 4 – High  8.1% 
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Fig.8. Distribution of the 37 genes potentially related to POI according to the association score. The number of 
the genes included is shown. 
 
Through bioinformatic analysis the genes were classified in four functional categories which 
contribute to ensure the proper ovarian development and homeostasis (Fig.9): 
A: genes involved in ovarian metabolism and homeostasis (19%); 
B: genes with a role in the intracellular trafficking, and in the regulation of cytoskeleton 
dynamics for oocyte asymmetric division (21.6%); 
C: genes involved in transcription and translation regulation, chromatin remodelling, 
maintenance of oocyte genomic integrity (35.1%); 
D: genes that play a role in ovarian differentiation, follicular development, and meiotic 
resumption (24.3%). 
 
Fig.9. Distribution of the 37 ovarian genes according to the functional class they belong. The number of genes is 
shown in each category. 
 
These data are summarized in Tab.13 where a detailed list of the 37 selected genes with their 
general function and role in the ovary is reported. For each gene the identification number of the 
Ovarian Kaleidoscope database submission (OKdb) is also shown. 
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Tab.13.Detailed list of the genes potentially perturbed by the identified rare CNVs and possibly implicated in POI pathogenesis. 
Gene 
POI 
ID 
General Function                                                                                                      
(from public databases: UCSC, GeneCards) 
 Role in the ovary 
POI 
score 
Functional 
Category 
OKdb # References 
RYR3 3 Ryanodine receptor 3. The protein encoded by this gene is a 
receptor which releases calcium from intracellular 
storage, contributes to cellular calcium ion homeostasis 
and plays a role in cellular calcium signaling. 
 Ryanodine receptors are expressed on the 
oocyte surface of mature bovine (expression 
increases in metaphase I) and anphibia. 
Changes in the levels of calcium are essential 
for the activation and the development of 
oocytes. 
2 A - [173,174] 
DIAPH2 6, 55 Diaphanous-related formin 2. The gene encodes a protein 
that in Drosophila plays a role in actin cytoskeleton 
organisation both in mitosis and meiosis. In human, it 
could be involved in oogenesis and in the regulation of 
endosome dynamics. 
 It plays a role in the development and normal 
function of the ovaries. Defects have been 
linked to premature ovarian failure 2A.  
4 B 37 [129,175,176] 
ELAVL2 7 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2. 
The encoded protein is a neural-specific RNA-binding 
protein that is known to bind to several 3' UTRs, 
including its own. 
 It plays a role during oocyte maturation and 
early embriogenesis in bovine and mouse.  
2 D 3896 [177,178] 
TP63 8, 10 Tumor protein p63. It encodes a member of the p53 family 
of transcription factors and acts as a sequence specific 
DNA binding transcriptional activator or repressor. 
Mutations are associated with several autosomal 
dominant syndromes: ectodermal dysplasia and cleft 
lip/palate syndrome 3 (EEC3); split-hand/foot 
malformation 4 (SHFM4); ankyloblepharon-ectodermal 
defects-cleft lip/palate; ADULT syndrome (acro-
dermato-ungual-lacrimal-tooth); limb-mammary 
syndrome; Rap-Hodgkin syndrome (RHS); and orofacial 
cleft 8.  
 It plays a role in the maintainance of oogonia 
genomic integrity, may be implicated in the 
meiosis and cell cycle control of germ cells in 
the mouse ovary. It is a main regulator to 
protect the fidelity of female germ cells 
during meiotic arrest. 
3 C 1885 [179,180,181,1
82] 
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PRKAA1 9, 11 Protein kinase, AMP-activated, alpha 1 catalytic subunit. The 
encoded protein belongs to the ser/thr protein kinase 
family. It is the catalytic subunit of the 5'-prime-AMP-
activated protein kinase (AMPK). It protects cells from 
stresses that cause ATP depletion by switching off ATP-
consuming biosynthetic pathways. 
 Murine and porcine animal models show the 
involvement of AMPK in oocytes meiotic 
resumption. The process is transiently 
blocked by PRKA activators in a dose-
dependent manner. Moreover, the absence of 
AMPK modifies murine oocyte quality 
through energy processes and oocyte/somatic 
cell communication. 
3 D 818 [183,184,185,
186,187,188] 
RREB1  12 Ras responsive element binding protein 1. It encodes a zinc 
finger transcription factor that binds to RAS-responsive 
elements (RREs) of gene promoters. It has been shown 
to increase expression of calcitonin, which may be 
involved in Ras/Raf-mediated cell differentiation. 
 Evidences from drosophila oocytes: link 
between human homolog RREB1 and 
regulation of cell adesion and migration. 
1 B - [189] 
SMYD3 13 SET and MYND domain containing 3. It encodes a histone 
methyltransferase which specifically methylates Lys- 4 
and Lys-5 of histone H3, inducing di- and tri-
methylation, but no monomethylation. Plays an 
important role in transcriptional activation as a member 
of an RNA polymerase complex.  
 Regulates the expression of transcriptional 
factors during bovine oocyte maturation and 
early embryonic development. 
2 C 4348 [190] 
HBE1 13 Hemoglobin, epsilon 1. HBE is normally expressed in the 
embryonic yolk sac: two epsilon chains together with 
two zeta chains (an alpha-like globin) constitute the 
embryonic hemoglobin Hb Gower I; two epsilon chains 
together with two alpha chains form the embryonic Hb 
Gower II. Both embryonic hemoglobins are normally 
supplanted by fetal, and later, adult hemoglobin.  
 It is associated with alterations in the 
development of the mouse gonads and thus 
might contribute to sexual dysgenesis 
syndromes. 
1 D 2986 [191] 
BMP15 14 Bone morphogenetic protein 15. The encoded protein is a 
member of the BMP family which is part of the 
transforming growth factor-beta superfamily (TGF-β). 
The TGF-β superfamily includes large families of growth 
and differentiation factors.  
 The protein may be involved in oocyte 
maturation and follicular development as a 
homodimer or by forming heterodimers with 
a related protein, Gdf9. Several BMP15 
mutations are involved in the pathogenesis of 
hypergonadotropic ovarian failure in humans. 
4 D 8 [94,96,97,98
] 
Tab.13. Continued 
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BMP4 18 Bone morphogenetic protein 4. The encoded protein is a 
member of the BMP family which is part of the 
transforming growth factor-beta superfamily (TGF-β). 
It induces cartilage and bone formation and acts in 
mesoderm induction, tooth development, limb 
formation and fracture repair.  
 BMP4 plays a role in follicular development 
and differentiation acting as a transition 
factor from primordial to primary mouse 
follicle. Knock-out mice are infertile. BMP4 
gene defects may not represent a risk factor 
in the development of POI among 99 Chinese 
Han women analyzed. 
3 D 976 [192,193,194,
195,196] 
MOV10 25 Moloney leukemia virus 10, homolog (mouse). It encodes a 
probable RNA helicase. Required for RNA-mediated 
gene silencing by the RNA-induced silencing complex 
(RISC).  
 The gene plays a role as a telomerase 
associated protein and its mRNA was found 
highly expressed in human testis and ovary. 
1 C 4113 [197] 
RHOC 25 Ras homolog family member C. It encodes a member of the 
Rho family of small GTPases. It is thought to be 
important in cell locomotion. Regulates a signal 
transduction pathway linking plasma membrane 
receptors to the assembly of focal adhesions and actin 
stress fibers. It serves as a microtubule-dependent signal 
required for the myosin contractile ring formation 
during cell cycle cytokinesis. 
 RHOC mRNA is expressed during mouse 
oocyte development from the primordial to 
large antral follicular stages. 
1 B 4750 [198] 
CAPZA1 25 Capping protein (actin filament) muscle Z-line, alpha 1. It 
encodes a member of the F-actin capping protein alpha 
subunit family. The protein regulates growth of the 
actin filament by capping their barbed end.  
 CAPZA1 mRNA is expressed during mouse 
oocyte development from the primordial to 
large antral follicular stages. 
1 B 4660 [198] 
LRIG2 25 Leucine-rich repeats and immunoglobulin-like domains 2. The 
encoded protein promotes epidermal growth factor 
signalling, resulting in increased proliferation.  
 LRIG2 mRNA is expressed during mouse 
oocyte development from the primordial to 
large antral follicular stages. 
1 C 2477 [198] 
PCSK5 33 Proprotein Convertase, Subtilisin/kexin-type, 5. The encoded 
protein belongs to the subtilisin-like proprotein 
convertase family. The members of this family process 
latent precursor proteins into their biologically active 
products.  
 The gene plays a role in the processing of 
mouse ovarian inhibin subunits during 
folliculogenesis and its enzymatic product 
has been suggested to be an important 
regulator of inhibin and activin 
bioavailability. 
3 A 1517 [199,200] 
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SLC5A5 38, 
39 
Solute carrier family 5 (sodium iodide symporter). It encodes a 
member of the sodium glucose cotransporter family 
responsible for the uptake of iodine in tissues such as 
the thyroid and lactating breast tissue. Gene mutations 
are associated with autosomal recessive thyroid 
dyshormonogenesis 1, leading to congenital 
hypothyroidism. 
 SLC5A5 mRNA is expressed during mouse 
oocyte development from the primordial to 
large antral follicular stages. 
1 A 1764 [198] 
DDX1 39 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1. It encodes a 
putative RNA helicase implicated in a number of cellular 
processes involving alteration of RNA secondary 
structure such as translation initiation, nuclear and 
mitochondrial splicing, and ribosome and spliceosome 
assembly. Based on their distribution patterns, some 
members of this family are believed to be involved in 
embryogenesis, spermatogenesis, and cellular growth 
and division. 
 It plays a role in fertility and development, 
and localizes in Drosophila oocyte during 
oogenesis.  
2 C - [201] 
MYCN 39 v-myc myelocytomatosis viral related oncogene, neuroblastoma 
derived. It is a member of the MYC family and encodes a 
protein with a basic helix-loop-helix (bHLH) domain. 
Gene amplification is associated with a variety of 
tumors, most notably neuroblastoma.  
 MYCN mRNA is expressed during mouse 
oocyte development from the primordial to 
large antral follicular stages. 
1 D 4089 [198] 
XPO1 42 Exportin 1. The encoded protein mediates leucine-rich 
nuclear export signal (NES)-dependent protein 
transport. It is involved in the control of several cellular 
processes by controlling the localization of cyclin B, 
MAPK, and MAPKAP kinase 2.  
 XPO1 mRNA is expressed during mouse 
oocyte development from the primordial to 
large antral follicular stages. 
1 B 4425 [198] 
VLDLR 44 Very low density lipoprotein receptor. It encodes a lipoprotein 
receptor that is a member of the LDLR family and plays 
important roles in VLDL-triglyceride metabolism and in 
the reelin signaling pathway.  
 VLDLR plays an important role in cholesterol 
and lipoprotein endocitosis in ovarian 
follicle. Several studies on bovine and 
chicken ovaries indicate its role during 
follicular development. Hens lacking a 
functional receptor are sterile. It is also 
associated with egg performance in duck. 
3 A 2159 [202,203,20
4,205] 
Tab.13. Continued 
 69 
 
PARD3 45 Partitioning defective 3 homolog. It encodes a member of the 
PARD protein family and interacts with other PARD 
family members and other proteins; it plays a role in 
asymmetrical cell division and directs polarized cell 
growth.  
 It plays a role in establishing asymmetry 
division in mouse and Xenopus oocytes and 
in defining the future site of polar body 
emission. 
3 B 4194 [206,207] 
NRP1 45 Neuropilin 1, vascular endothelial cell growth factor. The 
encoded protein plays a role in several different types of 
signaling pathways that control cell migration. It is 
involved in the development of cardiovascular system, 
angiogenesis, the formation of certain neuronal circuits 
and in organogenesis outside the nervous system. 
 The NRP1 gene is expressed in the granulosa 
and theca cells in the bovine ovary, 
suggesting its involvement in follicle 
development in the cow. 
2 C 1582 [208] 
CPEB1 46, 
54 
Cytoplasmic polyadenylation element binding protein 1. It 
encodes a member of the cytoplasmic polyadenylation 
element (CPE) binding protein family. This highly 
conserved protein binds to a specific RNA sequence 
called the CPE found in the 3' UTR of some mRNAs.  
 CPEB1 is an important regulator of 
translation in oocytes and neurons. It plays a 
role in asymmetric division of Xenopus 
oocytes and is involved in Cyclin B 
translation and meiotic resumption in 
porcine oocytes. Cpeb1 controls mouse germ 
cell differentiation by regulating the 
formation of the synaptonemal complex: KO 
mouse are infertile. Microdeletion in the gene 
was found in a patient with POI through 
high-resolution SNP array analysis. 
4 C 4491 [161,209,210,
211] 
AMFR 46 Autocrine motility factor receptor. It encodes a receptor 
whose ligand, autocrine motility factor, is a tumor 
motility-stimulating protein secreted by tumor cells. 
The receptor is a member of the E3 ubiquitin ligase 
family of proteins, catalyzes ubiquitination and 
endoplasmic reticulum-associated degradation of 
specific proteins.  
 AMFR mRNA is expressed during mouse 
oocyte development from the primordial to 
large antral follicular stages. 
1 A 1354 [198] 
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GRIA1 48 Glutamate receptor, ionotropic, AMPA 1. Glutamate receptors 
are the predominant excitatory neurotransmitter 
receptors in the mammalian brain and are activated in a 
variety of normal neurophysiologic processes. They are 
heteromeric protein complexes with multiple subunits, 
each possessing transmembrane regions, and all 
arranged to form a ligand-gated ion channel.  
 GRIA1 is a critical mediator of ovulation in 
cow and it might be a useful target for 
reproductive therapy. 
2 D 4841 [212,213] 
STS 50 Steroid sulfatase. The encoded protein catalyzes the 
conversion of sulfated steroid precursors to estrogens 
during pregnancy. It is found in the endoplasmic 
reticulum, where it acts as a homodimer.  
 STS increases StAR (steroidogenic acute 
regulatory) protein expression level and 
stimulates steroid production. It is also 
expressed in human cumulus cells and its 
mRNA levels are controlled by FSH. 
2 A 1166 [214,215] 
TSHZ2 52, 
62 
Teashirt zinc finger homeobox 2. It encodes a probable 
transcriptional regulator involved in developmental 
processes.  
 TSHZ2 mRNA is expressed during mouse 
oocyte development from the primordial to 
large antral follicular stages. 
1 C 4602 [198] 
FZD6 53 Frizzled family receptor 6. The encoded protein functions as 
a negative regulator of the canonical Wnt/beta-catenin 
signaling cascade, thereby inhibiting the processes that 
trigger oncogenic transformation, cell proliferation, and 
inhibition of apoptosis.  
 FZD6 mRNA is regulated by FSH during 
dominant follicle selection in bovine oocyte.  
2 D 2204 [216] 
SLMAP 54 Sarcolemma associated protein. It encodes a component of a 
conserved striatin-interacting phosphatase and kinase 
complex. Striatin family complexes participate in a 
variety of cellular processes including signaling, cell 
cycle control, cell migration, Golgi assembly, and 
apoptosis. 
 SLMAP mRNA is expressed during mouse 
oocyte development from the primordial to 
large antral follicular stages. 
1 C 4945 [198] 
WHAMM 54 WAS protein homolog associated with actin, golgi membranes and 
microtubules. The encoded protein acts as a nucleation-
promoting factor (NPF) that stimulates actin 
polymerization both at the Golgi apparatus and along 
tubular membranes. It participates in vesicle transport 
between the reticulum endoplasmic and the Golgi 
complex.  
 WHAMM is required for meiotic spindle 
migration and asymmetric cytokinesis in 
mouse oocytes.  
3 B 4788 [217] 
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BTBD1 54 BTB (POZ) domain containing 1 (BTBD1). It encodes a 
probable substrate-specific adapter of an E3 ubiquitin- 
protein ligase complex which mediates the 
ubiquitination and subsequent proteasomal degradation 
of target proteins. 
 Danio rerio homolog may have an important 
function in oogenesis and (or) early zebrafish 
development. 
1 A - [218] 
BNC1 54 Basonuclin 1. The encoded protein is a zinc finger protein 
present in the basal cell layer of the epidermis and in 
hair follicles. It is also found in abundance in the germ 
cells of testis and ovary. It is thought to play a regulatory 
role in keratinocyte proliferation and it may also be a 
regulator for rRNA transcription. Basonuclin is 
expressed in cells that are able to undergo division but 
are not necessarily in the division cycle; it is not found in 
terminally differentiated cells. 
 It may play a role in the differentiation of 
mouse oocytes. It increases transcription of 
the ribosomal RNA genes during mouse 
oogenesis. Moreover, mouse with null 
mutation is sub-fertil. 
3 C 101 [219,220] 
SH3GL3 54 SH3-domain GRB2-like 3 (Endophilin A3). SH3 domain is an 
evolutionarily conserved, 50- to 60-amino acid module, 
carried by intracellular proteins involved in the 
transduction of signals for cell polarization, motility, 
enzymatic activation, and transcriptional regulation. 
Implicated in endocytosis. May recruit other proteins to 
membranes with high curvature.  
 The endophilins differentially contribute to 
oocyte endocytosis and development in 
chicken. Duplication of the gene was found 
in Norling et al., 2014 by means of custom 
array-CGH analysis in a cohort of POI 
patients but an association with the disorder 
should be further investigated. 
2 B 1731 [159,221] 
MSL3 60 Male specific lethal 3 homolog (Drosophila). The encoded 
protein may be involved in chromatin remodeling and 
transcriptional regulation. May have a role in X 
inactivation and it has been found as part of a complex 
that is responsible for histone H4 lysine-16 acetylation.  
 MSL3 may be a candidate epigenetic 
reprogramming factor in human, rhesus 
monkey, and mouse oocyte. 
2 C 5012 [222] 
EEF2 63 Eucariotic tanslation elongation factor 2. It encodes a member 
of the GTP-binding translation elongation factor family. 
The protein, an essential factor for protein synthesis, 
promotes the GTP-dependent translocation of the 
nascent protein chain from the A-site to the P-site of the 
ribosome.  
 EEF2 mRNA is expressed during mouse 
oocyte development from the primordial to 
large antral follicular stages. 
1 C 306 [198] 
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MAP2K2 63 Mitogen-activated protein kinase kinase 2 (MEK2). The 
encoded protein is a dual specificity protein kinase that 
belongs to the MAP kinase kinase family. This kinase is 
known to catalyze the concomitant phosphorylation of a 
threonine and a tyrosine residue in a Thr-Glu-Tyr 
sequence located in MAP kinases.  
 MEK1/2 regulates spindle formation and 
meiotic resumption during mouse oocyte 
development. 
3 D - [223,224,22
5] 
SIRT6 63 Sirtuin 6. It encodes a member of the sirtuin family of 
proteins, homologs to the yeast Sir2 protein which is a 
NAD-dependent protein deacetylase. 
 SIRT6 plays a role in caloric restriction and 
high-fat diet which are important for oocyte 
development and to preserve the germ cells 
reserve in the mouse. Furthermore, SIRT6 
loss leads to genomic instability and aging-
like phenotype in mice. 
2 C 4470 [226,227] 
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Transcriptional expression of all the genes was then investigated on ovarian mRNAs. Both total 
fetal and blood mRNAs were analyzed as different control tissues. The experimental results are 
shown in Tab.14. 
Tab.14. Results from the mRNAs analysis: +, expressed; -, not expressed. 
  mRNA expression    mRNA expression  
  Ovary Fetal Blood   Ovary Fetal Blood 
AMFR + + + NRP1 + + + 
BMP15 + + + PARD3 + + + 
BMP4 + + + PCSK5 + + + 
BNC1 + + - PRKAA1 + + + 
BTBD1 + + + RBSG1 + + + 
CAPZA1 + + + RHOC + + + 
CPEB1 + + + RREB1 + + + 
DDX1 + + + RYR3 + + + 
DIAPH2 + + + SH3GL3 + + - 
EEF2 + + + SIRT6 + + + 
ELAVL2 + + - SLC5A5 + + + 
FZD6 + + + SLMAP + + + 
GRIA1 + + - SMYD3 + + + 
HBE1 + + + STS + + + 
LRIG2 + + + TP63 + + + 
MAP2K2 + + + TSHZ2 + + - 
MOV10 + + + VLDLR + + + 
MSL3 + + + WHAMM + + + 
MYCN + + + XPO1 + + + 
 
To find some functional relationship between the proteins encoded by array-CGH ovarian genes 
and the already known POI genes (see introduction), bioinformatic search was performed using 
STRING database (http://string-db.org/). The analysis revealed a link for 11 out of the 32 
proteins (Ddx1, Syce1, Xpo1, Eef2, Amfr, Cyp2e1, Smyd3, Prkaa1, Bmp15, Msl3, Sts) that is 
commented in the discussion. 
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3.3 Ovarian CNVs enrichment evaluation 
3.3.1 Array CGH and CNVs gene content analyses of an ad hoc control group 
All the CNVs detected were selected as rare according to the DGV. A limitation of this database 
is the lack of several informations regarding the healthy controls used: mainly it is unknown 
their gender and age. Moreover, considering that several pathologies have a late onset (e.g. 
secondary amenorrhea), it is possible to find these patients inside the DGV controls group. For 
this reason, it is crucial to compare the obtained data with a cohort of ad hoc controls. 
For Primary Ovarian Insufficiency patients, the ad hoc controls consist in healthy women with 
normal 46,XX karyotype who had a normal reproductive life and reached physiological 
menopause. 
Array CGH 244K and 400K previously performed on 140 control women were thus analyzed 
with the aim to find a real enrichment in potentially pathogenic ovarian CNVs in the POI 
patients. The analysis of the CNVs and their gene content in the control group was performed 
with the same method used for patients’ analysis.  
In 44 out of 140 controls we found 49 ovarian rare CNVs possibly implicated in POI 
etiopathogenesis, 25 duplications (51%) and 24 deletions (49%), ranging from 8 kb to 1.8 Mb. 
According to the type of rearrangement that involves the detected genes, the CNVs were 
classified as shown in Fig.10. 
 
 
 
Fig.10. Distribution of the 49 ovarian CNVs in control women. 19 gains and 6 losses involve the genes coding 
region resulting in intragenic, partial and complete deletion/duplication; 3 gains and 3 losses involve intronic 
sequences, whereas 18 CNVs (3 gains and 15 losses) are located in desert genomic regions that may result in a 
possible position effect on the adjacent genes. 
Subsequently the analysis of the CNVs gene content in the control group revealed a total of 54 
genes whose alteration might play a role in POI etiology. As well as patients, a POI score was 
attributed to each gene as shown in Fig.11. 
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Fig.11. Distribution of the 54 genes included in rare CNVs present in the POI control cohort and potentially 
related to POI according to the association score. The number of the genes included is shown. 
 
Furthermore, as well as in the POI cohort, “common” CNVs containing genes previously 
associated to the disorder (NAIP, DUSP22, SYCE1) [152,161], were identified: 
- 6 CNVs involving NAIP at 5q13.2 (3 duplication and 3 deletions), 
- 30 CNVs involving DUSP22 at 6p25.2 (19 duplications and 11 deletions),  
- 9 CNVs involving SYCE1, CYP2E1 at 10q26.3 (9 duplications and 0 deletion). 
 
3.3.2 Comparison between POI and ad hoc controls analyses 
Based on the results obtained from the analyses performed, 4 CNVs involving the same genes 
were detected in both patients and controls (Tab.15). 
Tab.15. CNVs in patients and controls involving the same genes. 
ID Chromosome Position(hg19) G/L Size Gene and rearrangement 
POI 25 chr1:113339006-113430121 Gain 91 kb MOV10, position effect 
CTRL_F122 chr1:113239072-113474655 Gain 236 kb MOV10, partial duplication 
POI 42 chr2:61795359-61831792 Loss 36 kb XPO1, position effect 
CTRL_F107 chr2:61877860-61888495 Gain 11 kb XPO1, position effect 
POI 50 chrX:6456036-8133172 Gain 1.7 Mb STS, complete duplication 
CTRL_F105 chrX:6449644-8133172 Gain 1.7 Mb STS, complete duplication 
POI 60 chrX:11249664-11996670 Gain 747 kb MSL3, complete duplication 
CTRL_F129 chrX:11686237-12187337 Gain 501 kb MSL3, complete duplication 
 
These results prompted us to further evaluate whether there was a real enrichment both in 
ovarian CNVs and in ovarian genes in the POI women. A preliminary estimation was performed 
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as shown (Fig.12) dividing each value for the total number of POI patients (67) and the ad hoc 
control group (140) analyzed. 
 
Ovarian CNVs Ovarian genes 
POI Controls POI Controls 
32 49 37 54 
 
 
Fig.12. Results obtained from the preliminary evaluation. The number of CNVs and genes with their respective 
percentage is shown for both POI and controls. 
As shown in the pre-analysis there seems to be a slight enrichment in favor of the group of 
patients. Thus, to underline eventual statistically significant differences between POI and ad hoc 
controls data, chi-square test was performed comparing the following values: 
- number of people positive and negative to the array CGH analysis, 
- number of CNVs involving exonic and non-exonic sequences, 
- number of genes with a higher (3,4) and lower (1,2) POI association score. 
None of the three analyses reached a statistical significance (p < 0.5) as shown in Tab.16. 
Tab.16. Results of the chi-square test. 
People Observed Frequencies     Expected Frequencies   
  
POI Controls Total 
 
POI Controls 
 
array-CGH Positive 28 44 72 array-CGH Positive 23.304 48.696 
 
array-CGH Negative 39 96 135 array-CGH Negative 43.696 91.304 
 
Total 67 140 207 
   
    
  chi-square   test 0.143 p>0.05 
                
CNVs Observed Frequencies     Expected Frequencies 
  
  
POI Controls Total 
 
POI Controls 
 
Exonic CNVs 18 25 43 Exonic CNVs 16.988 26.012 
 
Non-exonic CNVs 14 24 38 Non-exonic CNVs 15.012 22.988 
 
Totale 32 49 81 
   
    
  chi-square   test 0.645 p>0.05 
                
Genes Observed Frequencies     Expected Frequencies 
 
  
POI Controls Total   POI Controls 
 
gene score   3,4 12 12 24 gene score   3,4 9.758 14.242 
 
gene score   1,2 25 42 67 gene score   1,2 27.242 39.758 
 
Total 37 54 91 
   
    
  chi-square   test 0.278 p>0.05 
                
47.8% 35% 55.2% 38.6% vs vs 
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After, dividing the total count of “common” CNVs detected in the two groups by the total 
number of POI and controls, a comparative evaluation was performed and no differences were 
identified (Fig.13). Fisher’s exact test confirmation was also obtained (data not shown). 
 
Common 
CNVs 
POI 26 
 
 
 Controls 45 
 
Fig.13. Results obtained from the evaluation of common CNVs. The CNVs number with the respective percentage 
is shown for both POI and controls. 
 
Nevertheless, when one compares the number of rearrangements with the most probably 
deleterious effect on the genes with the highest association POI score (3,4), a difference can be 
observed. In detail, POI patients present 7 “deleterious” CNVs compared to the only one found 
in controls Tab.17.  
 
Tab.17. List of the highest association POI score genes with the respective rearrangement. 
POI Controls 
Gene Type of rearrangement 
POI 
score 
Gene Type of rearrangement 
POI 
score 
BMP15 Complete gene deletion 4 LHCGR Position effect 4 
CPEB1 (x2) Intronic deletion, complete 
gene deletion 
4 FSHR (x2) Position effect 4 
DIAPH2 (x2) Intronic duplication, position 
effect 
4 PTN Partial gene deletion 3 
TP63 (x2)* Intragenic duplication 3 ADAMTS9 Partial gene duplication 3 
VLDLR Partial gene deletion 3 PDE9A Partial gene duplication 3 
WHAMM Complete gene deletion 3 PRKCG Complete gene duplication 3 
BNC1 Complete gene deletion 3 DAB1 Intronic deletion 3 
PCSK5 Partial gene duplication 3 GREM2 Position effect 3 
MAP2K2 Complete gene duplication 3 FMN2 Position effect 3 
PRKAA1 (x2)* Intronic deletion 3 IL6ST Position effect 3 
BMP4 Position effect 3 ADAMTS19 Position effect 3 
PARD3 Position effect 3 AKAP2 Position effect 3 
* gene found in familial cases; 
Rearrangements with the most probably deleterious effect are shown in bold and underlined. 
(x2): found in two CNVs 
  
vs 
38.8% 
32.1% 
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3.4 Molecular characterization of selected CNVs and study of 
their putative involvement in POI pathogenesis 
3.4.1 POI 6: intronic duplication at Xq21.33 (DIAPH2) 
The 53 kb duplication inherited from the healthy father, ranges from oligonucleotide 
A_16_P03733864 to A_16_P03733968 involving intron 26 of the gene and the entire long non-
coding RNA named DIAPH2-antisense RNA 1 (RBSG1, chrX:96,692,826-96,819,534, hg19). As 
antisense RNAs play a regulatory role against the complementary genes, RT-qPCR on DIAPH2 
was performed to evaluate possible alterations at the transcript level. Two TaqMan assay probes 
were used: one specific for exons 15-16 junction, and the other specific for exons 26-27 
(including the IVS26 duplication). Both assays detected no mRNA level alterations (Fig.14). 
 
 
Fig.14. A) UCSC genome browser view of the region involved in DIAPH2 IVS26 gain (chrX:96,774,546-96,827,670, 
hg19). UCSC genes are shown in blue. Regulatory elements prediction based on ENCODE chromatin state 
segmentation in nine human cell lines is shown: red, promoter; yellow, weak enhancer; orange, strong enhancer; 
light green, weak transcribed; light grey, heterochromatin. Conservation in other species is shown. B) RT-qPCR 
results using TaqMan assay for exons 15-16; TBP normalization is shown. C) RT-qPCR results using TaqMan assay 
for exons 26-27; GUSB normalization is shown. C1-C10, controls (light grey bars). POI patient is depicted in dark 
grey. 
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3.4.2 POI 8 and 10: intragenic duplication at 3q28 (TP63) 
The 161 kb paternal intragenic duplication ranges from oligonucleotide A_16_P16543639 to 
A_16_P16544117 and involves exons 2 to 9 of the completeTP63 transcript composed of 14 exons, 
whereas it involves 5’UTR to exon 7 of the shortest transcripts (Fig.15). The outer duplication 
of about 170.6 kb starts after A_16_P00894458 and ends before A_16_P36592945 
(chr3:189,422,152-189,592,727, hg19). Based on these results it is unknown whether exon 10 (or 8 
for the shortest isoforms) is involved in the gain.  
 
Fig.15. UCSC genome browser view of the region involved in the intragenic TP63 gain (chr3:189,427,139-
189,588,477, hg19). UCSC genes are shown in blue. Regulatory elements prediction based on ENCODE chromatin 
state segmentation in nine human cell lines is shown: red, promoter; yellow, weak enhancer; orange, strong 
enhancer; dark green, transcriptional elongation; light green, weak transcribed; light blue, insulator; dark grey, 
polycomb-repressed; light grey, heterochromatin. Conservation in other species is shown. 
To understand how the duplication is relocated, LR-PCR was performed on patients DNA at 
the breakpoint junctions of the duplicated portions. In detail, a direct tandem relocation was 
considered as shown in Fig.16. 
        
 
Fig.16. Schematic representation of the duplication repositioning hypothesis involving TP63. A) The genomic 
duplication is shown as a box with the exons included in black (2 and 9 are shown). Dark and light blue points 
indicate the first and the last duplicated array spots respectively; black points indicate the first and the last array 
spots not duplicated. Inclusion of exon 10 (in red) in the duplication is unknown. Exon 11 (in black) is not included. 
B) A direct tandem orientation is depicted as indicated by the long purple arrows. Primers for LR-PCR are shown as 
short purple arrows. 
A B 
Results 
 
80 
 
Moreover, considering that the distance between: i) the last probe not duplicated and the first 
duplicated (black and dark blue in Fig.16) is 4.9 kb; ii) the last probe duplicated and the first 
not duplicated (light blue and black in Fig.16) is 4.2 kb, an LR-PCR amplification of maximum 
9.1 kb is expected. As a result, a product of about 7 kb was obtained and the subsequent Sanger 
sequencing revealed the expected sequence: the duplication relocated in a direct tandem 
orientation and exon 10 was found included in the gain (Fig.17). The shortest transcripts 
(composed by 8 exons) resulted fully duplicated. As shown in Fig.17 the duplication of 167.8 kb 
starts within intron 1 (31191 bp before exon 2) and ends within intron 11 (1360 bp after exon 10). 
An overlapping region of about 11 bp between the two introns was found. Considering the 
overlapping sequence as part of intron 11 the gain was refined at chr3:189,424,338-189,592,155 
(hg19). 
 
Fig.17. Schematic view of the duplication repositioning. The red box highlights the enlargement of the breakpoint 
junction shown below. 
To clarify whether the intragenic duplication results in an aberrant mRNA, a PCR reaction 
specific for the junction between exon 10 and 2 (Fig.18) was performed. The PCR product was 
then sequenced and revealed the expected sequence confirming that the duplication produces 
an aberrant transcript (Fig.18). 
 
 
Fig.18. TP63 cDNA representation of the duplication junction. Above, exons 10 and 2 are shown as blue boxes. 
PCR primers are depicted as short purple arrows. Below, the electropherogram of the breakpoint junction between 
the two exons is shown. The black lines represent the reading frame. 
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RT-qPCR analysis on TP63 was carried out using two TaqMan assays as shown in Fig.19A. The 
first one is located inside the duplication (ex 7-8, Fig.19A, in red) whereas the second is located 
outside (ex 11-12, Fig.19A, in blue). Likely due to the extreme variability among controls mRNA 
levels, neither the first assay nor the second detected any up or down regulation of the POI 10 
transcript levels when compared to controls (Fig.19B-C). Conversely, normalizing the Ct values 
of the first “duplicated” assay with the Ct values of the second “not duplicated” assay, it was 
possible to evidence an overexpression statistically significant in the patients compared to 
controls which is indicative of the amount of the aberrant transcript (Fig.19D). Thus, the RT-
qPCR results indicate that POI 10 presents a TP63 mRNA level comparable to the average 
variability of controls mRNA, but a small amount of this transcript is represented by the 
duplicated aberrant mRNA (about 30% of the total mRNA level). 
 
 
 
Fig.19. RT-qPCR results. A) Schematic representation of the TP63 aberrant transcript; TaqMan assays 7-8 and 11-
12 are shown as red and blue stars respectively. B-C) RT-qPCR results indicative of the “duplicated” (B) and “not 
duplicated” assay (C) normalized against RPLP0. D) RT-qPCR result indicative of the aberrant mRNA amount. C1-
C10, controls (light grey bars); POI patient is depicted in dark grey.* p<0.05 vs avg C.  
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The previous cDNA sequence analysis of the exon junction between exon 10 and 2, revealed that 
no changes in the reading frame occurred in the TP63 aberrant mRNA. Particularly, the new 
overlap splice site formed by CA nucleotides of exon 10 and T nucleotide of exon 2, encodes a 
hystidine (H) (Fig.20). 
 
 
 
Fig.20. Tp63 exon junction representation. Above, junction between wild-type exons 1-2; in the middle, junction 
between wild-type exons 10-11; below junction between aberrant exons 10-2. Protein and nucleotide sequences are 
shown. Exons 2 and 10 involved in the duplication are depicted in blue; the residues of overlap splice site are 
represented in red. The red vertical line indicates the junction between exons. 
 
The wild-type Tp63 protein sequence is constituted by 680 aa (Fig.21A). Considering that the 
intragenic duplication does not alter the reading frame, the hypothetical aberrant Tp63 protein 
might be formed by 1109 aa (Fig.21B). In detail, the duplication ranges from residue 22 to 449, 
involving a total of 429 aa, 428 of which completely duplicated in tandem (underlined in 
Fig.21A-B) and 1 aa derived from the new overlap splice site between exon 10 and 2 (H shown in 
red big and bolded in Fig.21B). The 1109 aa prediction was also confirmed by the “Expasy 
translate tool” (http://web.expasy.org/translate/). 
Furthermore, as shown in Fig.21C, the nine duplicated exons encode the principal domain of the 
protein, a DNA binding domain belonging to the p53 superfamily. 
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MNFETSRCATLQYCPDPYIQRFVETPAHFSWKESYYRSTMSQSTQTNEFLSPEVFQHIWDFLEQPICSVQPIDLNFVDEPSEDGAT
NKIEISMDCIRMQDSDLSDPMWPQYTNLGLLNSMDQQIQNGSSSTSPYNTDHAQNSVTAPSPYAQPSSTFDALSPSPAIPSNTD
YPGPHSFDVSFQQSSTAKSATWTYSTELKKLYCQIAKTCPIQIKVMTPPPQGAVIRAMPVYKKAEHVTEVVKRCPNHELSREFNEG
QIAPPSHLIRVEGNSHAQYVEDPITGRQSVLVPYEPPQVGTEFTTVLYNFMCNSSCVGGMNRRPILIIVTLETRDGQVLGRRCFEAR
ICACPGRDRKADEDSIRKQQVSDSTKNGDGTKRPFRQNTHGIQMTSIKKRRSPDDELLYLPVRGRETYEMLLKIKESLELMQYLPQ
HTIETYRQQQQQQHQHLLQKQTSIQSPSSYGNSSPPLNKMNSMNKLPSVSQLINPQQRNALTPTTIPDGMGANIPMMGTHM
PMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPYPTDCSIVSFLARLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAI
WKGILDHRQLHEFSSPSHLLRTPSSASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDARRNKQQRIKEEGE 
 
MNFETSRCATLQYCPDPYIQRFVETPAHFSWKESYYRSTMSQSTQTNEFLSPEVFQHIWDFLEQPICSVQPIDLNFVDEPSEDGAT
NKIEISMDCIRMQDSDLSDPMWPQYTNLGLLNSMDQQIQNGSSSTSPYNTDHAQNSVTAPSPYAQPSSTFDALSPSPAIPSNTD
YPGPHSFDVSFQQSSTAKSATWTYSTELKKLYCQIAKTCPIQIKVMTPPPQGAVIRAMPVYKKAEHVTEVVKRCPNHELSREFNEG
QIAPPSHLIRVEGNSHAQYVEDPITGRQSVLVPYEPPQVGTEFTTVLYNFMCNSSCVGGMNRRPILIIVTLETRDGQVLGRRCFEAR
ICACPGRDRKADEDSIRKQQVSDSTKNGDGTKRPFRQNTHGIQMTSIKKRRSPDDELLYLPVRGRETYEMLLKIKESLELMQYLPQ
HTIETYRQQQQQQHQHLLQKHFVETPAHFSWKESYYRSTMSQSTQTNEFLSPEVFQHIWDFLEQPICSVQPIDLNFVDEPSED
GATNKIEISMDCIRMQDSDLSDPMWPQYTNLGLLNSMDQQIQNGSSSTSPYNTDHAQNSVTAPSPYAQPSSTFDALSPSPAIPS
NTDYPGPHSFDVSFQQSSTAKSATWTYSTELKKLYCQIAKTCPIQIKVMTPPPQGAVIRAMPVYKKAEHVTEVVKRCPNHELSREF
NEGQIAPPSHLIRVEGNSHAQYVEDPITGRQSVLVPYEPPQVGTEFTTVLYNFMCNSSCVGGMNRRPILIIVTLETRDGQVLGRRC
FEARICACPGRDRKADEDSIRKQQVSDSTKNGDGTKRPFRQNTHGIQMTSIKKRRSPDDELLYLPVRGRETYEMLLKIKESLELMQ
YLPQHTIETYRQQQQQQHQHLLQKQTSIQSPSSYGNSSPPLNKMNSMNKLPSVSQLINPQQRNALTPTTIPDGMGANIPMMG
THMPMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPYPTDCSIVSFLARLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFR
HAIWKGILDHRQLHEFSSPSHLLRTPSSASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDARRNKQQRIKEEGE 
 
 
 
 
Fig.21. Tp63 protein representations. A-B) Protein sequence of the wild-type (A) and aberrant (B) Tp63; the 
underlined sequence represents the duplicated portion; alternating exons are shown in black and blue; the residues 
of overlap splice site are represented in red; aminoacid F big and bold indicates the beginning of exon 2; aminoacid 
K big and bold indicates the end of exon 10; aminoacid H big and bold indicates the new residue of overlap splice 
site between exon 10 and exon 2. C) Schematic view of Tp63 protein domain from ensembl database 
(www.ensembl.org/); black arrows indicate exons 2 and 10; a red line highlights the duplicated domain. 
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3.4.3 POI 9 and 11: intronic deletion at 5p13.1 (PRKAA1) 
The deletion found in POI sisters and inherited from the father involves PRKAA1 intron 1. Based 
on array CGH results the inner deletion of about 6.5 kb ranges from oligonucleotide 
A_16_P37159287 to A_16_P17099229 (chr5:40,779,232-40,785,703, hg19; Fig.22A), whereas the 
outer deletion of about 20 kb starts after probe A_16_P17099202 and ends before A_14_P135087 
(chr5:40,773,231-40,793,258, hg19). Considering that part of the exonic sequence of PRKAA1 
(exons 2, 3, and 4) was not covered by array CGH probes, qPCR on patients DNA using six 
primer pairs (above in the Fig.22A), was carried out to establish the extent of the deletion. The 
analysis excluded an involvement of the conding region, confirming an intronic deletion 
(Fig.22B). 
 
 
 
 
Fig.22. A) UCSC genome browser view of the region involved in the loss CNV (chr5:40,773,231-40,793,258, hg19). 
UCSC genes are shown in blue. Regulatory elements prediction based on ENCODE chromatin state segmentation in 
nine human cell lines is shown: red, promoter; yellow, weak enhancer; orange, strong enhancer; dark green, 
transcriptional elongation; light green, weak transcribed. Conservation in other species as well as array CGH 400K 
probes are shown. B) qPCR results relative to each of the 6 probes used (*p<0.01). PCNT normalization is shown. C, 
control (light grey bars). POI patients are depicted in dark grey. 
To test whether the intronic deletion alter mRNA level, RT-qPCR analysis was performed on 
both sisters. Two TaqMan assays (ex1-2, ex9-10) were used and Ct values were normalized 
against three different housekeeping genes. Unfortunately, the results obtained failed to provide 
reproducible and interpretable data on blood tissue analyzed. 
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3.4.4 POI 44: partial gene deletion at 9p24.2 (VLDLR) 
Array CGH analysis revealed a 14.6 kb deletion raging from probe A_16_P38628086 to 
A_16_P18531563 (chr9:2,654,203-2,668,811, hg19) and involving VLDLR 3’UTR (exon 19) and 
some predicted regulatory elements as enhancer and insulator (Fig.23).  
 
Fig.23. UCSC Genome Browser view of the region involved in the CNV.UCSC genes are shown in blue. Regulatory 
elements prediction based on ENCODE chromatin state segmentation in nine human cell lines is shown: light blue, 
insulator; yellow, weak enhancer; orange, strong enhancer; dark green, transcriptional elongation; light green, 
weak transcribed; light grey, heterochromatin. Conservation in other species as well as array CGH 400K probes are 
shown. 
Because the array probes which identified the rearrangement were 4, a validation was needed. 
Hence, exons 16, 17, and 18 resulted not covered by the array oligonucleotides. Thus, LR-PCR 
was carried out on patient DNA using primers specific for the deleted allele, taking into account 
the outer deletion raging from the non deleted probes A_16_P18531505 and A_16_P18531574 
(black spots in Fig.24A). The amplicon was then sequenced and revealed that the entire coding 
sequence of VLDLR gene was preserved. Therefore, just 1 out of 4 array probes was not validated. 
The subsequent complete reading of the sequence amplified, revealed that four breakpoints 
occurred and generated two deletions of about 3 kb and 9.4 kb respectively, separated by 140 bp 
not involved in the loss (Fig.24A). Thus, the effective deletion includes only the predicted 
regulatory region downstream of VLDLR. The detailed sequence of the breakpoints junction is 
shown (Fig.24A). 
Then, to figure out whether the deletion might have an effect on VLDLR gene expression by a 
“position effect”, RT-qPCR was performed on patient cDNA: the analysis revealed a statistically 
significant transcript downregulation compared to controls (Fig.24B). Moreover, the 
identification on patients DNA of an heterozygous SNP (rs6148) in the VLDLR coding region 
(exon 14), allowed to point out a monoallelic mRNA expression of the gene, suggesting that the 
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deletion was likely responsible for the lack of expression of the deleted allele in the blood tissue 
analyzed (Fig.24B). 
 
 
 
Fig.24. A) Schematic view of the array result. The 14.6 kb deletion detected by array CGH which maches with the 
four deleted spots (in red) is represented by a red box. Inside the red box: 3’ UTR of VLDLR is included, the enhancer 
element predicted is shown in yellow, the insulator in light blue. The array probes not deleted are shown as dark 
spots. Red arrows indicate the deletions breakpoints and the respective nucleotide position is written. Forward and 
Reverse primers used for LR-PCR are depicted as purple arrows. The regions not deleted after molecular 
characterization are highlighted in red, blue and green. Nucleotide sequence of the breakpoints junction is show: 
the sequence portions representative of the not deleted region (highlighted in A), are colored in red, blue, and 
green as well. The bases added and not present in the wild-type sequence are shown In bold and delimited by 
dashes. The bases included in parenthesis are not present in the breakpoints sequence contrary to the wild type 
sequence. B) RT-qPCR results on POI patient (dark grey) relative to VLDLR mRNA level. Average Controls levels are 
shown in light grey. *** p<0.001. Electopherogram showing the heterozygosity assay for SNP rs6148 identified in 
POI 44 (gDNA and cDNA sequences are reported). 
 
Therefore, to understand which is the role of the deleted genomic region, several luciferase 
assays were carried out using plasmid pGL3 (SV40 promoter) which was transfected in both 
granulosa (COV434) and HeLa cells. The cloning of different portions of the deleted region 
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(Fig.25B) revealed a strong enhancer role of the region including the predicted insulator and the 
following ~3000 bp (orange bars in Fig.25C); whereas the cloning of the only predicted insulator 
sequence, showed no signals (Fig.25C). This evidence was observed mainly in the COV 
analyzed (Fig.25C). Furthermore, the validation of the result was supported by cloning the 
VLDLR promoter region downstream the deleted region (insulator + 3000 bp) and upstream the 
reporter gene (plasmid pGL3b was used): a dramatic overexpression was observed (Fig.26B). 
 
Fig.25. A) UCSC Genome browser view of the deleted regions (DEL-1, DEL-2) involving the two predicted enhancer 
(in yellow) and insulator (in light blue). B) Schematic view of the luciferase constructs (arrows in different colors). C) 
Luciferase assay results using pGL3 vector (SV40 promoter) performed in both HeLa and COV434 cell lines.  
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Fig.26. Results of Luciferase assay performed by transfecting plasmid pGL3b with VLDLR promoter region into 
COV434 cells. A) Evaluation of the functionality of the region predicted as VLDLR promoter (in red). pGL3b control 
luminescence in grey. B) In red, luminescent signal of the VLDLR promoter region; in blue, luminescent signal of the 
insulator region cloned directly in pGL3b-VLDLR; in orange, luminescent signal of the insulator + 3000 bp construct 
cloned in pGL3b-VLDLR. *p<0.05; ***p<0.001. 
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3.4.5 POI 46: intronic homozygous deletion at 15q25.2 (CPEB1) 
The 8.7 kb homozygous deletion found in POI 46 and involving CPEB1, ranges from the array 
probe A_16_P40479359 to A_16_P03072633 (chr15:83,305,533-83,314,278, hg19; Fig.27A). Because 
the outer deletion extends from A_16_P40479345 to A_16_P03072640 (chr15:83,301,729-
83,318,591, hg19), it was not possible to assess the involvement of the CPEB1 promoter. Moreover, 
the region deleted in POI 46 was covered only by three oligonucleotide probes, thus making 
worthwhile a further validation. 
The 17 qPCR assays used on POI DNA, allowed both to validate the CNV and to further 
characterize the homozygous deletion which does not involve the 5’UTR region but only part of 
intron 1 (Fig.27A-B). A subsequent Long Range PCR refined the loss at nucleotide level, which 
extends from 83,303,439 to 83,314,290, for a total of 10.8 kb deleted (Fig.27A).  
 
 
Fig.27. A) UCSC Genome Browser view of the region involved in the CNV (chr15:83301729-83318591, hg19). Genes 
are shown in blue. Regulatory elements prediction based on ENCODE chromatin state segmentation in nine human 
cell lines is shown: purple, inactive promoter; red, active promoter; yellow, weak enhancer; orange, strong 
enhancer; dark green, transcriptional elongation; light green, weak transcribed; dark grey, polycomb-repressed; 
light grey, heterochromatin. CpG island, conservation in other species as well as array CGH 400K probes are shown. 
17 qPCR probes are colored in black (not deleted) and red (deleted). Loss breakpoints are delimited by red arrows. 
LR-PCR primers are shown as purple arrows. B) qPCR results relative to each of the 17 probes used (***p<0.0001). 
PCNT normalization is shown. C, control (light grey bars). POI patient is depicted in dark grey. 
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3.4.6 Common CNV: duplication and deletion at 10q26.3 (SYCE1) 
The common CNV found both in POI patients and controls, involves SYCE1 and CYP2E1 
(Fig.28). Considering that a block of segmental duplication (SD) is near the 5’UTR of SYCE1, the 
interpretation of the array data is not very informative for this region. Particularly, no 400K 
array probes cover the SD, whereas a 244K probe maps inside it but it is not informative. Thus it 
remains unclear whether SYCE1 5’UTR is involved or not in the CNV. Several qPCR experiments 
were carried out to assess the presence of putative differences in the type of rearrangement 
between patients and controls. They aimed at clarifying SYCE1 5’UTR complete or partial 
involvement in the CNV and consequently, its putative pathogenetic or susceptibility role in 
POI etiology. qPCR analyses revealed that SYCE1 results completely included in the CNVs 
(duplicated or deleted) and that there are no differences between POI women and controls 
(Fig.28B).  
 
Fig.28. A) UCSC Genome Browser view of the region involved in the common CNV (chr10:135,233,327-135,408,523, 
hg19). CNV deletion is shown as a red horizontal bar. CNVs duplications are shown as blue horizontal bars. UCSC 
genes are represented in blue. The red box highlights the qPCR probes used and the region to be investigated. 
Segmental duplication are colored in yellow and grey. Array CGH 244K and 400K probes are shown. B) RT-qPCR 
result of the assay number 4 which covers the 5’UTR of SYCE1. 5 out of 9 “duplicated” controls are shown. Dark 
grey, patients; light grey, controls; C, control without CNV in the region analyzed.  
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3.5 Whole Exome Sequencing preliminary analysis 
17 out of 67 primary amenorrhea patients (POI 48, 49, 50, 51, 52, 53, 54, 55, 57, 59, 60, 61, 62, 63, 
65, 66, 67) were processed by exome targeted Next Generation Sequencing to discover rare 
mutations possibly implicated in the onset of their POI phenotype. In detail, the preliminary 
results of the exome sequencing data analysis consist in Single Nucleotide Variants (SNVs) 
filtering based on: 
 41 ovarian genes probably perturbed by rare and common CNVs identified after analyzing 
array CGH data (AMFR, BMP15, BMP4, BNC1, BTBD1, CAPZA1, CPEB1, CYP2E1, DDX1, DIAPH2, 
DUSP22, EEF2, ELAVL2, FZD6, GRIA1, HBE1, LRIG2, MAP2K2, MOV10, MSL3, MYCN, NAIP, NRP1, 
PARD3, PCSK5, PRKAA1, RHOC, RREB1, RYR3, SH3GL3, SIRT6, SLC5A5, SLMAP, SMYD3, STS, 
SYCE1, TP63, TSHZ2, VLDLR, WHAMM, XPO1); 
 135 genes derived from the collection of genes known to be involved in i) non-syndromic 
POI, or ii) syndromic form of POI, or iii) ovarian growth and development [see 
introduction] (ADAMTS19, AFF2, AIRE, ALOX12, AMH, AMHR2, AR, ATM, BAX, BCL2L1, BDNF, 
BICD, BMP15, BMP2, BMP7, BMP8B, BMPR1A, BMPR1B, BMPR2, CDKN1A, CDKN1B, CGGBP1, 
CNOT6, CXCL12, CXCR4, CXCR7, CYP11A1, CYP17A1, CYP19A1, CYP1B1, DAZAP1, DAZL, DICER1, 
DMC1, DNAJC8, DNMT1, EIF2B, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, EIF2C2, eIF4ENIF1, 
EPB41L5, EPS8, ESR1, FANCA, FANCC, FANCG, FGF8, FIGLA, FMR1, FOXE1, FOXL2, FOXO1, 
FOXO3, FOXO4, FSHB, FSHR, FST, GALT, GDF9, GDNF, GHR, GJA1, GJA4, GNAS, HDC, HFM1, 
INHA, INHBA, INHBB, KIT, KITLG, LHCGR, LHR, LHX8, LHX9, LSH, MCM8, MCM9, MGAT1, MOS, 
MSH4, MSH5, MSY2, NANOS3, NGF, NOBOX, NOG, NR5A1, NT4, NTRK1, NTRK2, NXF5, OCT4, 
PDPK1, PGRMC1, PIN1, PMM2, POF1B, POG, POLG, PTEN, PTHB1, PTPRO, RAD51C, RALB, REC8, 
RERG, RFPL4, RPA2, RPL10, RSPO1, SALL4, SERPINE1, SMAD1, SMAD3, SMAD5, SMPDL3B, 
SOHLH1, SOHLH2, SPO11, STAG3, STAR, STRAP, TAF4B, TIAR, TMEM35, TSC2, WNT4, XPNPEP2, 
ZAR1, ZFX, ZNF654). 
 15 genes known to be interactors of the VLDLR (APOE, APOER2, DAB1, FYN, RELN), TP63 
(CHUK, ITCH, MDM2, TP53, TP63), and CPEB1 (APLP1, AURKA, BICC1, PLK1, PUM2) genes. 
These data were obtained from STRING analysis. 
The purpose of this approach was to find: 
- mutations in the array genes in order to validate their role in the disorder; 
- mutations in the known POI causative genes; 
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- mutations in new POI candidate ovarian genes. 
Only exonic variants were considered and based on the filtering steps shown in Fig.29 a total of 
50 variants were selected. 
 
 
Fig.29. Flowchart of the filtering steps (1-5) carried out in the selection of rare exonic SNVs in the 17 patients 
analyzed. The numbers in the boxes refer to the variants identified in the 191 genes. 
 
A detailed list of the 50 exonic SNVs is shown in Tab.18. It includes:  
- 46 nonsynonimous SNVs; 
- 1 frameshift insertion leading to a premature stop codon; 
- 1 frameshift deletion leading to a premature stop codon; 
- 1 nonframeshift deletion; 
- 1 nonsense mutation. 
19 out of 50 variants have never been reported so far in the databases investigated. Moreover, 
considering that 10 variants were reported as “low quality” sequencing data, Sanger validation 
was performed. No one of the 10 SNVs was confirmed. 
Up to now, other 6 variants were processed by Sanger sequencing (in progress analysis) and for 
all, validation was obtained (Tab.18). 
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Tab.18. Pathogenic or likely pathogenic SNVs found in the 17 POI patients analyzed by WES 
      
ID Chr Start# End# Ref Alt Gene ExonicFunction AAChange 1000G ExAC dbSNP* HGMD P1 P2 P3 V 
48 chr6 121768925 121768925 C - GJA1 frameshift deletion NM_000165:exon2:c.932delC:p.A311fs NA 0,0072 rs778110855 / / / / 
 
 
chr12 124111657 124111657 T C EIF2B1 nonsynonymous SNV NM_001414:exon5:c.A416G:p.E139G NA NA / / T P D 
 49 chr2 120776755 120776755 A G EPB41L5 nonsynonymous SNV NM_001184937:exon2:c.A95G:p.H32R NA 2,47E-05 rs138231769 / D D D 
 
 
chr17 7192970 7192970 G A YBX2 nonsynonymous SNV NM_015982:exon7:c.C923T:p.P308L NA 8,34E-06 rs756982334 / T B D 
 
 
chr19 4174745 4174745 C A SIRT6 LQ nonsynonymous SNV NM_001193285:exon7:c.G856T:p.A286S 0,001 0,0049 rs183444295 / T B N - 
50 chr2 219254672 219254672 T C SLC11A1 nonsynonymous SNV NM_000578:exon9:c.T875C:p.L292P 0,0006 0,0009 rs145536242 / D D D 
 
 
chr15 83481979 83481979 C T WHAMM nonsynonymous SNV NM_001080435:exon2:c.C734T:p.P245L NA NA / / D D D + 
 
chr17 56774110 56774110 A G RAD51CLQ nonsynonymous SNV NM_058216:exon3:c.A461G:p.E154G NA 0,0404 rs758847241 / D P D - 
 
chrX 84569452 84569452 G A POF1B nonsynonymous SNV NM_024921:exon9:c.C943T:p.R315C 0,0003 0,0008 rs149085556 / D D D + 
51 chr1 113242873 113242873 A G MOV10 nonsynonymous SNV NM_001130079:exon20:c.A2831G:p.Y944C NA NA / / T B D 
 
 
chr15 89868870 89868870 G A POLG nonsynonymous SNV NM_001126131:exon10:c.C1760T:p.P587L 0,0008 0,0017 rs113994096 CM031330 D D A 
 
 
chr15 89873415 89873415 G A POLG nonsynonymous SNV NM_001126131:exon3:c.C752T:p.T251I 0,0008 0,0017 rs113994094 CM021660 T B A 
 
 
chr16 89842176 89842176 C G FANCA nonsynonymous SNV NM_000135:exon21:c.G1874C:p.C625S 0,0012 0,0028 rs139235751 CM112454 D D D 
 
 
chr19 2251240 2251240 T C AMH nonsynonymous SNV NM_000479:exon5:c.T967C:p.F323L 0,0002 0 rs577002391 / T B N 
 52 chr5 42700021 42700021 C T GHR nonsynonymous SNV NM_001242460:exon4:c.C469T:p.R157C 0,0014 0,0041 rs121909362 CM930313 D B A 
 53 chr2 237490111 237490111 T G ACKR3 nonsynonymous SNV NM_020311:exon2:c.T1003G:p.S335A NA NA / / / B D 
 
 
chr6 108985176 108985176 - G FOXO3 frameshift insertion NM_001455:exon2:c.1141dupG:p.D380fs NA NA rs34133353 / / / / 
 
 
chr15 89865023 89865023 C T POLG nonsynonymous SNV NM_001126131:exon16:c.G2542A:p.G848S 0,0002 0,0002 rs113994098 CM021662 D D A 
 54 chr1 113232516 113232516 C A MOV10 nonsynonymous SNV NM_001130079:exon5:c.C632A:p.P211Q NA NA / / T D D 
 
 
chr4 48496243 48496243 C G ZAR1 nonsynonymous SNV NM_175619:exon4:c.C1257G:p.S419R 0,0002 0,0004 rs150750718 / D D D 
 
 
chr6 7211150 7211150 C A RREB1  LQ stopgain NM_001003698:exon7:c.C539A:p.S180X NA NA / / / / / - 
 
chr7 103197600 103197600 G T RELN nonsynonymous SNV NM_005045:exon38:c.C5621A:p.P1874Q NA NA / / T D D 
 
 
chr9 78953201 78953201 G T PCSK5LQ nonsynonymous SNV NM_001190482:exon34:c.G4723T:p.G1575W NA NA / / D / N - 
 
chr12 15652521 15652521 C G PTPRO nonsynonymous SNV NM_002848:exon4:c.C654G:p.H218Q NA NA / / T D D 
 55 chr1 91846517 91846517 G T HFM1 LQ nonsynonymous SNV NM_001017975:exon7:c.C825A:p.F275L NA NA / / D D D - 
 
chr5 128863507 128863507 C A ADAM TS19 LQ nonsynonymous SNV NM_133638:exon5:c.C1135A:p.L379M NA NA / / / D D - 
 
chr6 31138093 31138093 C A POU5F1LQ nonsynonymous SNV NM_002701:exon1:c.G305T:p.G102V NA NA / / T P N - 
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chr7 103474110 103474110 G T RELNLQ nonsynonymous SNV NM_005045:exon3:c.C347A:p.S116T NA NA / / D P D - 
 
chr15 84255764 84255764 C A SH3GL3LQ nonsynonymous SNV NM_001301108:exon7:c.C447A:p.F149L NA NA / / T B D - 
 
chr16 2121909 2121909 C T TSC2 nonsynonymous SNV NM_000548:exon19:c.C2071T:p.R691C NA 6,94E-05 rs760489473 / D D D 
 
 
chrX 128884450 128884450 C T XPNPEP2 nonsynonymous SNV NM_003399:exon8:c.C644T:p.T215I 0,0013 0,0044 rs138365897 / D B D 
 57 chr13 41134286 41134286 T C FOXO1 nonsynonymous SNV NM_002015:exon2:c.A1342G:p.S448G NA NA / / T B D 
 
 
chr15 33999240 33999240 G A RYR3 nonsynonymous SNV NM_001036:exon43:c.G6604A:p.A2202T NA NA / / T D D + 
 
chr19 3984203 3984203 C T EEF2 nonsynonymous SNV NM_001961:exon2:c.G149A:p.R50Q NA NA / / T B D 
 59 chr1 156849863 156849863 G A NTRK1 nonsynonymous SNV NM_001012331:exon15:c.G2101A:p.E701K NA 8,28E-06 rs747855434 / D D D 
 
 
chr2 38298394 38298394 C T CYP1B1 nonsynonymous SNV NM_000104:exon3:c.G1103A:p.R368H 0,0042 0,0062 rs79204362 CM000137 D D A 
 60 chr9 97879642 97879642 A C FANCC nonsynonymous SNV NM_000136:exon11:c.T1027G:p.Y343D NA NA / / T D N 
 
 
chrX 147026489 147026489 C T FMR1LQ nonsynonymous SNV NM_001185081:exon13:c.C1238T:p.A413V 0,0005 0,0012 rs143889976 / T / D - 
61 chr15 83932648 83932648 G A BNC1 nonsynonymous SNV NM_001301206:exon4:c.C1334T:p.P445L NA 8,24E-06 rs778369152 / D P D 
 62 chr19 36361822 36361822 C G APLP1 nonsynonymous SNV NM_001024807:exon3:c.C316G:p.R106G 0,0002 0,0002 rs144561889 / D D D 
 63 chr15 51520044 51520044 T C CYP19A1 nonsynonymous SNV NM_000103:exon4:c.A383G:p.H128R NA 5,77E-05 rs375975652 / D D D + 
65 chr9 34648433 34648433 C T GALT nonsynonymous SNV NM_001258332:exon5:c.C340T:p.R114C NA 2,47E-05 rs111033750 / D D D + 
 
chr16 8941654 8941654 G A PMM2 nonsynonymous SNV NM_000303:exon8:c.G713A:p.R238H NA 0,0006 rs151319324 / T D N 
 
 
chr17 56811542 56811542 A G RAD51C nonsynonymous SNV NM_058216:exon9:c.A1090G:p.S364G NA NA rs587782565 / D B N 
 
 
chr19 45412314 45412314 T A APOE nonsynonymous SNV NM_000041:exon4:c.T761A:p.V254E NA 0,0014 rs199768005 / D P N 
 66 chr18 23872246 23872246 G A TAF4B nonsynonymous SNV NM_001293725:exon8:c.G1642A:p.V548M NA NA / / T D D 
 
 
chr20 50407448 50407448 C T SALL4 nonsynonymous SNV NM_020436:exon2:c.G1574A:p.G525E NA 8,25E-06 rs746415699 / T P D 
 
 
chrX 24197772 24197774 AGA - ZFX nonframeshift deletion NM_001178084:exon3:c.531_533del:p.177_178del NA 2,28E-05 rs762873800 / / / / 
 67 chr9 2643709 2643709 G A VLDLR nonsynonymous SNV NM_001018056:exon6:c.G902A:p.R301Q 0,0004 0,0027 rs139671268 / T D D + 
 
chr15 89869870 89869870 C T POLG nonsynonymous SNV NM_001126131:exon9:c.G1685A:p.R562Q NA NA rs781168350 CM033443 D D D 
 #Physical position of the identified SNVs based on the UCSC Genome Browser, hg19, released February 2009 
*dbSNP release 144 
LQ: Low Quality site 
P1: SIFT prediction (T, tolerated; D, damaging) 
P2: Polyphen2 prediction (B, benign; P, possibly damaging; D, probably damaging) 
P3: MutationTaster prediction (N, polymorphism; D, disease causing; A, disease causing automatic) 
V: Sanger validation (in progress analysis); +, validated; -, not validated 
NA, not available 
In grey: SNVs detected in array-CGH genes 
 
Tab.18. Continued 
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Among the 50 SNVs, 11 fall in the group of the candidate ovarian genes detected by array-CGH: 
4 resulted false-positive (low quality SNVs), 3 were positive (WHAMM in POI 50, RYR3 in POI 57, 
VLDLR in POI 67), and the remaining 4 SNVs have validation in progress. 
To evaluate the presence of positive VLDLR SNVs in the other 50 patients of the present cohort, 
exon 6 sanger sequencing was performed. rs139671268 was further found in POI 46 for a total of 
two positive patients. Frequencies of the identified SNVs are reported below in Tab.19. 
 
Tab.19. Frequencies relative to rs139671268 
Total 
Patients  
Positive 
patients  
Allelic 
frequency  
Allelic 
frequency  
1000 Genomes  
Allelic 
frequency  
ExAC  
Genotype 
frequency  
Genotype 
frequency  
1000 Genomes  
Genotype 
frequency  
ExAC  
67 2 0,015 
(2/134)  
0,001 
(1/1006)  
0,0034 
(229/66730)  
0,03 
(2/67)  
0,002 
(1/503)  
0.007 
(229/33365) 
 
Interestingly, the analysis performed on POI 67’s parents showed the presence of VLDLR SNVs 
also in her mother who suffered of premature menopause. 
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4. DISCUSSION 
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4.1 Sample cohort selection and investigation 
Primary Ovarian Insufficiency is an extremely heterogeneous disorder with a great impact on 
women's life, not only from the perspective of reproduction/fertility but also from a general 
point of view, as the young women have to deal with problems arising from low estrogen levels. 
The etiology of the disease is complex and encompasses infectious, metabolic, and autoimmune 
causes, iatrogenic treatments, and environmental factors. Also the genetic causes are thought to 
be prevalent in the pathogenesis of idiopathic POI patients, as supported by the occurrence of 
families with several affected women, corresponding to an incidence from 4 to 31%, depending 
on the studied population [10,60]. Thus far, genetic screening of FMR1 premutations is critical to 
evaluate non-syndromic forms of POI. Also the assessment of patient’s karyotype is crucial in 
order to identify X chromosome abnormalities and therefore exclude the presence of syndromic 
conditions of POI (e.g., Turner Syndrome). 
Several causative genes for POI onset are already known (BMP15, GDF9, HFM1, DIAPH2 etc.). 
However, the existence of idiopathic cases suggests that other genes should be involved. Thus, it 
appears more and more obvious that POI is a very heterogeneous disease and that the molecular 
pathways underlying women’s reproductive life are extremely complex and not yet clarified.  
Based on these evidences, the aim of the present thesis work was to analyze by high resolution 
array-CGH (244K and 400K) a cohort of stringently selected non-syndromic patients affected 
by the most severe phenotype, namely 67 women with PA. The analysis might allow to identify 
CNVs possibly implicated in POI pathogenesis, involving genes with a role in the early phases of 
ovarian follicles growth and development. These CNVs, if disregulated, are supposed to have a 
more deleterious effect. Up to date, there are five publications in which array-CGH technique 
(whole genome or custom for X chromosome) was used to identify rare CNVs possibly 
implicated in POI etiology [159,160,163,164,165]: however the sample cohorts screened have 
always been phenotypically "mixed", including both PA and SA affected women. Only the study 
by Liao et al. [153] selected women with a POI extreme phenotype (PA), although it applied 
genome-wide association as technological approach. 
The cohort recruited for the current study consists of 53 sporadic (79.1%) and 14 familial 
(20.9%) cases including six sisters pairs, and two patients with relatives affected by SA (not 
included in the analyzed cohort). The familial cases will support the importance of the genetic 
component and therefore may help to identify more easily the molecular defect. At the same time 
the analysis of a large group of sporadic cases could help to discover defects in the same genes, 
thus supporting their role in the onset of the disease. 
Discussion 
 
98 
 
In the present work the identification of rare CNVs, never reported or reported at a very 
low frequency, might allow to identify high-penetrance variants with a more severe impact. 
However, it cannot be excluded that “common” CNVs may have modulated the phenotype of the 
reported POI patients, increasing the complexity of inter-individual genetic variability. It is for 
this reason that “common” CNVs previously associated with POI [152,161] were also valued.  
Another point deserving attention is the control group to which all the CNVs data were 
compared. The DGV tool, which contains CNVs reported in healthy controls of different 
populations whose gender and age are unknown, does not match with the ideal set of 
population control for POI disease. For this reason, as done in the study of Norling et al. [159], an 
ad hoc control cohort was considered. This cohort includes 140 healthy women with normal 
reproductive life and physiological menopause, who have been previously analyzed with the 
same method of patients.  
First, rare CNVs according to the DGV were selected and those involving “ovarian” genes were 
considered. Secondly the selected CNVs were investigated in the control group to determine 
whether there was a real enrichment in ovarian genes in the POI cohort [see chapter 2]. 
The evidence that 39 patients resulted negative for rare ovarian CNVs (58.2%), suggested to 
combine different genomic approaches in order to increase the detection rate of the disorder. In 
the present work, 17 out of 67 collected patients, were then submitted to WES analysis. 
Particularly, the preliminary WES screening attempted to highlight i) the presence of rare 
variants involving the array-CGH candidate genes in order to support their role in POI etiology; 
ii) the presence of likely pathogenic variants in genes already associated to POI or in genes 
which play a role in ovarian maturation and differentiation. 
To our knowledge this is the first study in which a combined approach of high-resolution array 
CGH and WES is used to analyze a cohort of women affected by the most severe POI 
phenotype. 
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4.2 Array-CGH: rare CNVs detection and ad hoc control group 
analysis 
28 out of 67 women resulted positive to array-CGH analysis because having at least one rare 
CNV involving genes with a role in oocyte maturation and differentiation, for a total number of 
32 CNVs. Thus the detection rate of the method resulted 48.3% which is comparable to that 
reported in two whole genome array-CGH publications by Norling et al. (42.3%: 11 rare ovarian 
CNVs in 11/26 patients [159]), and Ledig et al. (41.9%: 44 rare CNVs in 31/74 patients [160]).  
Based on array-CGH results, 4 patients (POI 13, 39, 46, 54) have more than one rare 
“ovarian” CNV. Moreover, 14 women positive for rare “ovarian” CNVs (POI 6, 9, 11, 13, 33, 39, 42, 
44, 48, 50, 52, 53, 60, 62), have at least one common CNVs with a putative susceptibility role 
(Tab.10). These evidences support the existence of a genetic model characterized by oligogenic 
heterozygosity i.e., the simultaneous presence in a single patient of multiple heterozygous 
quantitative variants/rare mutations, both de novo and/or inherited, affecting multiple genes. In 
this model, when more than one rare CNVs is found in a single patient, it is difficult to attribute 
a “major” causative role to one of them. 
To better understand their contribution in POI onset, the same array-CGH data analysis was 
performed on ad hoc controls population composed by 140 healthy women. The majority of rare 
“ovarian” CNVs detected in patients were not found in the control group thus supporting their 
association with POI. Only 4/32 rare CNVs involving STS, MSL3, XPO1, MOV10 genes were found 
also in controls (Tab.15). Particularly, the CNVs including STS have identical extension both in 
patients and controls, whereas the CNVs involving the other three genes have no recurrent 
breakpoints. Hence, their causative role remain unclear, but considering POI onset as an 
oligogenic heterozygosity model, their involvement cannot be ruled out. 
Moreover, to evaluate the consistency of our methodological approach, rare “ovarian” CNVs 
were searched in the control population too. In 44 women, 49 rare “ovarian” CNVs were found 
for a detection rate of 31.4% which is lower if compared to the patients’ one (48.3%). 
Furthermore, to evaluate the presence of a significant enrichment in “ovarian” CNVs in the POI 
group, several statistical analyses were performed comparing patients’ to controls’ data (number 
of positive and negative people to array-CGH; number of exonic, non-exonic CNVs; number of 
genes with higher and lower association score), revealing no differences. This finding, which 
was never assessed in the previous studies, emphasizes that POI is not a disease statistically 
enriched in “ovarian” CNVs, as it is reported for other disorders (e.g.: autism, schizophrenia, 
etc.)[156,157,158]. Notewortly, regarding the type of rearrangement (certain or hypothetically 
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deleterious) involving the ovarian genes, a difference between patients and controls can be 
observed: if the genes with the highest POI association score are considered (score 3,4), the 
CNVs assumed to be more harmful involve 5 genes in patients’ group (BMP15, CPEB1, TP63, 
WHAMM, BNC1) but only 1 gene in controls’ group (PTN, growth factor expressed in bovine and 
mouse follicular fluid during oocyte development [228,229]) (Tab.17). In detail, the most 
deleterious rearrangements considered, were: 
- i) complete gene deletion and partial gene deletion that might lead to haploinsufficiency 
(BMP15, CPEB1, WHAMM, BNC1, PTN); ii) intragenic duplication/deletion that might lead 
to a new gene formation with duplicated or deleted exons, possibly resulting in aberrant 
mRNA (if translated in aberrant protein) or leading to haploinsufficiency (TP63). 
Moreover, some of the controls’ genes with high score (3,4; Tab.17) and an already reported POI 
association, are not directly involved by the CNVs, but might be disrupted by a position effect. 
This is a condition that does not always occur, it relies on the regulatory elements eventually 
contained in the CNVs, and it is difficult to predict if they have a real effect on the adjacent 
genes [230,231]. For instance it referes to LHCGR and FSHR (gonadotropin receptors) as well as 
GREM2 (BMP antagonist with a role inregulating ovarian primordial to primary follicle 
transition [232]), FMN2 (formin-2 with a role in regulating actin assembly during meiosis [233]), 
IL6ST (membrane receptor involved in ovarian steroid metabolism [234]), ADAMTS19 
(metalloproteinase whose SNPs were associated to POI [148,150]), and AKAP2 (protein kinase 
involved in cAMP signaling implicated in meiotic arrest e meiotic resumption [235]).  
Besides position effect, the other less harmful CNVs considered were:  
- i) complete duplication leading to an increase of the corresponding protein, as well as 
mild or null effect; ii) partial gene duplication for which it is difficult to predict the real 
effect of the rearrangement on the involved genes, as it depends on the orientation in 
which the duplicated portion is relocated: in case of a tandem direct orientation, mild or 
null perturbation of the gene expression might be expected; iii) intronic 
duplication/deletion which generally does not result in a deleterious effect unless 
splicing regulatory elements are embedded. 
Regarding the “common” CNVs identified, no difference about the frequency of these variants 
in patients compared to controls (38.8% vs 32.1%) was found confirming the data reported in 
Castronovo et al. [67]. However, as mentioned before, it cannot be excluded a susceptibility role 
in combinations with other common/rare CNVs, then supporting the oligogenic heterozygosity 
model.  
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4.3 Gene content analysis and CNVs characterization: genotype-
phenotype correlations 
The finding of 37 genes likely to be involved in POI etiology, highlights and confirms the high 
genetic heterogeneity associated with the disorder. Indeed, the same affected loci were detected 
only in few unrelated patients (DIAPH2 in patients 6 and 55, CPEB1 in patients 46 and 54, and 
TSHZ2 in patients 52 and 62) and the presence of 4 patients having more than one rare CNVs, 
further corroborates the genetic complexity of POI.  
A classification based on their known/possible role in the pathogenesis was made, giving a score 
from 1 (low association) to 4 (high) (Tab.12). Most of the selected genes have never been 
reported in association with POI (score 1, 2, 3), and thus they are suggested as new candidate 
loci. Among them, the genes with score 3 have strong molecular evidences supporting their 
involvement in the disorder (e.g.: TP63, VLDLR, WHAMM, BNC1, PRKAA1, BMP4). Whereas few 
genes with an already known association with POI were found (score 4, e.g.: DIAPH2, BMP15, 
CPEB1).  
The identified genes were then divided in 4 classes according to their function (Fig.9) (genes 
with the highest POI score are marked in bold): 
- genes involved in ovarian metabolism and homeostasis (19%: RYR3, PCSK5, SLC5A5, 
VLDLR, AMFR, STS, BTBD1): e.g. PCSK5, involved in the processing of mouse ovarian 
inhibin subunits during folliculogenesis [199,200], and VLDLR, which plays an 
important role in cholesterol and lipoprotein endocytosis in ovarian follicle 
[202,203,204,205,236]; 
- genes with a role in the intracellular trafficking, and in the regulation of cytoskeleton 
dynamics for oocyte asymmetric division (21.6%: DIAPH2, RREB1, RHOC, CAPZA1, XPO1, 
PARD3, WHAMM, SH3GL3): e.g. DIAPH2, causative of POF2A (OMIM #300511), 
encodes a protein associated with cytoskeleton and involved in metaphase chromosome 
alignment during oogenesis [129,175,176]; PARD3, known to play a role in establishing 
asymmetric division in mouse and Xenopus oocytes [206,207]; WHAMM, required for 
meiotic spindle migration and asymmetric cytokinesis in mouse oocytes [217]; 
- genes involved in transcription and translation regulation, chromatin remodelling, and 
maintenance of oocyte genomic integrity (35.1%: TP63, SMYD3, MOV10, LRIG2, DDX1, 
NRP1, CPEB1, TSHZ2, SLMAP, BNC1, MSL3, EEF2, SIRT6): e.g. TP63, plays a role in the 
maintainance of oogonia genomic integrity and may be implicated in meiosis and cell 
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cycle control of germ cells in the mouse ovary [179,180,181,182,237]; CPEB1, plays a role in 
regulating mRNA translation of proteins involved in synaptonemal complex formation 
during oocyte maturation [209,210,211]; BNC1, may play a role in the differentiation of 
mouse oocytes increasing transcription of the ribosomal RNA genes during mouse 
oogenesis [219,220]; 
- genes playing a role in ovarian differentiation, follicular development, and meiotic 
resumption (24.3%: ELAVL2, PRKAA1, HBE1, BMP15, BMP4, MYCN, GRIA1, FZD6, 
MAP2K2): e.g. PRKAA1, involved in murine and porcine oocyte meiotic resumption 
[184,185,186,187,188]; BMP15, plays a role in oocyte maturation and follicular 
development as homodimer or heterodimers with a related protein (Gdf9); moreover, 
several mutations were found in POI women [94,95,96,97,98]; BMP4, plays a role in 
follicular development and differentiation acting as a transition factor from primordial to 
primary mouse follicle [192,193,194,195,196]; MAP2K2, regulates spindle formation and 
meiotic resumption during mouse oocyte development [223,224,225]. 
Although these selected ovarian genes have an interesting function likely and/or hypothetically 
related to POI etiology, it is also important to validate and characterize the CNVs affecting 
them, as well as to study their possible perturbation at mRNA level, in order to perform a 
correct genotype-phenotype correlation. Hereafter some of the “ovarian” rare CNVs detected are 
discussed. 
 
In POI 6 an intronic duplication, inherited from the father, between exons 26-27 of 
DIAPH2 at Xq21.33 was detected. Inside the duplicated region, an isoform of DIAPH2-antisense1 
(RBSG1) was found, resulting fully duplicated. 
Considering that DIAPH2 is an already reported POI gene with a peculiar action in female 
gonads [74,78,79,129,238], it is most likely that the CNVs contributed to the patients phenotype. 
Although intronic duplications are considered less harmful rearrangements than exonic 
duplications, it is possible that in POI 6 the antisense mRNA duplication resulted in a 
deleterious effect on the target gene. 
Based on the function of mRNA-antisense in modulating the transcription of the 
complementary gene, Real Time RT-PCR analysis was performed on DIAPH2 mRNA, but no 
differences between POI 6 and controls were detected in the peripheral blood tissue analyzed. 
DIAPH2 maps on X chromosome and the controls used in the analysis were both female and 
male. RT-qPCR showed the same mRNA levels between female and male controls indicating an 
X inactivation (preferential or casual) of the gene in blood. Moreover, the father who has the 
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same X-linked CNV, did not show any transcript downregulation in the tissue analyzed, 
highlighting that in blood the CNV might not result in transcript perturbation. However, based 
on these evidences and taking into account that the gene may escape the X inactivation [239], it 
cannot be excluded that mRNA alterations occurred in other tissues, mainly in the early stages 
of development in the tissues involved in ovarian growth. 
 
A paternal  intragenic duplication at 3q28 involving TP63 gene was found in sisters POI 8 
and 10 (Fig.30). The characterization of the CNV on POI 10 gDNA was performed by Long-
Range PCR and Sanger sequencing, revealing the involvement from exon 2 to exon 10 of the 
main isoform. This molecular deepening was crucial to understand that the resultant allele has a 
direct tandem duplication from exon 2 to 10; particularly, an overlapping region of 11 bp (present 
both in intron 11 and 1) corresponds to the breakpoint junction of the rearrangement (Fig.17). 
 
Fig.30. array-CGH result showing TP63 intragenic duplication in POI 10. 
 
The extension of the analysis on POI 10 cDNA by RT-qPCR and direct sequencing between 
exons junction 10-2, allowed to confirm that the aberrant gene results in a stable aberrant 
mRNA as well. RT-qPCR using two different TaqMan probes (one outside and the other inside 
the duplicated region), also revealed that the aberrant mRNA consists about 30% of the total 
transcript. Regarding the reading frame, no changes were identified, thus, if NMD (non-sense 
mediated decay) process does not occur, probably an aberrant protein with the main functional 
domain completely duplicated (p-53 DNA binding domain) is translated (Fig.31B). 
TP63 could be considered a new candidate POI gene: it encodes a protein of tumor suppressor 
p53 family and it is a main regulator to protect the genomic integrity of female germ cells during 
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meiotic arrest. Moreover, null mice are infertile, because their oocytes do not undergo apoptosis 
after DNA damage [181]. 
 
Fig.31. A) TP63 mRNA and protein are shown. Main isoform has in the promoter region a transactivating domain 
(TA), whereas the shortest isoform has a ΔN promoter region, lacking the TA domain. Both isoforms have: DNA 
binding domain, oligomerization domain (Oligo), a sterile alpha motif (SAM) and a transactivation inhibitory 
domain (TID). B) Mutated TP63 mRNA and hypothetical proteins are shown. The image was modified from [182]. 
 
Indeed, after DNA damage, Tp63 is activated by kinases phosforylation and dimers opening lead 
to tetramerization (Fig.32). Thus, Tp63 triggers apoptosis, by activation of pro-apoptotic 
factors Puma and Noxa, whose function is to inhibit the survival family Bcl [237,240]. 
It is worthwhile to infer that whether the aberrant TP63 transcript in POI 8 and 10 results in no 
translation, the adequate protein level mandatory for oocyte maturation might be missed from 
the earliest stages of fetal development, thus resulting in a deleterious effect for the correct 
oogenesis. Contrary, the presence of an aberrant protein, might have altered the proper protein 
folding, preventing the tetramer formation and resulting in few functional wild-type proteins 
able to protect oocyte genome [180].  
 
Fig.32. Tp63 activation (TAp63a) after DNA damage during oocyte development [180,237]. 
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Notably the patients’ father, having the same CNV, died in young age from cancer. Since Tp63 is 
a tumor suppressor, the deleterious effect of the CNV is further supported. Thus, it could be 
strongly suggested that the alteration in Tp63 in POI 8 and 10 leads to their fertility problems: 
nevertheless it is appropriate to address the patients also to a proper cancer screening 
surveillance. 
 
In sisters POI 9 and 11, an intronic deletion in PRKAA1 inherited from the father was 
detected (Fig.33). CNV validation and characterization was crucial also in this case because 
only two array spots identified the loss and the adjacent exons 2, 3, and 4 were not covered by 
the array probes. qPCR on gDNA excluded the perturbation of PRKAA1 coding regions 
confirming an intronic deletion and the subsequent RT-qPCR did not allow to evaluate a 
transcript alteration due to the extreme variability of mRNA levels in the blood tissue analyzed. 
Nevertheless, it cannot be excluded that mRNA alterations occurred in other tissues during 
ovarian development. Indeed, murine, porcine and hen animal models showed the involvement 
of PRKAA1 in oocyte meiotic resumption [184,185,186,188,241]. Particularly, the process is 
regulated by the kinase in a dose-dependent manner. 
The CNV detected is reported at a very low frequency (5/2562) in DGV: thus, its causative role 
has yet to be elucidated. 
 
Fig.33. array-CGH result showing the two spots deletion involving PRKAA1 (POI 30 is depicted) 
 
Another example of the importance of array CGH data validation and characterization, is 
represented by a 4 spots deletion involving VLDLR 3’UTR (exon 19) and the proximal 14 kb 
identified in POI 44 (Fig.34). Array-CGH analysis was not performed on patient’s parents 
because they were not available. 
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As in the previous characterization, exons 16, 17, 18 were not covered by array probes. Long-
Range PCR and Sanger sequencing allowed not only to exclude the involvement of the three 
exons, but also to evaluate that the array probe covering VLDLR 3’UTR was a fake. In addition, 
sequencing of the deletion breakpoints revealed how the formation of genomic rearrangements 
maay be complex. In detail, the deletion downstream VLDLR includes the proximal 3 kb, and 
after 140 bp conserved, the following 9.4 kb which correspond to the 3 deleted array spots 
(Fig.24A). 
 
Fig.34. array-CGH result showing the VLDLR partial deletion in POI 44. 
 
Thus, the gene is not included in the CNV but might be perturbed by a position effect mediated 
by the downstream deletion. In support to this hypothesis, the analysis performed at mRNA 
level showed a drastic transcript downregulation and the heterozygosity assay confirmed a 
monoallelic expression of VLDLR in the patient. Furthermore, functional studies carried out 
using luciferase assay in a granulosa cell line, highlighted an enhancer role of the region 
including the ENCODE predicted insulator and the 3000 bp downstream deleted in the patient 
(Fig.35). These findings support that the CNV deregulate VLDLR gene by position effect in the 
blood tissue analyzed and that the deleted region has a regulatory role in oocyte. Particularly, 
luciferase assay using pGL3b vector with VLDLR promoter, showed that the deleted region plays 
a crucial role in VLDLR regulation (Fig.26).  
Remarkably, the prediction performed in ENCODE project considers 9 different cell lines 
(GM12878: B-lymphocyte, lymphoblastoid cell line; H1-hESC: embryonic stem cells; HepG2: 
hepatocellular carcinoma; HMEC: mammary epithelial cells; HSMM: skeletal muscle myoblasts; 
HUVEC: umbilical vein endothelial cells; K562: leukemia; NHEK: epidermal keratinocytes; 
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NHLF: lung fibroblasts[242]), among which no ovarian cell line is present. Thus, it is likely that 
the ENCODE prediction of “heterochromatin” region (Fig.35, red box) does not occur in ovary. 
 
Fig.35. UCSC genome browser view (hg19). VLDLR gene is shown in blue; downstream the deleted regions are 
shown in red. The region with an enhancer role in COV434 is shown in orange. Regulatory elements prediction 
based on ENCODE chromatin state segmentation in nine human cell lines is shown: red, promoter; pourple, poised 
promoter; yellow, weak enhancer; orange, strong enhancer; dark green, transcriptional elongation; light green, 
weak transcribed; light blue, insulator; dark grey, polycomb-repressed; light grey, heterochromatin. Conservation in 
other species is shown. 
 
Mutations in the gene have never been reported in human POI, but homozygous mutations are 
associated to Cerebellar hypoplasia and mental retardation with or without quadrupedal 
locomotion 1 (OMIM #224050). However, VLDLR in human is very important for 
steroidogenesis; in particular, the protein regulates lipoprotein endocytosis in order to ensure 
the correct follicular growth and its mRNA is mainly found in granulosa cells of preovulatory 
follicles [243,244]. This finding is supported by several publications in which the role of 
lipoprotein receptor is discussed in animal models: 
- hens lacking a functional receptor due to a point mutation are sterile, the oocytes fail to 
growth, become necrotic and do not ovulate. Moreover, mutant chickens present also 
severe hyperlipidemia and show atherosclerotic lesions [203,204]; 
- in bovine, Argov et al. [205,236] reported for the first time the expression of VLDLR 
throughout different stages of follicular development. In particular VLDLR was 
expressed in the granulosa cells in early and preovulatory follicle, and in theca cells in 
preovulatory follicle; 
- it is also associated with egg performance in duck, in which two VLDLR transcripts were 
identified: VLDLR-a mainly expressed in muscle tissue, and VLDLR-b in reproductive 
COV434 
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organs, with a huge amount in theca and granulosa cells from early stages of follicle 
development [202,245].  
Based on gene function, it might be hypothesized that in POI 44, VLDLR haploinsufficiency is 
responsible for a modified cholesterol endocytosis in oocytes leading to an improper estrogen 
production, and resulting in hypogonadism and then POI. 
Concerning the functional pathways in which it is involved, Vldlr protein associates with 
another receptor, namely Apoer2 (cholesterol transport protein apolipoprotein E). Besides 
cholesterol endocytosis, the receptors are involved in the signaling pathway mediated by Reelin 
(RELN), which is important for neuronal migration during brain development, and learning and 
memory during adult life [246,247]. Particularly, Reelin interacts with Vldlr and Apoer2 
extracellular component, causing their clusterization and the activation of the signaling 
pathway. Dab1, one of the intracellular interactors, is then phosphorylated and activates a 
pathway involved in cellular motility, adhesion and shape (Fig.36) [248,249,250,251]. Besides its 
role in central nervous system (CNS), Reelin resulted also expressed in mouse ovary [252] and 
in a publication by Fayad et al. its mRNA was found in bovine oocytes, mainly in theca cells of 
dominant follicles [253]. 
 
 
Fig.36. Reelin signaling pathway. Reelin binds Vldlr and Apoer2 receptors triggering src-family kinase (SFK) 
activation and Dab1 phosphorylation. Dab1 binds to the NPxY motif of both receptors. Upon Reelin stimulation, 
phosphoDab1 (P-Dab1) interacts with Lis1 and with other signal transduction molecules (grey circles). Signaling 
molecules downstream of Lis1 and Dab1 affect cytoskeleton dynamics by acting on microtubules (thick lines) or 
actin filaments (thin lines), thereby controlling cellular migration and formation[246]. 
 
This finding sheds light on the brain-ovarian functions of several genes. An example is 
the neurotrophin family, which includes: nerve growth factor (NGF), neurotrophin 3 (NT3), 
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neurotrophin 4/5 (NT4/5), brain-derived neurotrophic factor (BDNF), glial derived neurotrophic 
factor (GDNF) and vasointestinal peptide (VIP). Besides their predominant role in brain, these 
factors act also during ovarian physiological and pathological processes, as recently reported by 
Streiter et al. [254]. They promote follicular cell proliferation, ovulation, inhibit follicular 
apoptosis, promote oocyte maturation, and stimulate steroidogenesis. 
Consistently, among the ovarian genes identified by array-CGH (Tab.13), three have also a brain 
function: PARD3 (POI 45) is required for establishment of neuronal polarity and normal axon 
formation in cultured hippocampal neurons but it is also involved in establishing asymmetric 
division in mouse and xenopus oocytes [206,207]; NRP1 (POI 45) plays a role in the formation of 
certain neuronal circuits but it is also expressed both in granulosa and theca cells in bovine 
ovary [208]; GRIA1 (POI 48) encodes a glutamate receptor which is the predominant excitatory 
neurotransmitter receptors in the mammalian brain and is activated in a variety of normal 
neurophysiological processes, but it is also suggested as a critical mediator of ovulation in cow 
[212,213]. 
 
In POI 46, a homozygous intronic deletion at 15q25.2 in CPEB1 (Fig.37) was 
characterized in order to evaluate the involvement of gene promoter region in the CNV. The 
analyses performed on gDNA confirmed a homozygous deletion in intron 1 of about 10.8 kb. 
Unfortunately, gDNA from patient’s parents, as well as mRNA from POI 46 were not available 
for further analyses. 
The involved region is predicted to be transcriptionally repressed, and the promoter region of 
the isoform included in the CNV results a poised promoter in the cellular lines investigated by 
the ENCODE project [242]. Based on the functional studies performed on VLDRL one may 
speculate that it is an ovarian specific isoform and that the deletion might involve some 
regulatory elements (not predicted by ENCODE project) with a pivotal function in CPEB1 
regulation. Thus, its haploinsufficiency might disrupt the proper ooctyes maturation and 
development.  
Furthermore, the gene was found fully deleted in POI 54, who has a CNV of about 1.6 Mb which 
involves other three ovarian genes (Tab.11). To support its role in POI onset, one very similar 
variation was also reported by McGuire et al. [161] in a patient with PA. 
CPEB1 is preferentially expressed in oocyte and is involved in synaptonemal complex formation 
during oocyte maturation as proved by several animal models (mouse, xenopus, porcine 
[209,210,211]). Female null mice lack follicles due to oocytes premature loss, and female embryos 
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show oocytes stalled at pachitene [209]. CPEB1 is also important in regulating cellular cycle 
progression during mitotic embryonic division [255]. 
 
Fig.37. array-CGH results showing the CNVs involving CPEB1 in POI 46 and 54, respectively. 
Particularly, during zygotene to pachytene transition in meiosis, Cpeb1 is phosphorylated by 
Aurora A kinase (Fig.38) and activated with the subsequent transcription of proteins involved 
in synaptonemal complex formation (Scp1, Scp3). In mouse KO, these proteins are not 
translated and the complex is not formed with the following stall of follicular development. 
When wild-type Cpeb1 progresses to diplotene, is dephosphorylated and thus inactivated. 
During ovulation, oocyte resumes meiosis and Cpeb1 is activated again promoting Mos and 
CyclinB1 transcription (Fig.38) [256]. 
 
Fig.38. Cpeb1 activity during oogenesis and oocyte maturation in mice [256]. 
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Therefore its role in POI etiology is clear: the haploinsufficiency in human might accelerate the 
loss of primordial germ cells and thus it may contribute to the extreme phenotype onset shown 
by POI 46 and 54. 
As aforementioned, the frequency of “common” CNVs does not change between patients 
and controls. Among these CNVs, that with the most relevant evidence about its putative role in 
POI onset is the duplication/deletion involving SYCE1 gene. The duplication which appears most 
frequently according to DGV, was found in 4 patients and detected nine times in controls. By 
contrast, the only deletion found in POI 60 was never reported in the ad hoc control group, but it 
was previously detected in a patient with premature SA (21 years) discussed by McGuire et al. 
[161] (Fig.39).  
 
Fig.39. array-CGH results showing the CNVs involving SYCE1 gene found in POI cohort. 
 
Syce1 is part of the synaptonemal complex, plays a role in ensuring complex stability together 
with other proteins (Cesc1, Sycp1) and in recombination during meiosis (Fig.40). In Syce1 
nullmouse, DNA damage repair pathway is changed and after DSB, oocytes undergo apoptosis 
leading to infertility [147]. In humans, haploinsufficiency might result in a similar effect, thus in 
POI 60, the SYCE1 deletion could have a major contribution in POI etiology, leading to 
premature oocytes loss. This hypothesis is supported by a recent publication in which SYCE1 
haploinsufficiency by a homozygous mutation was associated to POI [146]. Hence, it will be 
appropriate to exclude any loss-of-function alterations in the wild-type allele of POI 60. 
Regarding duplications, it was not possible to understand both in patients and in controls 
whether SYCE1 was completely involved in the CNVs due to the presence of segmental 
duplication near the promoter region. Even if no differences about the frequency were shown, it 
seemed crucial to assess whether the size of the rearrangement was the same between patients 
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and controls thus leading to a different effect. qPCR revealed no differences and SYCE1 was fully 
duplicated both in POI and controls. However, one cannot ruled out that these CNVs, in 
combination with others, might have a susceptibility role in POI onset. 
 
 
 
Fig.40. Schematic representation of the synaptonemal complex. Dimers or multimers of SYCE1 and CESC1 
associate with the N-terminal region of SYCP1 forming the central region. C, carboxyl-terminus; CE, central 
element; LE, lateral element; N, amino-terminus [144]. 
 
 
4.3.1 Bioinformatic analysis 
To detect a potential link between array candidate genes and the ones known to be involved in 
POI onset, bioinformatic analysis was performed. Since few genes were detected (37) it was not 
possible to predict a statistically significance enrichment in term of Gene Ontology (GO), 
biological processes, as well as KEGG pathways. For this reason STRING software was used to 
verify any protein connections. Some interesting data were obtained, thus supporting the 
possible causative role of the following genes in POI etiology (Fig.41): 
- Sts, the steroidogenic factor, as well as Amfr and Cyp2e1, were annotated in the same 
pathway “Steroid Hormone biosynthesis” of Cyp17a1 and Cyp19a1 [KEGG]; 
- Smyd3, (regulator of transcription factors) shows a moderate binding score (0.576) with 
Esr1, (estrogen receptor) [257]. Particularly, it is required for transcription of genes 
regulated by Esr1 in estrogen signaling pathway; 
- Prkaa1 is involved in post-translation modification of FOXO family members in the 
“FoxO signaling pathway” [KEGG]; 
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- Syce1 shows a high binding score (0.900) with Stag3, in synaptonemal complex 
formation [Reactome]. 
Due to the identification of several ovarian genes which could be selected as new candidates for 
POI onset, array CGH is therefore a very useful approach to be adopted, both in familial and 
idiopathic cases.  
 
Fig.41. Output representation of STRING analysis. The proteins encoded by array-CGH detected genes are shown 
in red. The proteins encoded by already reported POI genes are shown in black. Purple line: 
experimental/biochemical data; light purple line: homology; blue line: co-occurence across genome; light blue line: 
association in curated databases; black line: coexpression. 
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4.4 Preliminary WES analysis 
Based on the present literature, few WES analyses have been carried out, mainly on POI non-
syndromic familial cases with women affected by both PA and SA [116,135,136,146,167]. Only in 
the study by Fonseca et al. [166], twelve sporadic POI patients affected by SA were analyzed. 
Here, it is reported the first WES investigation on non-syndromic unrelated patients affected by 
the extreme POI phenotype (PA). 
Particularly, WES analysis was performed in 17 out of 67 patients, thanks to a collaboration 
with Genetics of Common Disorders Unit at San Raffaele Hospital. The preliminary approach in 
the identification of rare SNVs consisted in the screening of a total of 191 selected genes derived 
from array-CGH data, and literature regarding POI and ovary (http://omim.org/,[155]). In 
addition, the interactors of the three array genes VLDLR, TP63, CPEB1 (http://string-db.org/), 
were considered in the research, based on their function, their high association to POI and the 
molecular evidences obtained in this thesis work. 
The variants obtained were filtered according to the steps shown in Fig.6 and Fig.29. In detail, 
considering POI a heterogeneous complex disorder and based on the purpose of this study, the 
most rare SNVs with MAF < 0.5% were considered. Then based on the evidence that ExAC 
browser collects about 60,700 exome sequencing data from several pathological individuals, 
variants with a higher frequency (> 5%) were excluded because considered benign according to a 
recent publication [258]. 
The variant annotation software used (wANNOVAR) collects all the information from several 
databases but does not consider the HGMD mutation database. Moreover for some submitted 
SNVs, dbSNP ID is not reported. Thus, the variants obtained were analyzed individually 
consulting several bioinformatic databases, to clarify their benign or pathological effect. HGMD, 
dbSNP, ensembl, ClinVar as well as aminoacid substitution prediction softwares (SIFT [170], 
Polyphen [171], MutationTaster [172]) were interrogated and a total of 50 “uncertain 
significance”, “likely pathological”, and “pathological” variants [258] were obtained. 10 out of 50 
SNVs were signed as low quality data, indeed they were not confirmed by Sanger validation. 
Among the array genes, 7 “likely pathological” variants were detected and validation for 3 of 
them was obtained supporting their putative role in the disorder. They are discussed below. 
- In POI 50, positive to array-CGH analysis (STS fully duplicated), a WHAMM missense 
variant c.C734T was detected. It resulted never reported in the databases investigated 
and predicted “damaging” for the three main softwares consulted. The protein encoded 
acts as a nucleation-promoting factor (NPF) that stimulates actin polymerization both 
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at the Golgi apparatus and along tubular membranes. Only one publication highlights its 
role in ovary: Huang et al. [217], examined its localization and function in mouse oocytes 
during meiosis. Particularly, WHAMM silencing by interfering siRNA lead to failure of 
spindle migration and alterations in the correct asymmetric division during oocyte 
maturation. 
- In POI 57, negative to array CGH analysis, the yet unreported RYR3 missense variant 
c.G6604A was found. The gene encodes a receptor which contributes to cellular calcium 
ion homeostasis and plays a role in cellular calcium signaling. It is expressed on the 
oocyte surface of mature bovine and anphibia [173,174]. The SNV with a predicted 
“damaging” effect could have changed the ovarian calcium levels which are essential for 
the activation and the development of oocytes. 
- In POI 67, negative to array CGH analysis, a VLDLR missense variant c.G902A was 
detected. It is reported as rs139671268, with a very low frequency (MAF: 0.001).  
After Sanger sequencing of VLDLR exon 6 in the rest of POI cohort, the SNV was also 
found in POI 46, (carrier of the homozygous intronic deletion in CPEB1). rs139671268 
allele frequency in the present cohort resulted higher (0.015) compared to the control 
population (0.001) (Tab.19) thus supporting an association with POI onset. In addition, 
the mother of POI 67 who underwent premature menopause, presents the same SNV. 
It is further interesting to note that variants involving genes with a role in the same 
VLDLR pathways were discovered: i.e. RELN, c.C5621A in POI54 (carrier of two rare 
CNVs involving SLMAP and CPEB1, WHAMM with other genes, respectively); APOE, 
rs199768005 in POI 65 (negative to array-CGH). 
Notably, for RYR3 and VLDLR missense variants, “damaging” prediction was obtained in 
Polyphen and MutationTaster, but it was “tolerated” in SIFT. The discordance between these 
predictions is quite common and depends on type of source and algorithm used by the different 
tools. Indeed, SIFT is considered a prediction software based on “Evolutionary conservation”, 
whereas Polyphen and Mutation Taster are also based on “ protein structure and function” 
[258]. In the present thesis work, Polyphen was mainly considered in the interpretation of data 
because its prediction is correlated to human phenotypes [171]. 
Noteworthy the present WES preliminary analysis allowed to confirm the importance of 
some array CGH candidate genes in POI onset: e.g.VLDLR gene, for which more molecular and 
literature evidences are present. Moreover, the exome sequencing findings support the 
heterogeneity of POI: every patient has at least one rare SNV in the ovarian genes selected and 
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some of POI women are also carriers of rare “ovarian” CNVs. The combination of these 
molecular evidences, with major or minor contribution, might define the underlying mechanism 
of their POI phenotype. 
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4.5 Conclusions and future perspectives 
The data obtained in the present work, confirm the extreme heterogeneity of Primary Ovarian 
Insufficiency, in which the combination of more rare/common variants seems to concur in the 
phenotypic onset. 
The analysis of POI patients affected by the most severe phenotype enabled to detect new 
candidate ovarian genes never reported before. Indeed, the combined genome wide approach of 
array-CGH and WES techniques, resulted an efficient tool to identify rare variants (CNVs and 
SNVs) involving both genes already reported in POI, and new candidate genes with a role in 
oocyte maturation and differentiation. 
Hence, the present tool is strongly recommended to be adopted in the continuous growing 
understanding of the genetic basis of POI. The characterization and the discovery of POI 
molecular causes in each patient, will help not only to shed light on the pathways underlying 
women reproduction but also to ensure a proper diagnosis and then an appropriate therapeutic 
intervention. Moreover, the new candidate genes could be specifically analyzed in the future for 
both diagnostic and prognostic purposes. 
 
Finally, it will be appropriate to: 
- deepen the most interesting results emerged from array-CGH analysis in order to 
support their putative pathogenic effect (e.g. Tp63 Western Blot to detected the 
presence of an aberrant protein; functional studies on the main candidate genes); 
- complete WES analysis on the 17 patients and process the other 50 POI; 
- validate WES data by Sanger sequencing; 
- confirm the actual rarity of the identified variants screening the ad hoc control group with 
the same WES approach. 
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